BioMedLib Search Engine
[ goto HOMEPAGE ]
Find more relevant answers, faster!
Skip to content
Advanced Search
Search History
MeSH Query
Page Format
Query is expanded
Login
Skip to content
Export Citations
Search Results
RSS
Email
Articles' Details
Start new query
Reset All
Refine your query
(more in Advanced-Search):
Search all of MEDLINE
Focus on the recent 5 years
Focus on the current year
Focus on the last 30 days
More choices ...
Focus on articles with free fulltexts
More choices ...
Do simple 'keyword' search (no query expansion)
[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click
here to
RESET
all values
Click
here to
GO BACK
without resetting any value
Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.
+
Publication-Date
Published in the last:
30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years
Or published in the following date range: From (yyyy/mm/dd - month and day are optional)
to ('to' is optional)
+
Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+
Sort-Order
Sort the retrieved articles by:
relevance
publication date
+
Language
And with languages:
English
French
German
Italian
Japanese
Russian
Spanish
More languages:
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Bengali
Bosnian
Bulgarian
Catalan
Chinese
Czech
Danish
Dutch
Esperanto
Estonian
Finnish
Georgian
Scottish Gaelic
Greek, Modern
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Kinyarwanda
Korean
Latin
Latvian
Lithuanian
Macedonian
Malayalam
Maori
Malay
Multiple languages
Norwegian
Persian
Polish
Portuguese
Pushto
Romanian
Sanskrit
Serbian
Croatian
Slovak
Slovenian
Swedish
Thai
Turkish
Ukrainian
Undetermined
Urdu
Vietnamese
Welsh
+
Publication-Type
And with publication types:
Clinical Trial
Editorial
Letter
Meta-Analysis
Practice Guideline
Randomized Controlled Trial
Review
More publication types:
Addresses
Bibliography
Biography
Case Reports
Classical Article
Clinical Conference
Clinical Trial, Phase I
Clinical Trial, Phase II
Clinical Trial, Phase III
Clinical Trial, Phase IV
Comment
Comparative Study
Congresses
Consensus Development Conference
Consensus Development Conference, NIH
Controlled Clinical Trial
Corrected and Republished Article
Dictionary
Directory
Duplicate Publication
English Abstract
Evaluation Studies
Festschrift
Government Publications
Guideline
Historical Article
Interactive Tutorial
Interview
Introductory Journal Article
In Vitro
Journal Article
Lectures
Legal Cases
Legislation
Multicenter Study
News
Newspaper Article
Overall
Patient Education Handout
Periodical Index
Portraits
Published Erratum
Retracted Publication
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Retraction of Publication
Scientific Integrity Review
Technical Report
Twin Study
Validation Studies
+
Species
And for:
Humans
Animals
+
Gender
And for:
Male
Female
+
Age
And for these age groups:
Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years
+
Title
And for this query matching the titles:
+
Transliterated-Title
And for this query matching the title in original language:
+
Abstract
And for this query matching the abstratcs:
+
Major-Mesh
And for this query matching the MeSH-Major terms:
+
Mesh
And for this query matching any MeSH terms:
+
Journal
And for one or more of these journal abbreviated names:
OR
OR
(see
title abbreviations
)
+
Volume
And with journal volume number:
+
Issue
And with journal issue number:
+
Page
And with page number:
+
ISSN
And with ISSN:
+
Publication-Place
And with journal's country of publication:
+
Author
And for...
all these author names:
AND
AND
(see
help
)
one or more of these author names:
OR
OR
but not having any of these unwanted author names:
NOT
NOT
+
Affiliation
And with affiliation to:
+
Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior)
+
PMID
Show me only articles for these PMIDs (PubMed IDs):
+
Semantic-Type
And with semantic types:
A. Entity
A1. Physical Object
A1.1. Organism
A1.1.1. Archaeon
A1.1.2. Bacterium
A1.1.3. Eukaryote
A1.1.3.1. Animal
A1.1.3.1.1. Vertebrate
A1.1.3.1.1.1. Amphibian
A1.1.3.1.1.2. Bird
A1.1.3.1.1.3. Fish
A1.1.3.1.1.4. Mammal
A1.1.3.1.1.4.1. Human
A1.1.3.1.1.5. Reptile
A1.1.3.2. Fungus
A1.1.3.3. Plant
A1.1.4. Virus
A1.2. Anatomical Structure
A1.2.1. Embryonic Structure
A1.2.2. Anatomical Abnormality
A1.2.2.1. Congenital Abnormality
A1.2.2.2. Acquired Abnormality
A1.2.3. Fully Formed Anatomical Structure
A1.2.3.1. Body Part, Organ, or Organ Component
A1.2.3.2. Tissue
A1.2.3.3. Cell
A1.2.3.4. Cell Component
A1.2.3.5. Gene or Genome
A1.3. Manufactured Object
A1.3.1. Medical Device
A1.3.1.1. Drug Delivery Device
A1.3.2. Research Device
A1.3.3. Clinical Drug
A1.4. Substance
A1.4.1. Chemical
A1.4.1.1. Chemical Viewed Functionally
A1.4.1.1.1. Pharmacologic Substance
A1.4.1.1.1.1. Antibiotic
A1.4.1.1.2. Biomedical or Dental Material
A1.4.1.1.3. Biologically Active Substance
A1.4.1.1.3.1. Neuroreactive Substance or Biogenic Amine
A1.4.1.1.3.2. Hormone
A1.4.1.1.3.3. Enzyme
A1.4.1.1.3.4. Vitamin
A1.4.1.1.3.5. Immunologic Factor
A1.4.1.1.3.6. Receptor
A1.4.1.1.4. Indicator, Reagent, or Diagnostic Aid
A1.4.1.1.5. Hazardous or Poisonous Substance
A1.4.1.2. Chemical Viewed Structurally
A1.4.1.2.1. Organic Chemical
A1.4.1.2.1.5. Nucleic Acid, Nucleoside, or Nucleotide
A1.4.1.2.1.6. Organophosphorus Compound
A1.4.1.2.1.7. Amino Acid, Peptide, or Protein
A1.4.1.2.1.8. Carbohydrate
A1.4.1.2.1.9. Lipid
A1.4.1.2.1.9.1. Steroid
A1.4.1.2.1.9.2. Eicosanoid
A1.4.1.2.2. Inorganic Chemical
A1.4.1.2.3. Element, Ion, or Isotope
A1.4.2. Body Substance
A1.4.3. Food
A2. Conceptual Entity
A2.1. Idea or Concept
A2.1.1. Temporal Concept
A2.1.2. Qualitative Concept
A2.1.3. Quantitative Concept
A2.1.4. Functional Concept
A2.1.4.1. Body System
A2.1.5. Spatial Concept
A2.1.5.1. Body Space or Junction
A2.1.5.2. Body Location or Region
A2.1.5.3. Molecular Sequence
A2.1.5.3.1. Nucleotide Sequence
A2.1.5.3.2. Amino Acid Sequence
A2.1.5.3.3. Carbohydrate Sequence
A2.1.5.4. Geographic Area
A2.2. Finding
A2.2.1. Laboratory or Test Result
A2.2.2. Sign or Symptom
A2.3. Organism Attribute
A2.3.1. Clinical Attribute
A2.4. Intellectual Product
A2.4.1. Classification
A2.4.2. Regulation or Law
A2.5. Language
A2.6. Occupation or Discipline
A2.6.1. Biomedical Occupation or Discipline
A2.7. Organization
A2.7.1. Health Care Related Organization
A2.7.2. Professional Society
A2.7.3. Self-help or Relief Organization
A2.8. Group Attribute
A2.9. Group
A2.9.1. Professional or Occupational Group
A2.9.2. Population Group
A2.9.3. Family Group
A2.9.4. Age Group
A2.9.5. Patient or Disabled Group
B. Event
B1. Activity
B1.1. Behavior
B1.1.1. Social Behavior
B1.1.2. Individual Behavior
B1.2. Daily or Recreational Activity
B1.3. Occupational Activity
B1.3.1. Health Care Activity
B1.3.1.1. Laboratory Procedure
B1.3.1.2. Diagnostic Procedure
B1.3.1.3. Therapeutic or Preventive Procedure
B1.3.2. Research Activity
B1.3.2.1. Molecular Biology Research Technique
B1.3.3. Governmental or Regulatory Activity
B1.3.4. Educational Activity
B1.4. Machine Activity
B2. Phenomenon or Process
B2.1. Human-caused Phenomenon or Process
B2.1.1. Environmental Effect of Humans
B2.2. Natural Phenomenon or Process
B2.2.1. Biologic Function
B2.2.1.1. Physiologic Function
B2.2.1.1.1. Organism Function
B2.2.1.1.1.1. Mental Process
B2.2.1.1.2. Organ or Tissue Function
B2.2.1.1.3. Cell Function
B2.2.1.1.4. Molecular Function
B2.2.1.1.4.1. Genetic Function
B2.2.1.2. Pathologic Function
B2.2.1.2.1. Disease or Syndrome
B2.2.1.2.1.1. Mental or Behavioral Dysfunction
B2.2.1.2.1.2. Neoplastic Process
B2.2.1.2.2. Cell or Molecular Dysfunction
B2.2.1.2.3. Experimental Model of Disease
B2.3. Injury or Poisoning
Page Format
Any submit button will submit all of the items you have changed.
[theme]
Use this page design theme:
original
twenty ten
[shown]
Results per page:
5
10
20
50
100
200
500
[expand/collapse]
show these sections expanded by default:
Advanced search
MeSH query
Search history
Page format
Query expansion
Articles details
Export citations
Email
[text size]
use this font size for text:
25%
50%
75%
100%
125%
150%
200%
or enter your choice of font size:
[page width]
use this page width (relative to the default initial value):
25%
50%
75%
100%
125%
150%
200%
or enter your choice of page width:
[highlight color]
use this color to highlight query words in the articles:
red
green
blue
black
purple
yellow
orange
navy
olive
maroon
none
[query history]
maximum number of queries shown in the history section:
[annotate]
Annotate these parts of each article:
title
abstract
both
none
Reset all values
Find best MeSH terms for
Search History
1
adult t cell lymphoma 2005:2010[pubdate] *count=100
4713 results
Searchbox
Export
PDF
RSS
Email
Delete
Email this search result to the following email address:
[X] Close
Expand the query
'
adult t cell lymphoma
' expanded to all its synonyms;
details
Email the results to the following email address:
Export the checked citations in RIS format (RIS format is used by RefWorks, Endnote, among others).
Items 1 to 100 of about 4713
1.
Sabloff M, Atkins HL, Bence-Bruckler I, Bredeson C, Fergusson D, Genest P, Hopkins H, Hutton B, Mcdiarmid S, Huebsch LB:
A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma.
Biol Blood Marrow Transplant
; 2007 Aug;13(8):956-64
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A 15-year analysis of early and late autologous hematopoietic stem
cell
transplant in relapsed, aggressive, transformed, and nontransformed follicular
lymphoma
.
Autologous stem
cell
transplant (ASCT) has been shown to be an effective treatment for follicular
lymphoma
(FL).
We explored our experience in ASCT for FL among all patients treated over a 15-year period from
diagnosis
through their entire treatment history including relapse post ASCT.
The median OS from
diagnosis
was 16 years for the FL-NT.
Unpurged ASCT is an effective tool in the treatment of relapsed, aggressive FL-NT and FL-T, is superior to retreatment with standard chemotherapy, is effective at various stages of treatment, is likely to have a beneficial influence on the natural history of this
disease
, and the
disease
is amenable to salvage therapy post-ASCT relapse.
[MeSH-major]
Hematopoietic Stem
Cell
Transplantation / adverse effects.
Lymphoma
, Follicular / therapy. Neoplasm Recurrence, Local / therapy. Salvage Therapy / methods
[MeSH-minor]
Adult
. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Disease
-Free Survival. Female. Humans. Longitudinal Studies. Male. Middle Aged. Ontario. Retrospective Studies. Transplantation, Autologous / methods
Genetic Alliance.
consumer health - Follicular Lymphoma
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17640600.001).
[ISSN]
1083-8791
[Journal-full-title]
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
[ISO-abbreviation]
Biol. Blood Marrow Transplant.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
2.
Oyekunle AA, Kröger N, Zabelina T, Ayuk F, Schieder H, Renges H, Fehse N, Waschke O, Fehse B, Kabisch H, Zander AR:
Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up.
Bone Marrow Transplant
; 2006 Jan;37(1):45-50
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Allogeneic stem-
cell
transplantation in patients with refractory
acute leukemia
: a long-term follow-up.
We examined retrospectively 44 patients with refractory
acute leukemia
(
acute
myeloid
leukemia
(AML)/
acute
lymphoblastic
leukemia
=25/19) who underwent allogeneic transplantation at our center between 11/1990 and 04/2004.
All patients had graft-versus-host
disease
(GVHD) prophylaxis with cyclosporin and methotrexate.
Severe
acute
-GVHD and chronic-GVHD appeared in eight and 14 patients, respectively.
We conclude that patients with refractory
leukemia
can benefit from allogeneic BMT, especially with < or =20% marrow blast.
[MeSH-major]
Blast Crisis / therapy.
Leukemia
, Myeloid,
Acute
/ therapy. Precursor
Cell
Lymphoblastic
Leukemia
-
Lymphoma
/ therapy. Stem
Cell
Transplantation. Transplantation Conditioning
[MeSH-minor]
Adolescent.
Adult
. Busulfan / administration & dosage. Child. Child, Preschool. Cyclophosphamide / administration & dosage.
Disease
-Free Survival. Female. Graft vs Host
Disease
/ etiology. Graft vs Host
Disease
/ prevention & control. Humans. Male. Middle Aged. Myeloablative Agonists / administration & dosage. Retrospective Studies. Transplantation, Homologous. Whole-Body Irradiation / methods
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
BUSULFAN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16258531.001).
[ISSN]
0268-3369
[Journal-full-title]
Bone marrow transplantation
[ISO-abbreviation]
Bone Marrow Transplant.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Myeloablative Agonists; 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan
3.
Mori T, Aisa Y, Nakazato T, Yamazaki R, Shimizu T, Mihara A, Yamane A, Ikeda Y, Okamoto S:
Tacrolimus and methotrexate for the prophylaxis of graft-versus-host disease after unrelated donor cord blood transplantation for adult patients with hematologic malignancies.
Transplant Proc
; 2007 Jun;39(5):1615-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Tacrolimus and methotrexate for the prophylaxis of graft-versus-host
disease
after unrelated donor cord blood transplantation for
adult
patients with hematologic malignancies.
Eighteen patients with hematologic malignancies underwent cord blood transplantation (CBT) from unrelated donors after being conditioned with myeloablative or reduced-intensity regimens, and received tacrolimus and methotrexate (15 mg/m(2) on day 1, 10 mg/m(2) on days 3 and 6) as graft-versus-host
disease
(GVHD) prophylaxis.
Of the 16 evaluable patients, five and eight had grades I and II
acute
GVHD, respectively, and none had grades III/IV
acute
GVHD.
The cumulative incidence of grade II
acute
GVHD was 44.4%.
Of the 18 patients, 14 were alive and
disease
-free between 173 and 1514 days after CBT (median 746 days).
The probability of
disease
-free survival at 2 years was 79.1%.
These results, although in a retrospective study, suggested that tacrolimus and short-term methotrexate effectively prevented the occurrence of severe
acute
GVHD after unrelated CBT, and may contribute to a high survival rate.
[MeSH-major]
Cord Blood Stem
Cell
Transplantation / adverse effects. Graft vs Host
Disease
/ prevention & control. Hematologic Neoplasms / therapy. Methotrexate / therapeutic use. Tacrolimus / therapeutic use
[MeSH-minor]
Adult
.
Disease
-Free Survival. Female. Humans. Immunosuppressive Agents / therapeutic use.
Leukemia
/ therapy. Leukocyte Count.
Lymphoma
/ therapy. Male. Middle Aged. Myelodysplastic Syndromes / therapy. Neutrophils. Probability. Transplantation Conditioning
Genetic Alliance.
consumer health - Transplantation
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
METHOTREXATE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17580201.001).
[ISSN]
0041-1345
[Journal-full-title]
Transplantation proceedings
[ISO-abbreviation]
Transplant. Proc.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Immunosuppressive Agents; WM0HAQ4WNM / Tacrolimus; YL5FZ2Y5U1 / Methotrexate
Advertisement
4.
Heesch S, Goekbuget N, Stroux A, Tanchez JO, Schlee C, Burmeister T, Schwartz S, Blau O, Keilholz U, Busse A, Hoelzer D, Thiel E, Hofmann WK, Baldus CD:
Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia.
Haematologica
; 2010 Jun;95(6):942-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in
adult
acute
T-lymphoblastic
leukemia
.
BACKGROUND: The role of the Wilms tumor 1 gene (WT1) in
acute leukemias
has been underscored by mutations found in
acute
myeloid
leukemia
identifying patients with inferior survival.
Furthermore, aberrant expression of WT1 in
acute
myeloid
leukemia
was
associated
with an increased risk of relapse.
No larger studies have performed a combined approach including WT1 mutation and expression analyses in
acute
T-lymphoblastic
leukemia
.
DESIGN AND METHODS: We analyzed the WT1 mutations and the expression status in a total of 252 consecutive
adult
patients with newly diagnosed T-lymphoblastic
leukemia
, who were registered on the GMALL 06/99 and 07/03 protocols and had sufficient material available.
The GMALL protocols included intensive chemotherapy as well as stem
cell
transplantation according to a risk-based model with indication for stem
cell
transplantation in first complete remission for early and mature T-lymphoblastic
leukemia
patients; patients with thymic T-lymphoblastic
leukemia
were allocated to a standard risk group and treated with intensive chemotherapy.
In thymic T-lymphoblastic
leukemia
, WT1mut patients had an inferior relapse-free survival compared to WT1 wild-type patients.
T-lymphoblastic
leukemia
patients with aberrant WT1 expression (high or negative) showed a higher relapse rate and an inferior outcome compared to patients with intermediate WT1 expression.
In the standard risk group of thymic T-lymphoblastic
leukemia
, aberrant WT1 expression was predictive for an inferior relapse-free survival as compared to patients with intermediate expression.
CONCLUSIONS: WT1 mutations were
associated
with an inferior relapse-free survival in standard risk thymic T-lymphoblastic
leukemia
patients.
Moreover, altered expression
associated
with inferior outcome also suggests a role of WT1 in T-lymphoblastic
leukemia
and the potential use of molecularly-based treatment stratification to improve outcome.
[MeSH-major]
Gene Expression Regulation, Neoplastic. Genes, Wilms Tumor / physiology. Mutation / genetics. Precursor T-
Cell
Lymphoblastic
Leukemia
-
Lymphoma
/
diagnosis
. Precursor T-
Cell
Lymphoblastic
Leukemia
-
Lymphoma
/ genetics
[MeSH-minor]
Adolescent.
Adult
. Female. Humans. Male. Middle Aged. Prognosis. Survival Rate / trends. Young
Adult
Genetic Alliance.
consumer health - Acute Lymphoblastic Leukemia
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Leukemia. 1995 Oct;9(10):1783-6
[
7564526.001
]
[Cites]
Leukemia. 1995 Jun;9(6):1060-7
[
7596170.001
]
[Cites]
Exp Hematol. 1997 Apr;25(4):312-20
[
9131006.001
]
[Cites]
Leukemia. 1997 May;11(5):639-43
[
9180285.001
]
[Cites]
Blood. 1997 Aug 1;90(3):1217-25
[
9242555.001
]
[Cites]
Blood. 1998 Apr 15;91(8):2961-8
[
9531607.001
]
[Cites]
EMBO J. 1999 Jul 15;18(14):3990-4003
[
10406804.001
]
[Cites]
Hematology Am Soc Hematol Educ Program. 2004;:80-97
[
15561678.001
]
[Cites]
Leukemia. 2005 Aug;19(8):1416-23
[
15920493.001
]
[Cites]
Blood. 2005 Dec 15;106(13):4414-5
[
16326981.001
]
[Cites]
Blood. 2006 Feb 1;107(3):1116-23
[
16195338.001
]
[Cites]
Leukemia. 2006 Feb;20(2):254-63
[
16341043.001
]
[Cites]
Haematologica. 2006 Feb;91(2):270-1
[
16461320.001
]
[Cites]
J Clin Oncol. 2006 Apr 1;24(10):1507-15
[
16575000.001
]
[Cites]
Oncogene. 2006 Jul 13;25(30):4217-29
[
16518414.001
]
[Cites]
Leukemia. 2007 Mar;21(3):550-1; author reply 552
[
17205055.001
]
[Cites]
Leukemia. 2007 May;21(5):868-76
[
17361230.001
]
[Cites]
Expert Rev Mol Med. 2007;9(14):1-17
[
17524167.001
]
[Cites]
J Clin Oncol. 2007 Aug 20;25(24):3739-45
[
17646667.001
]
[Cites]
Leukemia. 2008 Apr;22(4):762-70
[
18185524.001
]
[Cites]
Leukemia. 2008 Jun;22(6):1154-60
[
18368072.001
]
[Cites]
J Clin Oncol. 2008 Oct 1;26(28):4595-602
[
18559874.001
]
[Cites]
J Clin Oncol. 2008 Nov 20;26(33):5429-35
[
18591546.001
]
[Cites]
Blood. 2009 Jul 30;114(5):1038-45
[
19494353.001
]
[Cites]
Blood. 2006 Apr 15;107(8):3303-12
[
16380455.001
]
[Cites]
EMBO J. 2001 Apr 17;20(8):1897-909
[
11296223.001
]
[Cites]
Leukemia. 2001 Dec;15(12):1914-22
[
11753613.001
]
[Cites]
Br J Haematol. 2002 Feb;116(2):409-20
[
11841446.001
]
[Cites]
Int J Hematol. 2003 Jun;77(5):463-70
[
12841384.001
]
[Cites]
Leukemia. 2003 Aug;17(8):1589-95
[
12886247.001
]
[Cites]
Leukemia. 2003 Dec;17(12):2474-86
[
14562124.001
]
[Cites]
N Engl J Med. 2004 Apr 15;350(16):1617-28
[
15084694.001
]
[Cites]
Blood. 2004 Jul 15;104(2):558-60
[
15044257.001
]
[Cites]
Haematologica. 2004 Aug;89(8):926-33
[
15339675.001
]
[Cites]
Science. 2004 Oct 8;306(5694):269-71
[
15472075.001
]
[Cites]
Blood. 1989 Apr;73(5):1247-58
[
2467704.001
]
[Cites]
J Biol Chem. 1994 Feb 25;269(8):6198-206
[
8119964.001
]
[Cites]
Hum Mutat. 1997;9(3):209-25
[
9090524.001
]
(PMID = 20435628.001).
[ISSN]
1592-8721
[Journal-full-title]
Haematologica
[ISO-abbreviation]
Haematologica
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Italy
[Other-IDs]
NLM/ PMC2878792
5.
Laybourn P:
The ups and downs of Tax and histones in adult T-cell leukemogenesis.
Future Oncol
; 2008 Jun;4(3):311-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The ups and downs of Tax and histones in
adult T
-
cell
leukemogenesis.
[MeSH-major]
Gene Products, tax / physiology. Histones / metabolism.
Leukemia
-
Lymphoma
,
Adult T
-
Cell
/ metabolism
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18518755.001).
[ISSN]
1744-8301
[Journal-full-title]
Future oncology (London, England)
[ISO-abbreviation]
Future Oncol
[Language]
eng
[Publication-type]
Editorial
[Publication-country]
England
[Chemical-registry-number]
0 / Gene Products, tax; 0 / Histones
6.
Archambault-Grenier MA, Roy J, Beauchemin N, Cohen S, Lachance S, Kiss T:
Munchausen's syndrome in the allogeneic stem cell transplantation setting: a rare but potentially devastating condition.
Bone Marrow Transplant
; 2010 Mar;45(3):600-1
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Munchausen's syndrome in the allogeneic stem
cell
transplantation setting: a rare but potentially devastating condition.
[MeSH-major]
Munchausen Syndrome /
diagnosis
. Munchausen Syndrome / psychology. Stem
Cell
Transplantation / psychology
[MeSH-minor]
Female. Humans. Precursor
Cell
Lymphoblastic
Leukemia
-
Lymphoma
/ psychology. Precursor
Cell
Lymphoblastic
Leukemia
-
Lymphoma
/ therapy. Transplantation, Homologous. Young
Adult
Genetic Alliance.
consumer health - Transplantation
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19668234.001).
[ISSN]
1476-5365
[Journal-full-title]
Bone marrow transplantation
[ISO-abbreviation]
Bone Marrow Transplant.
[Language]
eng
[Publication-type]
Case Reports; Letter
[Publication-country]
England
7.
Asgarian Omran H, Shabani M, Shahrestani T, Sarafnejad A, Khoshnoodi J, Vossough P, Faranoush M, Sharifian RA, Jeddi-Tehrani M, Rabbani H, Shokri F:
Immunophenotypic subtyping of leukemic cells from Iranian patients with acute lymphoblastic leukaemia: association to disease outcome.
Iran J Immunol
; 2007 Mar;4(1):15-25
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Immunophenotypic subtyping of leukemic cells from Iranian patients with
acute
lymphoblastic
leukaemia
: association to
disease
outcome.
BACKGROUND: Immunophenotypic characterization of the leukemic cells has been widely used as a tool for
diagnosis
, classification, stratification and prognosis of
leukaemia
.
OBJECTIVE: To investigate the immunophenotypic subtype profiles of Iranian patients with
acute
lymphoblastic
leukemia
(ALL) and its association to
disease
outcome.
Clinical
manifestations and laboratory findings of the patients did not reveal association with immunophenotypic subtypes of ALL, with the exception of mediastinal mass and WBC count at the time of
diagnosis
which were found to be significantly higher in patients with T-ALL compared with B-ALL (p=0.001 and 0.014), respectively.
CONCLUSION: Our results indicate that overall the immunophenotypic profile of Iranian ALL patients is similar to previous reports and it might be used for monitoring of minimal residual
disease
and prognosis.
[MeSH-major]
Immunophenotyping.
Leukemia
, B-
Cell
/ immunology. Precursor
Cell
Lymphoblastic
Leukemia
-
Lymphoma
/ immunology
[MeSH-minor]
Adult
. Child.
Disease
Progression. Humans. Iran / epidemiology. Predictive Value of Tests. Recurrence
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17652839.001).
[ISSN]
1735-1383
[Journal-full-title]
Iranian journal of immunology : IJI
[ISO-abbreviation]
Iran J Immunol
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Iran
8.
Di Sabatino A, Miceli E, Dhaliwal W, Biancheri P, Salerno R, Cantoro L, Vanoli A, De Vincenzi M, Blanco Cdel V, MacDonald TT, Corazza GR:
Distribution, proliferation, and function of Paneth cells in uncomplicated and complicated adult celiac disease.
Am J Clin Pathol
; 2008 Jul;130(1):34-42
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Distribution, proliferation, and function of Paneth cells in uncomplicated and complicated
adult
celiac
disease
.
Because controversies remain concerning Paneth
cell
numbers and function in celiac
disease
(CD), we quantified Paneth cells and
human
alpha-defensin (HD)-5 and HD-6 in 28 patients with uncomplicated CD, 8 patients with complicated CD (3 with ulcerative jejunoileitis, 2 with refractory sprue, and 3 with enteropathy-
associated
T-
cell lymphoma
), and 14 control subjects.
Paneth
cell
numbers and proliferation did not differ in uncomplicated untreated and treated CD and control cases.
Paneth
cell
numbers and alpha-defensins are unchanged in the mucosa in uncomplicated CD.
[MeSH-major]
Celiac
Disease
/ pathology. Paneth Cells / pathology
[MeSH-minor]
Adult
. Aged.
Cell
Proliferation. Duodenum / pathology. Female. Humans. Intestinal Mucosa / pathology. Ki-67 Antigen / analysis. Male. Middle Aged. RNA, Messenger / metabolism. alpha-Defensins / analysis
Genetic Alliance.
consumer health - Celiac Disease
.
MedlinePlus Health Information.
consumer health - Celiac Disease
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18550468.001).
[ISSN]
0002-9173
[Journal-full-title]
American journal of clinical pathology
[ISO-abbreviation]
Am. J. Clin. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Ki-67 Antigen; 0 / RNA, Messenger; 0 / alpha-Defensins; 0 / human neutrophil peptide 1
9.
Mark T, Jayabalan D, Coleman M, Pearse RN, Wang YL, Lent R, Christos PJ, Lee JW, Agrawal YP, Matthew S, Ely S, Mazumdar M, Cesarman E, Leonard JP, Furman RR, Chen-Kiang S, Niesvizky R:
Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.
Br J Haematol
; 2008 Dec;143(5):654-60
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are
associated
with a high degree of response in multiple myeloma.
The M-protein is the major reference measure for response in multiple myeloma (MM) and its correct interpretation is key to
clinical
management.
The emergence of oligoclonal banding is recognized as a benign
finding
in the postautologous stem
cell
transplantation setting (ASCT) for MM but its significance during non-myeloablative therapy is unknown.
ASIPs were not
associated
with new clonal plasma cells or other lymphoproliferative processes, and molecular remissions were documented.
Analogous to the ASCT experience, ASIPs do not signal incipient
disease
progression, but rather herald robust response.
Genetic Alliance.
consumer health - Multiple myeloma
.
MedlinePlus Health Information.
consumer health - Multiple Myeloma
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
DEXAMETHASONE
.
Hazardous Substances Data Bank.
THALIDOMIDE
.
Hazardous Substances Data Bank.
Clarithromycin
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Blood. 1994 Dec 15;84(12):4374-82
[
7994052.001
]
[Cites]
Nephrol Dial Transplant. 1997 Jun;12(6):1199-203
[
9198051.001
]
[Cites]
Blood. 1998 May 1;91(9):3518-23
[
9558413.001
]
[Cites]
Br J Haematol. 1998 Sep;102(5):1115-23
[
9753033.001
]
[Cites]
J Clin Oncol. 1999 Jan;17(1):208-15
[
10458235.001
]
[Cites]
Blood. 2005 Feb 15;105(4):1614-21
[
15507523.001
]
[Cites]
Mayo Clin Proc. 2006 May;81(5):693-703
[
16706268.001
]
[Cites]
Leukemia. 2006 Sep;20(9):1467-73
[
16855634.001
]
[Cites]
Nat Rev Immunol. 2006 Oct;6(10):741-50
[
16977339.001
]
[Cites]
Nat Immunol. 2007 Apr;8(4):419-29
[
17322888.001
]
[Cites]
Br J Haematol. 2004 Aug;126(3):348-54
[
15257706.001
]
[Cites]
Blood. 2003 Sep 1;102(5):1927-9
[
12738666.001
]
[Cites]
Leuk Lymphoma. 2002 Sep;43(9):1777-82
[
12685831.001
]
[Cites]
J Clin Oncol. 2000 Jun;18(11):2273-81
[
10829048.001
]
[Cites]
Bone Marrow Transplant. 2000 Apr;25(7):723-8
[
10745257.001
]
[Cites]
Clin Chem. 1991 Aug;37(8):1334-7
[
1907894.001
]
[Cites]
Blood. 1989 Dec;74(8):2764-8
[
2819246.001
]
[Cites]
Blood. 2008 Feb 1;111(3):1101-9
[
17989313.001
]
[Cites]
Blood. 1993 Jun 1;81(11):3153-7
[
8499649.001
]
(PMID = 18950461.001).
[ISSN]
1365-2141
[Journal-full-title]
British journal of haematology
[ISO-abbreviation]
Br. J. Haematol.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / K23 CA109260; United States / NCI NIH HHS / CA / K23 CA109260-01
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Immunoglobulins; 0 / Myeloma Proteins; 0 / multiple myeloma M-proteins; 4Z8R6ORS6L / Thalidomide; 7S5I7G3JQL / Dexamethasone; F0P408N6V4 / lenalidomide; H1250JIK0A / Clarithromycin
[Other-IDs]
NLM/ NIHMS453628; NLM/ PMC3626496
10.
Marchi E, Alinari L, Tani M, Stefoni V, Pimpinelli N, Berti E, Pagano L, Bernengo MG, Zaja F, Rupoli S, Pileri S, Baccarani M, Zinzani PL:
Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients.
Cancer
; 2005 Dec 1;104(11):2437-41
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Gemcitabine as frontline treatment for cutaneous T-
cell lymphoma
: phase II study of 32 patients.
BACKGROUND: Based on the activity of gemcitabine in heavily pretreated patients with cutaneous T-
cell lymphoma
(CTCL), the objective of the current study was to determine the role of gemcitabine in the treatment of patients with advanced, untreated CTCL.
METHODS: Between June 2002 and February 2004, 32 untreated patients with mycosis fungoides (MF) (n = 26 patients); peripheral T-
cell lymphoma
, unspecified (PTCLU) with exclusive skin involvement (n = 5 patients); and Sezary syndrome (SS) (n = 1 patient) were enrolled in a 7-institution, Phase II trial and treated with gemcitabine.
[MeSH-major]
Antimetabolites, Antineoplastic / therapeutic use. Antimetabolites, Antineoplastic / toxicity. Deoxycytidine / analogs & derivatives.
Lymphoma
, T-
Cell
, Cutaneous / drug therapy
[MeSH-minor]
Adult
. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Survival Analysis. Treatment Outcome
Genetic Alliance.
consumer health - Cutaneous T-Cell Lymphoma
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16216001.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Publication-type]
Clinical Trial, Phase II; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
11.
Pais-Correia AM, Sachse M, Guadagnini S, Robbiati V, Lasserre R, Gessain A, Gout O, Alcover A, Thoulouze MI:
Biofilm-like extracellular viral assemblies mediate HTLV-1 cell-to-cell transmission at virological synapses.
Nat Med
; 2010 Jan;16(1):83-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Biofilm-like extracellular viral assemblies mediate
HTLV
-1
cell
-to-
cell
transmission at virological synapses.
Human
T cell
leukemia virus
type 1 (
HTLV
-1) is
a lymphotropic
retrovirus whose
cell
-to-
cell
transmission requires
cell
contacts.
HTLV
-1-infected T lymphocytes form 'virological synapses', but the mechanism of
HTLV
-1 transmission remains poorly understood.
We show here that
HTLV
-1-infected T lymphocytes transiently store viral particles as carbohydrate-rich extracellular assemblies that are held together and attached to the
cell
surface by virally-induced extracellular matrix components, including collagen and agrin, and cellular linker proteins, such as tetherin and galectin-3.
Extracellular viral assemblies rapidly adhere to other cells upon
cell
contact, allowing
virus
spread and infection of target cells.
Their removal strongly reduces the ability of
HTLV
-1-producing cells to infect target cells.
Our findings unveil a novel
virus
transmission mechanism based on the generation of extracellular viral particle assemblies whose structure, composition and function resemble those of bacterial biofilms.
HTLV
-1 biofilm-like structures represent a major route for
virus
transmission from
cell
to
cell
.
[MeSH-major]
CD4-
Positive
T-Lymphocytes / virology. Extracellular Matrix / virology.
HTLV
-I Infections / transmission.
Human
T-
lymphotropic virus
1 / physiology
[MeSH-minor]
Biofilms. Concanavalin A. Gene Products, env / metabolism. Humans. Microscopy, Electron, Transmission.
Virus
Assembly / physiology.
Virus
Attachment.
Virus
Internalization
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Nat Med. 2010 Jan;16(1):25-7
[
20057417.001
]
(PMID = 20023636.001).
[ISSN]
1546-170X
[Journal-full-title]
Nature medicine
[ISO-abbreviation]
Nat. Med.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Gene Products, env; 11028-71-0 / Concanavalin A
12.
Yu Q, Minoda Y, Yoshida R, Yoshida H, Iha H, Kobayashi T, Yoshimura A, Takaesu G:
HTLV-1 Tax-mediated TAK1 activation involves TAB2 adapter protein.
Biochem Biophys Res Commun
; 2008 Jan 4;365(1):189-94
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
HTLV
-1 Tax-mediated TAK1 activation involves TAB2 adapter protein.
Human
T cell
leukemia virus
type 1 (
HTLV
-1) Tax is an oncoprotein that plays a crucial role in the proliferation and transformation of
HTLV
-1-infected T lymphocytes.
[MeSH-major]
Adaptor Proteins, Signal Transducing / metabolism. Gene Products, tax / metabolism.
Human
T-
lymphotropic virus
1 / metabolism. MAP Kinase Kinase Kinases / metabolism
[MeSH-minor]
Binding Sites.
Cell
Line. Humans. NF-kappa B / metabolism. Ubiquitin-Protein Ligases / metabolism
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17986383.001).
[ISSN]
1090-2104
[Journal-full-title]
Biochemical and biophysical research communications
[ISO-abbreviation]
Biochem. Biophys. Res. Commun.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Adaptor Proteins, Signal Transducing; 0 / Gene Products, tax; 0 / NF-kappa B; 0 / TAB2 protein, human; 0 / tax protein, Human T-lymphotrophic virus 1; EC 2.7.11.25 / MAP Kinase Kinase Kinases; EC 2.7.11.25 / MAP kinase kinase kinase 7; EC 6.3.2.19 / Ubiquitin-Protein Ligases
13.
Yano H, Ishida T, Inagaki A, Ishii T, Kusumoto S, Komatsu H, Iida S, Utsunomiya A, Ueda R:
Regulatory T-cell function of adult T-cell leukemia/lymphoma cells.
Int J Cancer
; 2007 May 1;120(9):2052-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Regulatory T-
cell
function of
adult T
-
cell
leukemia
/
lymphoma
cells.
Adult T
-
cell
leukemia
/
lymphoma
(
ATLL
) patients are highly immunocompromised, but the underlying mechanism responsible for this state remains obscure.
Recent studies demonstrated that FOXP3, which is a master control gene of naturally occurring regulatory T (Treg) cells, is expressed in the tumor cells from a subset of patients with
ATLL
.
Since most
ATLL
cells express both CD4 and CD25, these tumors might originate from CD4(+)CD25(+)FOXP3(+) Treg cells, based on their phenotypic characteristics.
However, whether
ATLL
cells actually function as Treg cells has not yet been clearly demonstrated.
Here, we show that
ATLL
cells from a subset of patients are not only hypo-responsive to T-
cell
receptor-mediated activation, but also suppress the proliferation of autologous CD4(+) non-
ATLL
cells.
Furthermore,
ATLL
cells from this subset of patients secrete only small amounts of IFN-gamma, and suppress IFN-gamma production by autologous CD4(+) non-
ATLL
cells.
These are the first data showing that
ATLL
cells from a subset of patients function as Treg cells in an autologous setting.
The present study provides novel insights into understanding the immunopathogenesis of
ATLL
, i.e., how
HTLV
-1-infected cells can survive in the face of host immune responses.
It also adds to our understanding of
ATLL
patients' severely immunocompromised state.
[MeSH-major]
Leukemia
-
Lymphoma
,
Adult T
-
Cell
/ immunology. T-Lymphocytes, Regulatory / physiology
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2007 Wiley-Liss, Inc.
(PMID = 17278106.001).
[ISSN]
0020-7136
[Journal-full-title]
International journal of cancer
[ISO-abbreviation]
Int. J. Cancer
[Language]
eng
[Databank-accession-numbers]
ClinicalTrials.gov/ NCT00355472
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / CCR4 protein, human; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / RNA, Messenger; 0 / Receptors, CCR4; 0 / Receptors, Chemokine; 82115-62-6 / Interferon-gamma
14.
Grabher C, von Boehmer H, Look AT:
Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia.
Nat Rev Cancer
; 2006 May;6(5):347-59
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Notch 1 activation in the molecular pathogenesis of T-
cell
acute
lymphoblastic
leukaemia
.
The chromosomal translocation t(7;9) in
human
T-
cell
acute
lymphoblastic
leukaemia
(T-ALL) results in deregulated expression of a truncated, activated form of Notch 1 (TAN1) under the control of the T-
cell
receptor-beta (TCRB) locus.
Although TAN1 efficiently induces T-ALL in mouse models, t(7;9) is present in less than 1% of
human
T-ALL cases.
The recent discovery of novel activating mutations in NOTCH1 in more than 50% of
human
T-ALL samples has made it clear that Notch 1 is far more important in
human
T-ALL pathogenesis than previously suspected.
[MeSH-major]
Gene Expression Regulation, Leukemic.
Leukemia
-
Lymphoma
,
Adult T
-
Cell
/ metabolism. Receptor, Notch1 / metabolism
COS Scholar Universe.
author profiles
.
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16612405.001).
[ISSN]
1474-175X
[Journal-full-title]
Nature reviews. Cancer
[ISO-abbreviation]
Nat. Rev. Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
[Publication-country]
England
[Chemical-registry-number]
0 / NOTCH1 protein, human; 0 / Receptor, Notch1
[Number-of-references]
175
15.
Pennanen H, Kuittinen O, Soini Y, Turpeenniemi-Hujanen T:
Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma.
Eur J Haematol
; 2008 Oct;81(4):289-97
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular
lymphoma
.
OBJECTIVES: p53 mutations and high protein expression are
associated
with adverse prognosis in several
lymphoma
subtypes.
Matrix metalloproteinase-9 (MMP-9) has also been found to correlate with poor survival in
all lymphomas
studied.
The data concerning the
clinical
role of protein expression of p53 or gelatinases and their inhibitors in follicular
lymphoma
are rare.
The purpose of this study was to evaluate the prognostic and
clinical
implications of the immunoreactive proteins p53, MMP-2, MMP-9, tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) and TIMP-2 in follicular
lymphoma
.
METHODS: The material consisted of 67 patients with primarily non-transformed follicular
lymphoma
.
CONCLUSIONS: In this study, p53 over-expression predicted both transformation to diffuse large B-
cell lymphoma
and poorer overall and cause-specific survival of patients with follicular
lymphoma
.
[MeSH-major]
Gene Expression Regulation, Leukemic.
Lymphoma
, Follicular / metabolism. Matrix Metalloproteinase 9 / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis
[MeSH-minor]
Adult
. Aged. Aged, 80 and over.
Disease
-Free Survival. Female. Humans. Immunochemistry. Lymph Nodes / metabolism. Lymph Nodes / pathology.
Lymphoma
, Large B-
Cell
, Diffuse / drug therapy.
Lymphoma
, Large B-
Cell
, Diffuse / metabolism.
Lymphoma
, Large B-
Cell
, Diffuse / mortality.
Lymphoma
, Large B-
Cell
, Diffuse / pathology. Male. Matrix Metalloproteinase 2 / biosynthesis. Middle Aged. Predictive Value of Tests. Retrospective Studies. Survival Rate. Tissue Inhibitor of Metalloproteinase-1 / biosynthesis. Tissue Inhibitor of Metalloproteinase-2 / biosynthesis
Genetic Alliance.
consumer health - Follicular Lymphoma
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18616513.001).
[ISSN]
1600-0609
[Journal-full-title]
European journal of haematology
[ISO-abbreviation]
Eur. J. Haematol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Denmark
[Chemical-registry-number]
0 / TP53 protein, human; 0 / Tissue Inhibitor of Metalloproteinase-1; 0 / Tumor Suppressor Protein p53; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.24 / MMP2 protein, human; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
16.
Luther N, Greenfield JP, Chadburn A, Schwartz TH:
Intracranial nasal natural killer/T-cell lymphoma: immunopathologically-confirmed case and review of literature.
J Neurooncol
; 2005 Nov;75(2):185-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Intracranial nasal natural killer/T-
cell lymphoma
: immunopathologically-confirmed case and review of literature.
Advances in immunophenotypic profiling now permit characterization of natural killer/T-
cell
(NK/T-
cell
)
lymphoma
as distinct from other extranodal T- and B-
cell
Non-Hodgkin's
lymphomas
.
NK/T-
cell lymphoma
presents most commonly in the nasal cavity.
Disease
progression to the central nervous system (CNS) is a rare phenomenon.
We present here, to our knowledge, the first immunophenotypically-confirmed case of direct extension of nasal NK/T-
cell lymphoma
to the brain.
In addition, we review the literature with respect to NK/T-
cell lymphoma
metastasis to the CNS.
The overall prevalence of NK/T-
cell lymphoma
CNS metastasis is less than 3%.
[MeSH-major]
Killer Cells, Natural / pathology.
Lymphoma
, T-
Cell
/ immunology.
Lymphoma
, T-
Cell
/ pathology. Nose Neoplasms / immunology. Nose Neoplasms / pathology
[MeSH-minor]
Adult
. Anti-Bacterial Agents / therapeutic use. Antigens, CD3 / immunology. Antigens, CD4 / immunology. Antigens, CD56 / immunology. Craniotomy. Fatal Outcome. Follow-Up Studies. Humans. Immunophenotyping. Magnetic Resonance Imaging. Male. Pseudomonas aeruginosa / drug effects. Pseudomonas aeruginosa / isolation & purification. Staphylococcus aureus / drug effects. Staphylococcus aureus / isolation & purification. Time Factors
MedlinePlus Health Information.
consumer health - Nasal Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Blood. 2004 Jan 1;103(1):216-21
[
12933580.001
]
[Cites]
J Clin Oncol. 2000 Jan;18(1):54-63
[
10623693.001
]
[Cites]
Int J Cancer. 1984 Aug 15;34(2):143-8
[
6381328.001
]
[Cites]
Am J Surg Pathol. 1999 Nov;23(11):1356-69
[
10555004.001
]
[Cites]
Am J Hematol. 1999 Feb;60(2):161-3
[
9929112.001
]
[Cites]
Acta Oncol. 1997;36(3):307-11
[
9208902.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1991 Apr;20(4):797-802
[
2004957.001
]
[Cites]
J Clin Oncol. 1995 Mar;13(3):666-70
[
7884427.001
]
[Cites]
J Clin Oncol. 2001 Sep 1;19(17):3766-70
[
11533100.001
]
[Cites]
Leuk Lymphoma. 2000 Sep;39(1-2):139-44
[
10975392.001
]
[Cites]
Clin Lab Haematol. 2000 Aug;22(4):215-20
[
11012633.001
]
[Cites]
Am J Surg Pathol. 1996 Jan;20(1):103-11
[
8540601.001
]
[Cites]
Leuk Lymphoma. 2001 Nov-Dec;42(6):1297-303
[
11911411.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):182-90
[
12182990.001
]
[Cites]
Acta Oncol. 2003;42(7):779-83
[
14690165.001
]
[Cites]
Am J Ophthalmol. 2002 Sep;134(3):406-10
[
12208253.001
]
[Cites]
Curr Opin Oncol. 2003 Sep;15(5):353-62
[
12960516.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1228-33
[
11728681.001
]
[Cites]
Hematology Am Soc Hematol Educ Program. 2001;:259-81
[
11722988.001
]
[Cites]
Histopathology. 1995 Aug;27(2):139-48
[
8835262.001
]
[Cites]
J Clin Oncol. 1998 Jan;16(1):70-7
[
9440725.001
]
[Cites]
Med Oncol. 2003;20(1):13-7
[
12665679.001
]
(PMID = 16283442.001).
[ISSN]
0167-594X
[Journal-full-title]
Journal of neuro-oncology
[ISO-abbreviation]
J. Neurooncol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Anti-Bacterial Agents; 0 / Antigens, CD3; 0 / Antigens, CD4; 0 / Antigens, CD56
[Number-of-references]
24
17.
Mebazaa A, Dupuy A, Rybojad M, Mouly F, Moulonguet I, Vignon-Pennamen MD, Rivet J, Janin A, Lebbé C, Dubertret L, Morel P, Bachelez H, Brice P:
ESHAP for primary cutaneous T-cell lymphomas: efficacy and tolerance in 11 patients.
Hematol J
; 2005;5(7):553-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
ESHAP for primary cutaneous T-
cell
lymphomas
: efficacy and tolerance in 11 patients.
Systemic multiagent hemotherapy has been used to treat aggressive forms of primary cutaneous T-
cell
lymphomas
(CTCL) with controversial results.
Two patients achieved complete remissions lasting 30+ and 6+ months, seven had partial remissions of short duration, one had stable
disease
and one experienced
disease
progression.
Genetic Alliance.
consumer health - Cutaneous T-Cell Lymphoma
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
Hazardous Substances Data Bank.
CYTARABINE
.
Hazardous Substances Data Bank.
CIS-DIAMINEDICHLOROPLATINUM
.
Hazardous Substances Data Bank.
ETOPOSIDE
.
Hazardous Substances Data Bank.
METHYLPREDNISOLONE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15692599.001).
[ISSN]
1466-4860
[Journal-full-title]
The hematology journal : the official journal of the European Haematology Association
[ISO-abbreviation]
Hematol. J.
[Language]
ENG
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone
18.
Lim Z, Gupta S, Salisbury JR, Elias D, Venkatram NK, Mufti GJ, Pagliuca A:
T-cell lymphoblastic lymphoma presenting as an intra-muscular mass.
Br J Haematol
; 2006 Mar;132(5):537
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
T-
cell
lymphoblastic
lymphoma
presenting as an intra-muscular mass.
[MeSH-major]
Fibula / pathology.
Lymphoma
, T-
Cell
, Peripheral /
diagnosis
. Magnetic Resonance Imaging. Muscle, Skeletal / pathology. Tibia / pathology
[MeSH-minor]
Adult
. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Leukemic Infiltration. Male. Positron-Emission Tomography. Testis / pathology
Genetic Alliance.
consumer health - Lymphoblastic lymphoma
.
MedlinePlus Health Information.
consumer health - MRI Scans
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16445824.001).
[ISSN]
0007-1048
[Journal-full-title]
British journal of haematology
[ISO-abbreviation]
Br. J. Haematol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
England
19.
Suzuki S, Uozumi K, Utsunomiya A, Ishitsuka K, Masamoto I, Owatari S, Makino T, White Y, Arima N:
Aggressive NK cell leukaemia after splenectomy: association with CD95-resistant memory T-cell proliferation and recalcitrant clinical course of haemophagocytic syndrome.
Eur J Haematol
; 2008 Sep;81(3):236-41
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Aggressive NK
cell
leukaemia
after splenectomy: association with CD95-resistant memory T-
cell
proliferation and recalcitrant
clinical
course of haemophagocytic syndrome.
We describe a 44-yr-old Japanese woman with persistent polyclonal T-
cell
proliferation and recalcitrant
clinical
course of haemophagocytic syndrome (HPS).
T cells bearing alphabeta T-
cell
receptors (TCR) expressed increased amounts of CD95 and of CD45RO, which are phenotypically memory T cells.
Aggressive natural killer
cell
leukaemia
(ANKL) without an association with Epstein-Barr
virus
was detected 1 month after therapeutic splenectomy that followed 3 yr of immunosuppressive therapy against HPS.
The immunophenotype of these
leukaemia
cells was CD56, CD16(dim), CD7, CD45RA and they expressed some CD2, CD8 and HLA-DR.
Latent NK-
cell
malignancy seemed to cause the CD95-resistant memory T-
cell
proliferation and splenectomy resulted in overt ANKL progression.
There should be careful consideration of the risks versus benefits of splenectomy in HPS, in light of the possibility of fatal
leukaemia
/
lymphoma
progression.
[MeSH-major]
Antigens, CD95 / physiology. Killer Cells, Natural / immunology.
Leukemia
/ immunology.
Leukemia
/ therapy. Lymphohistiocytosis, Hemophagocytic / immunology. Lymphohistiocytosis, Hemophagocytic / therapy. Splenectomy / adverse effects
[MeSH-minor]
Adult
.
Cell
Proliferation. Chromosome Aberrations.
Disease
Progression. Fatal Outcome. Female. Flow Cytometry. Follow-Up Studies. Humans. Immunophenotyping. Immunosuppressive Agents / therapeutic use. Karyotyping. Risk Factors
MedlinePlus Health Information.
consumer health - Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18510705.001).
[ISSN]
1600-0609
[Journal-full-title]
European journal of haematology
[ISO-abbreviation]
Eur. J. Haematol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Denmark
[Chemical-registry-number]
0 / Antigens, CD95; 0 / Immunosuppressive Agents
20.
Tesfa D, Gelius T, Sander B, Kimby E, Fadeel B, Palmblad J, Hägglund H:
Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis.
Med Oncol
; 2008;25(4):374-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Late-onset neutropenia
associated
with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis.
Late-onset neutropenia, i.e. an absolute neutrophil count of <1.5 x 10(9)/l, may follow 4 weeks or more after therapy with rituximab for
lymphoma
.
In a retrospective study of 113 consecutive
lymphoma
patients treated with rituximab, with or without chemotherapy, we found eight patients (7%) with late-onset neutropenia (LON).
Four of the eight patients underwent stem
cell
transplantation.
In four subsequently identified patients with severe LON, a maturation arrest at the (pro)myelocyte stage was observed in the bone marrow, similar to that found in severe congenital neutropenia or Kostmann
disease
.
[MeSH-minor]
Adaptor Proteins, Signal Transducing.
Adult
. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-
Derived
.
Cell
Differentiation / drug effects. DNA Mutational Analysis. Female. Humans.
Lymphoma
/ drug therapy. Male. Middle Aged. Proteins / genetics. Rituximab. Time
Hazardous Substances Data Bank.
RITUXIMAB
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Semin Hematol. 2002 Apr;39(2):113-20
[
11957194.001
]
[Cites]
Eur J Haematol Suppl. 2007 Jan;(67):5-14
[
17206982.001
]
[Cites]
Eur J Haematol Suppl. 1996;60:93-7
[
8987249.001
]
[Cites]
Haematologica. 2007 Feb;92(2):e20-3
[
17405749.001
]
[Cites]
Int J Hematol. 2006 Oct;84(3):242-7
[
17050199.001
]
[Cites]
Biol Blood Marrow Transplant. 2000;6(6):628-32
[
11128813.001
]
[Cites]
Acta Paediatr. 2007 Jun;96(6):813-9
[
17537008.001
]
[Cites]
Ann Pharmacother. 2005 Dec;39(12):2091-5
[
16249269.001
]
[Cites]
Autoimmun Rev. 2006 Jan;5(1):18-24
[
16338207.001
]
[Cites]
Curr Drug Metab. 2006 Apr;7(3):219-29
[
16611018.001
]
[Cites]
Blood. 2005 Aug 1;106(3):795-802
[
15718416.001
]
[Cites]
Br J Haematol. 2003 Jun;121(6):913-8
[
12786803.001
]
[Cites]
J Immunol. 2005 Jul 15;175(2):1232-8
[
16002727.001
]
[Cites]
Haematologica. 2004 Mar;89(3):361-3
[
15020279.001
]
[Cites]
Acta Paediatr. 2006 Dec;95(12):1526-32
[
17129957.001
]
[Cites]
Leuk Lymphoma. 2006 Jun;47(6):1013-7
[
16840190.001
]
[Cites]
Leuk Res. 2002 Jun;26(6):597-600
[
12007508.001
]
[Cites]
Bull Cancer. 2007 Feb;94(2):198-202
[
17337389.001
]
[Cites]
Cancer Treat Rev. 2005 Oct;31(6):456-73
[
16054760.001
]
[Cites]
Nature. 1996 Aug 15;382(6592):635-8
[
8757135.001
]
[Cites]
Semin Hematol. 2006 Jul;43(3):189-95
[
16822461.001
]
[Cites]
Blood. 2004 May 1;103(9):3355-61
[
14764541.001
]
[Cites]
Bone Marrow Transplant. 2004 May;33(9):921-3
[
15034544.001
]
[Cites]
Nat Genet. 2007 Jan;39(1):86-92
[
17187068.001
]
[Cites]
Br J Haematol. 2005 Apr;129(2):275-8
[
15813856.001
]
[Cites]
Ann Oncol. 2007 Feb;18(2):364-9
[
17079695.001
]
[Cites]
N Engl J Med. 2003 Jun 26;348(26):2691-4; discussion 2691-4
[
12826650.001
]
(PMID = 18278570.001).
[ISSN]
1357-0560
[Journal-full-title]
Medical oncology (Northwood, London, England)
[ISO-abbreviation]
Med. Oncol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Adaptor Proteins, Signal Transducing; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / HAX1 protein, human; 0 / Proteins; 4F4X42SYQ6 / Rituximab
21.
Ngeow JY, Quek RH, Ng DC, Hee SW, Tao M, Lim LC, Tan YH, Lim ST:
High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma.
Ann Oncol
; 2009 Sep;20(9):1543-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
High SUV uptake on FDG-PET/CT predicts for an aggressive B-
cell lymphoma
in a prospective study of primary FDG-PET/CT staging in
lymphoma
.
BACKGROUND: Data assessing the role of positron emission tomography (PET)/computed tomography (CT) imaging in
lymphoma
staging is still being accumulated and current staging is based primarily on CT.
This study aims to compare the value of PET/CT over conventional CT and bone marrow biopsy (BMB) in the initial evaluation of patients with
lymphoma
.
RESULTS: Among the 122 patients, 101 had non-Hodgkin's
lymphoma
(NHL) and 21 had Hodgkin's
lymphoma
(HL).
Compared with conventional CT, PET/CT upstaged 21 (17%) cases [B-
cell
non-Hodgkin's
lymphoma
(B-NHL), 12; T-
cell
non-Hodgkin's
lymphoma
(T-NHL), 3; HL, 6].
A maximum FDG uptake of >10 standardized uptake value (SUV) seems to significantly correlate with an aggressive B-
cell
lineage (odds ratio 2.47, 95% confidence interval 2.23-2.70).
In HL, our data show that PET scan and marrow results agreed in 19 of the cases (90%), being concordantly negative in 18 cases and concordantly
positive
in one, giving a negative predictive value (NPV) of 100%, sensitivity of 100% and specificity of 90%.
In patients with aggressive B-NHL, BMB and PET/CT agreed in 58 patients (92%) and disagreed in five (8%), while the corresponding rates in indolent B-
cell lymphoma
were 14 (67%) and seven patients (33%), respectively.
MedlinePlus Health Information.
consumer health - CT Scans
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19474116.001).
[ISSN]
1569-8041
[Journal-full-title]
Annals of oncology : official journal of the European Society for Medical Oncology
[ISO-abbreviation]
Ann. Oncol.
[Language]
ENG
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0Z5B2CJX4D / Fluorodeoxyglucose F18
22.
Miura H, Maeda M, Yamamoto N, Yamaoka S:
Distinct IkappaB kinase regulation in adult T cell leukemia and HTLV-I-transformed cells.
Exp Cell Res
; 2005 Aug 1;308(1):29-40
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Distinct IkappaB kinase regulation in
adult T cell
leukemia
and
HTLV
-I-transformed cells.
We have recently shown constitutive IkappaB kinase (IKK) activation and aberrant p52 expression in
adult T cell
leukemia
(
ATL
) cells that do not express
human
T cell
leukemia virus
type I (
HTLV
-I) Tax, but the mechanism of IKK activation in these cells has remained unknown.
Here, we demonstrate distinct regulation of IKK activity in
ATL
and
HTLV
-I-transformed T cells in response to protein synthesis inhibition or arsenite treatment.
Protein synthesis inhibition for 4 h by cycloheximide (CHX) barely affects IKK activity in Tax-
positive HTLV
-I-transformed cells, while it diminishes IKK activity in Tax-negative
ATL
cells.
Treatment of
ATL
cells with a proteasome inhibitor MG132 prior to protein synthesis inhibition reverses the inhibitory effect of CHX, and MG132 alone greatly enhances IKK activity.
In addition, treatment of
HTLV
-I-transformed cells with arsenite for 1 h results in down-regulation of IKK activity without affecting Tax expression, while 8 h of arsenite treatment does not impair IKK activity in
ATL
cells.
These results indicate that a labile protein sensitive to proteasome-dependent degradation governs IKK activation in
ATL
cells, and suggest a molecular mechanism of IKK activation in
ATL
cells distinct from that in
HTLV
-I-transformed T cells.
[MeSH-major]
Cell
Transformation, Viral / physiology.
Leukemia
-
Lymphoma
,
Adult T
-
Cell
/ metabolism. Protein-Serine-Threonine Kinases / metabolism
[MeSH-minor]
Arsenites / pharmacology.
Cell
Line, Transformed.
Cell
Line, Tumor. Cycloheximide / antagonists & inhibitors. Cycloheximide / pharmacology. Enzyme Inhibitors / pharmacology.
Human
T-
lymphotropic virus
1 / physiology. Humans. I-kappa B Kinase. Leupeptins / pharmacology. Proteasome Endopeptidase Complex / metabolism. Protein Synthesis Inhibitors / pharmacology. T-Lymphocytes / drug effects. T-Lymphocytes / metabolism
Hazardous Substances Data Bank.
CYCLOHEXIMIDE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15878527.001).
[ISSN]
0014-4827
[Journal-full-title]
Experimental cell research
[ISO-abbreviation]
Exp. Cell Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Arsenites; 0 / Enzyme Inhibitors; 0 / Leupeptins; 0 / Protein Synthesis Inhibitors; 133407-82-6 / benzyloxycarbonylleucyl-leucyl-leucine aldehyde; 98600C0908 / Cycloheximide; EC 2.7.1.- / IKBKE protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.10 / CHUK protein, human; EC 2.7.11.10 / I-kappa B Kinase; EC 2.7.11.10 / IKBKB protein, human; EC 3.4.25.1 / Proteasome Endopeptidase Complex; N5509X556J / arsenite
23.
Khosravi Shahi P, Díaz Muñoz de la Espada VM:
[Extranodal T/NK-cell lymphoma, nasal type: a case report and review of the literature].
An Med Interna
; 2005 Dec;22(12):597-600
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Extranodal T/NK-
cell lymphoma
, nasal type: a case report and review of the literature].
[Transliterated title]
Linfoma
T/NK extraganglionar tipo nasal: caso clínico y revisión
de
la literatura.
Extranodal T/NK-
cell lymphoma
, nasal type: a case report and review of the literature.
Extranodal NK/T-
cell lymphoma
, nasal type, is an extranodal
lymphoma
, usually with an NK-
cell
phenotype and EBV
positive
, with a broad
morphologic
spectrum, frequent necrosis and angioinvasion, and most commonly presenting in the midfacial region, but also in other extranodal sites.
The
diagnosis
of the case was Extranodal T/NK-
cell lymphoma
, nasal type.
There was not disseminated
disease
in the extent studies.
With the
diagnosis
of localized extranodal T/NK-
cell lymphoma
and reactive thrombocytosis, the patient was treated with chemotherapy and sequential radiotherapy, followed by bone marrow transplantation.
[MeSH-major]
Killer Cells, Natural.
Lymphoma
, T-
Cell
/ pathology. Nose Neoplasms / pathology
[MeSH-minor]
Adult
. Humans. Immunophenotyping. Male
MedlinePlus Health Information.
consumer health - Nasal Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16454602.001).
[ISSN]
0212-7199
[Journal-full-title]
Anales de medicina interna (Madrid, Spain : 1984)
[ISO-abbreviation]
An Med Interna
[Language]
spa
[Publication-type]
Case Reports; English Abstract; Journal Article; Review
[Publication-country]
Spain
[Number-of-references]
16
24.
Wain EM, Antony F, Appleton MA, Whittaker SJ, Robson A:
Genital herpes masquerading as a cutaneous T-cell lymphoma: a report of two cases.
J Cutan Pathol
; 2008 Aug;35(8):770-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Genital herpes masquerading as a cutaneous T-
cell lymphoma
: a report of two cases.
Genital herpes simplex
virus
(HSV) infection is usually a straightforward
clinical diagnosis
, rarely requiring histological confirmation.
We report two cases of immunosuppressed patients in which the
clinical
and pathological features were initially suspicious for cutaneous
lymphoma
with a T-
cell
clone detected in one case.
A diagnosis
of HSV infection was eventually made on the basis of histological features and confirmed with immunohistochemistry.
[MeSH-major]
Herpes Genitalis / pathology. Immunocompromised Host.
Lymphoma
, T-
Cell
, Cutaneous / pathology
[MeSH-minor]
Adult
.
Diagnosis
, Differential. Humans. Immunohistochemistry / methods. Male
Genetic Alliance.
consumer health - Cutaneous T-Cell Lymphoma
.
MedlinePlus Health Information.
consumer health - Genital Herpes
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18422691.001).
[ISSN]
1600-0560
[Journal-full-title]
Journal of cutaneous pathology
[ISO-abbreviation]
J. Cutan. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Denmark
25.
Karaosmanoglu D, Karcaaltincaba M, Oguz B, Akata D, Ozmen M, Akhan O:
CT findings of lymphoma with peritoneal, omental and mesenteric involvement: peritoneal lymphomatosis.
Eur J Radiol
; 2009 Aug;71(2):313-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
CT findings of
lymphoma
with peritoneal, omental and mesenteric involvement: peritoneal lymphomatosis.
PURPOSE: We aimed to describe computed tomography (CT) findings in patients with peritoneal, omental and mesenteric
lymphoma
involvement.
MATERIALS AND METHODS: We searched our archive retrospectively to find out patients with peritoneal, omental and mesenteric
lymphoma
involvement.
We found 16 patients with non-Hodgkin
lymphoma
meeting these criteria.
CT studies of these patients were reevaluated for the presence of peritoneal involvement, ascites, omental mass, organomegaly, retroperitoneal lymphadenopathy, bowel wall thickening and other
associated
findings.
RESULTS: There were 14 males and 2 females with peritoneal and/or mesenteric and omental
lymphoma
involvement.
Subgroups of non-Hodgkin
lymphoma
were diffuse large B-
cell lymphoma
(n=11), small
cell
lymphocytic
lymphoma
(n=2), small cleaved
cell lymphoma
(n=1), T-
cell lymphoma
(n=1) and Burkitt's
lymphoma
(n=1).
CONCLUSION: Peritoneal involvement can be seen in many subtypes of
lymphoma
and most frequently in diffuse large B-
cell lymphoma
.
Peritoneal lymphomatosis can mimic peritoneal carcinomatosis and should be included in the differential
diagnosis
list in patients with ascites, hepatosplenic lesions and unidentified cause of peritoneal thickening on CT in a male patient.
[MeSH-major]
Lymphoma
/ radiography. Mesentery / radiography. Omentum / radiography. Peritoneal Neoplasms / radiography. Tomography, X-Ray Computed / methods
[MeSH-minor]
Adolescent.
Adult
. Aged. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Retrospective Studies. Young
Adult
MedlinePlus Health Information.
consumer health - CT Scans
.
MedlinePlus Health Information.
consumer health - Lymphoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18513906.001).
[ISSN]
1872-7727
[Journal-full-title]
European journal of radiology
[ISO-abbreviation]
Eur J Radiol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Ireland
26.
Parker NP, Pearlman AN, Conley DB, Kern RC, Chandra RK:
The dilemma of midline destructive lesions: a case series and diagnostic review.
Am J Otolaryngol
; 2010 Mar-Apr;31(2):104-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: Midline destructive lesions (MDLs) of the nose are a diagnostic dilemma due to an extensive differential
diagnosis
and vague presenting signs and symptoms.
Laboratory tests included complete blood count, basic metabolic panel, erythrocyte sedimentation rate, angiotensin-converting enzyme, antineutrophil antibodies, rheumatoid factor, anti-Ro and anti-La antibodies, Epstein-Barr
virus
antibodies, coccidiomycosis serology, HIV antibodies, fluorescent treponemal antibody absorption, classic antineutrophil cytoplasmic antibodies, perinuclear antineutrophil cytoplasmic antibody, proteinase 3, and myeloperoxidase.
Two patients were diagnosed with natural killer/T-
cell lymphoma
, 2 were diagnosed with Wegener's granulomatosis, and 4 remained idiopathic, despite the extensive workup.
CONCLUSIONS: The
diagnosis
of MDLs remains difficult but is aided by a systematic approach and familiarity with multiple diagnostic techniques.
It is imperative to take multiple tissue specimens from various sites, send them fresh, and communicate suspicion of
lymphoma
.
[MeSH-major]
Granuloma, Lethal Midline /
diagnosis
[MeSH-minor]
Adult
. Algorithms.
Diagnosis
, Differential. Female. Granulomatosis with Polyangiitis /
diagnosis
. Humans.
Lymphoma
, T-
Cell
/
diagnosis
. Male. Middle Aged
COS Scholar Universe.
author profiles
.
HIV InSite.
treatment guidelines - Cardiac Cardiac Manifestations of HIV
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright (c) 2010 Elsevier Inc. All rights reserved.
(PMID = 20015726.001).
[ISSN]
1532-818X
[Journal-full-title]
American journal of otolaryngology
[ISO-abbreviation]
Am J Otolaryngol
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
25
27.
Ohsugi T, Kumasaka T, Okada S, Ishida T, Yamaguchi K, Horie R, Watanabe T, Umezawa K:
Dehydroxymethylepoxyquinomicin (DHMEQ) therapy reduces tumor formation in mice inoculated with tax-deficient adult T-cell leukemia-derived cell lines.
Cancer Lett
; 2007 Nov 18;257(2):206-15
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Dehydroxymethylepoxyquinomicin (DHMEQ) therapy reduces tumor formation in mice inoculated with tax-deficient
adult T
-
cell
leukemia
-
derived
cell
lines.
Adult T
-
cell
leukemia
(
ATL
) is an aggressive neoplasm caused by
human
T-
cell
leukemia virus
type I (
HTLV
-I), which induces nuclear factor-kappaB (NF-kappaB), a molecule central to the ensuing neoplasia.
The NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) has been shown to inhibit NF-kappaB activation in Tax-expressing
HTLV
-I-infected cells.
In this study, we used NOD/SCID beta2-microglobulin(null) mice to show that intraperitoneal inoculation with Tax-deficient
ATL
cell
lines caused rapid death, whereas DHMEQ-treated mice survived.
Furthermore, DHMEQ treatment after subcutaneous inoculation inhibited the growth of transplanted
ATL
cells.
These results demonstrate that DHMEQ has therapeutic efficacy on
ATL
cells, regardless of Tax expression.
[MeSH-major]
Benzamides / pharmacology. Cyclohexanones / pharmacology. Gene Products, tax / deficiency.
Leukemia
, T-
Cell
/ prevention & control. Xenograft Model Antitumor Assays / methods
[MeSH-minor]
Adult
. Animals. Apoptosis / drug effects.
Cell
Line, Tumor.
Human
T-
lymphotropic virus
1 / genetics.
Human
T-
lymphotropic virus
1 / metabolism. Humans. Mice. Mice, Inbred NOD. Mice, Knockout. Mice, SCID. NF-kappa B / antagonists & inhibitors. NF-kappa B / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis. Tumor Burden. beta 2-Microglobulin / genetics. beta 2-Microglobulin / metabolism
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17764832.001).
[ISSN]
0304-3835
[Journal-full-title]
Cancer letters
[ISO-abbreviation]
Cancer Lett.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Ireland
[Chemical-registry-number]
0 / Benzamides; 0 / Cyclohexanones; 0 / Gene Products, tax; 0 / NF-kappa B; 0 / RNA, Messenger; 0 / beta 2-Microglobulin; 0 / dehydroxymethylepoxyquinomicin
28.
Tanosaki R, Uike N, Utsunomiya A, Saburi Y, Masuda M, Tomonaga M, Eto T, Hidaka M, Harada M, Choi I, Yamanaka T, Kannagi M, Matsuoka M, Okamura J:
Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome.
Biol Blood Marrow Transplant
; 2008 Jun;14(6):702-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Allogeneic hematopoietic stem
cell
transplantation using reduced-intensity conditioning for
adult T cell
leukemia
/
lymphoma
: impact of antithymocyte globulin on
clinical
outcome.
Allogeneic hematopoietic stem
cell
transplantation (HSCT) is an effective treatment for
adult T cell
leukemia
/
lymphoma
(
ATLL
), but shows high mortality.
We evaluated the feasibility of reduced-intensity transplantation using fludarabine and busulfan, with particular focus on the
clinical
impact of antithymocyte globulin (ATG) in the conditioning regimen.
Fourteen elderly patients with aggressive
ATLL
were enrolled in the current study without ATG, and were compared to those in 15 patients who were treated similarly, but with ATG, in our previous study.
Analysis of combined data from both our current and previous studies disclosed that grade I-II
acute
GVHD was the only factor that favorably affected OS and PFS.
These data suggested the presence of a graft-versus-
ATLL
effect and the feasibility of a transplant procedure without ATG in elderly
ATLL
patients, but could not demonstrate the
clinical
benefit of incorporating ATG.
[MeSH-major]
Antilymphocyte Serum / therapeutic use. Hematopoietic Stem
Cell
Transplantation. Immunosuppressive Agents / therapeutic use.
Leukemia
-
Lymphoma
,
Adult T
-
Cell
/ surgery. Transplantation Conditioning / methods
[MeSH-minor]
Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy.
Disease
-Free Survival. Feasibility Studies. Female. Graft vs Host
Disease
/ etiology. Graft vs Host
Disease
/ mortality. Graft vs Host
Disease
/ prevention & control.
Human
T-
lymphotropic virus
1 / isolation & purification. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Proportional Hazards Models. Proviruses / isolation & purification. Survival Analysis. T-Lymphocytes. Transplantation, Homologous. Treatment Outcome
Genetic Alliance.
consumer health - Transplantation
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18489996.001).
[ISSN]
1523-6536
[Journal-full-title]
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
[ISO-abbreviation]
Biol. Blood Marrow Transplant.
[Language]
eng
[Publication-type]
Clinical Trial, Phase I; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antilymphocyte Serum; 0 / Immunosuppressive Agents
29.
Li SL, Zhang XL, Han HX, Chen B:
[Imaging features of primary bone lymphoma and its histopathology].
Nan Fang Yi Ke Da Xue Xue Bao
; 2007 Feb;27(2):201-4
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Imaging features of primary bone
lymphoma
and its histopathology].
OBJECTIVE: To study the imaging features of primary bone of the
lymphoma
PLB on X-ray, CT and magnetic resonance imaging (MRI).
Histological examination identified B-
cell lymphoma
in 5 cases and T-
cell lymphoma
in 4 cases.
[MeSH-major]
Bone Neoplasms / radiography.
Lymphoma
/ radiography. Magnetic Resonance Imaging / methods. Tomography, X-Ray Computed / methods
[MeSH-minor]
Adolescent.
Adult
. Child. Female. Humans. Male. Middle Aged. Retrospective Studies
MedlinePlus Health Information.
consumer health - Bone Cancer
.
MedlinePlus Health Information.
consumer health - CT Scans
.
MedlinePlus Health Information.
consumer health - Lymphoma
.
MedlinePlus Health Information.
consumer health - MRI Scans
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17355937.001).
[ISSN]
1673-4254
[Journal-full-title]
Nan fang yi ke da xue xue bao = Journal of Southern Medical University
[ISO-abbreviation]
Nan Fang Yi Ke Da Xue Xue Bao
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
30.
Falini B, Nicoletti I, Bolli N, Martelli MP, Liso A, Gorello P, Mandelli F, Mecucci C, Martelli MF:
Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias.
Haematologica
; 2007 Apr;92(4):519-32
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Translocations and mutations involving the nucleophosmin (NPM1) gene in
lymphomas
and
leukemias
.
The gene NPM1 that encodes for nucleophosmin (NPM1) is translocated or mutated in various
lymphomas
and
leukemias
, forming fusion proteins (NPM-ALK, NPM-RARalpha, NPM-MLF1) or NPM mutant products.
Here, we review the structure and functions of NPM, as well as the biological,
clinical
and pathological features of
human
hematologic malignancies with NPM1 gene alterations.
NPM-ALK indentifies a new category of T/Null
lymphomas
with distinctive molecular and clinico-pathological features, that is going to be included as a novel
disease
entity (ALK+ anaplastic large
cell lymphoma
) in the new WHO classification of lymphoid neoplasms.
NPM1 mutations occur specifically in about 30% of
adult
de
novo AML and cause aberrant cytoplasmic expression of NPM (hence the term NPMc+ AML).
NPMc+ AML associates with normal karyotpe, and shows wide morphological spectrum, multilineage involvement, a unique gene expression signature, a high frequency of FLT3-internal tandem duplications, and distinctive
clinical
and prognostic features.
The availability of specific antibodies and molecular techniques for the detection of NPM1 gene alterations has an enormous impact in the biological study
diagnosis
, prognostic stratification, and monitoring of minimal residual
disease
of various
lymphomas
and
leukemias
.
[MeSH-major]
Leukemia
, Myeloid / genetics.
Lymphoma
, Large-
Cell
, Anaplastic / genetics. Nuclear Proteins / physiology
[MeSH-minor]
Acute Disease
.
Adult
. Age of Onset. Alternative Splicing. Amino Acid Motifs. Biological Transport.
Cell
Nucleolus / metabolism.
Cell
Nucleus / metabolism. Child. Chromosomes,
Human
, Pair 5 / genetics. Cytoplasm / metabolism. Humans. Karyotyping. Mutation. Neoplasm Proteins / genetics. Neoplasm Proteins / physiology. Oncogene Proteins, Fusion / genetics. Oncogene Proteins, Fusion / physiology. Prognosis. Protein-Tyrosine Kinases / genetics. Protein-Tyrosine Kinases / physiology. Ribosomes / metabolism. Structure-Activity Relationship. Translocation, Genetic. Treatment Outcome
Genetics Home Reference.
consumer health - NPM1 gene
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17488663.001).
[ISSN]
1592-8721
[Journal-full-title]
Haematologica
[ISO-abbreviation]
Haematologica
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
Italy
[Chemical-registry-number]
0 / NPM-MLF1 protein, human; 0 / NPM-RARalpha protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 117896-08-9 / nucleophosmin; EC 2.7.1.- / p80(NPM-ALK) protein; EC 2.7.10.1 / Protein-Tyrosine Kinases
[Number-of-references]
166
31.
Buie LW, Epstein SS, Lindley CM:
Nelarabine: a novel purine antimetabolite antineoplastic agent.
Clin Ther
; 2007 Sep;29(9):1887-99
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: Nelarabine was approved by the US Food and Drug Administration (FDA) in October 2005 for the treatment of T-
cell
acute
lymphoblastic
leukemia
(T-ALL) and T-
cell
lymphoblastic
lymphoma
(T-LBL) that has not responded to or has relapsed after treatment with at least 2 chemotherapy regimens.
Also reviewed are nelarabine's
clinical
efficacy in T-ALL, T-LBL, and other hematologic malignancies; its toxicity profile, dosage, and administration; and areas of ongoing and future research.
Nelarabine has activity in T-
cell
malignancies, as evaluated in 2 Phase I and 5 Phase II studies.
Among patients with central nervous system-
positive
T-ALL or T-
cell
non-Hodgkins
lymphoma
(T-NHL) (n = 21), 33% had an objective response (5 CR and 2 PR); among patients with T-ALL or T-NHL with extramedullary relapse (n = 22), 14% had a PR.
CALGB 19801 included 39
adult
patients with T-
cell
malignancies, of whom 7 (18%) had a CR and an additional 2 (5%) had a CR without full hematologic recovery.
Objective response rates in Phase II
clinical
trials of nelarabine have ranged from 11% to 60%.
[MeSH-major]
Antimetabolites, Antineoplastic / therapeutic use. Arabinonucleosides / therapeutic use. Hematologic Neoplasms / drug therapy.
Leukemia
-
Lymphoma
,
Adult T
-
Cell
/ drug therapy.
Lymphoma
, T-
Cell
/ drug therapy. Purine Nucleosides / therapeutic use
SciCrunch.
DrugBank: Data: Chemical
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18035189.001).
[ISSN]
0149-2918
[Journal-full-title]
Clinical therapeutics
[ISO-abbreviation]
Clin Ther
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Antimetabolites, Antineoplastic; 0 / Arabinonucleosides; 0 / Purine Nucleosides; 60158CV180 / nelarabine
[Number-of-references]
29
32.
Jian D, Wu S, Chen D, Ying M, Yang B, You Z, Liu L, Ding Z:
[Nasal NK/T cell lymphoma: a report of 11 cases].
Lin Chuang Er Bi Yan Hou Ke Za Zhi
; 2005 Jul;19(14):638-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Nasal NK/
T cell lymphoma
: a report of 11 cases].
OBJECTIVE: To investigate the
clinical diagnosis
consideration of nasal NK/
T cell lymphoma
.
METHOD: Reviewing the
clinical
data of 11 patients with nasal NK/
T cell lymphoma
between 1992 to 2003.
CONCLUSION: Nasal NK/
T cell lymphoma
is easily misdiagnosed.
The right
diagnosis
can be built with
clinical
, pathological and imaging examination.
[MeSH-major]
Diagnostic Errors.
Lymphoma
, Extranodal NK-T-
Cell
. Nose Neoplasms
[MeSH-minor]
Adolescent.
Adult
. Female. Humans. Male. Middle Aged. Retrospective Studies. Young
Adult
MedlinePlus Health Information.
consumer health - Nasal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16248460.001).
[Journal-full-title]
Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology
[ISO-abbreviation]
Lin Chuang Er Bi Yan Hou Ke Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
33.
Zheng YY, Chen G, Zhou XG, Zhang SH, Zhang YN:
[Morphologic and immunophenotypic analysis of angioimmunoblastic T-cell lymphoma].
Zhonghua Bing Li Xue Za Zhi
; 2009 Mar;38(3):173-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[
Morphologic
and immunophenotypic analysis of angioimmunoblastic T-
cell lymphoma
].
OBJECTIVE: To study the
morphologic
and immunophenotypic features of angioimmunoblastic T-
cell lymphoma
(AITL), as well as the origin of the proliferative follicular dendritic cells (FDCs) in AITL.
Cases of peripheral T-
cell lymphoma
, unspecified, extranodal NK/T-
cell lymphoma
, nasal-type, enteropathy-type T-
cell lymphoma
, anaplastic large
cell lymphoma
, subcutaneous panniculitis-like T-
cell lymphoma
and reactive lymphoid proliferation were selected as controls.
RESULTS: Amongst the 29 cases of AITL studied, 75.9% (22/29) showed aberrant expression of CD10, while all except one of the controlled cases were negative, 82.8% (24/29) of the AITL cases expressed CXCL13, while all cases of peripheral T-
cell lymphoma
, unspecified were negative.
As for bcl-6 staining, although the highest percentage of bcl-6-
positive
cells was observed in AITL, the expression pattern was not useful in differentiating AITL from peripheral T-
cell lymphoma
, unspecified and lymphoid reaction.
Two of the cases, which contained obvious germinal centers, had the follicular dendritic
cell
meshwork extending beyond the lymphoid follicles.
[MeSH-major]
Chemokine CXCL13 / metabolism. Dendritic Cells, Follicular / pathology. Immunoblastic Lymphadenopathy / pathology.
Lymphoma
, T-
Cell
, Peripheral / pathology. Neprilysin / metabolism
[MeSH-minor]
Adult
. Aged. Female. Humans. Immunophenotyping. Male. Middle Aged. Proto-Oncogene Proteins c-bcl-6 / metabolism. Receptors, Complement 3d / metabolism
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19575853.001).
[ISSN]
0529-5807
[Journal-full-title]
Zhonghua bing li xue za zhi = Chinese journal of pathology
[ISO-abbreviation]
Zhonghua Bing Li Xue Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
China
[Chemical-registry-number]
0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Receptors, Complement 3d; EC 3.4.24.11 / Neprilysin
34.
Munir S, Le Nouen C, Luongo C, Buchholz UJ, Collins PL, Bukreyev A:
Nonstructural proteins 1 and 2 of respiratory syncytial virus suppress maturation of human dendritic cells.
J Virol
; 2008 Sep;82(17):8780-96
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Nonstructural proteins 1 and 2 of respiratory syncytial
virus
suppress maturation of
human
dendritic cells.
Human
respiratory syncytial
virus
(RSV) is the most important agent of serious pediatric respiratory tract
disease
worldwide.
One of the main characteristics of RSV is that it readily reinfects and causes
disease
throughout life without the need for significant antigenic change.
The
virus
encodes nonstructural protein 1 (NS1) and NS2, which are known to suppress type I interferon (IFN) production and signaling.
In the present study, we monitored the maturation of
human
monocyte-
derived
myeloid dendritic cells (DC) following inoculation with recombinant RSVs bearing deletions of the NS1 and/or NS2 proteins and expressing enhanced green fluorescent protein.
Deletion of the NS1 protein resulted in increased expression of
cell
surface markers of DC maturation and an increase in the expression of multiple cytokines and chemokines.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Am J Respir Cell Mol Biol. 2004 Jun;30(6):893-900
[
14722224.001
]
[Cites]
J Immunol. 2004 Sep 1;173(5):3408-17
[
15322205.001
]
[Cites]
N Engl J Med. 1979 Mar 8;300(10):530-4
[
763253.001
]
[Cites]
Nature. 1980 Apr 10;284(5756):555-6
[
6245367.001
]
[Cites]
Biochem Biophys Res Commun. 1986 Mar 13;135(2):397-402
[
3457562.001
]
[Cites]
Am J Pathol. 1990 Mar;136(3):593-608
[
2156431.001
]
[Cites]
Vaccine. 1990 Oct;8(5):497-502
[
2251875.001
]
[Cites]
J Infect Dis. 1991 Apr;163(4):693-8
[
2010624.001
]
[Cites]
J Immunol. 1991 Dec 15;147(12):4307-12
[
1753101.001
]
[Cites]
J Immunol. 1992 Jul 15;149(2):735-42
[
1378080.001
]
[Cites]
Biochim Biophys Acta. 1994 Apr 5;1197(1):63-93
[
8155692.001
]
[Cites]
J Immunol. 1995 Apr 15;154(8):3821-35
[
7706722.001
]
[Cites]
Immunology. 1995 Jul;85(3):364-72
[
7558123.001
]
[Cites]
J Exp Med. 1995 Nov 1;182(5):1545-56
[
7595224.001
]
[Cites]
J Clin Invest. 1995 Nov;96(5):2445-53
[
7593633.001
]
[Cites]
Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11563-7
[
8524804.001
]
[Cites]
J Infect Dis. 1996 Sep;174(3):456-62
[
8769600.001
]
[Cites]
J Infect Dis. 1997 Mar;175(3):497-504
[
9041319.001
]
[Cites]
J Immunol. 2007 Jul 1;179(1):673-81
[
17579090.001
]
[Cites]
J Biol Chem. 2007 Jul 13;282(28):20053-7
[
17502368.001
]
[Cites]
Immunity. 2007 Aug;27(2):240-52
[
17723216.001
]
[Cites]
Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):425-33
[
17683972.001
]
[Cites]
Vaccine. 2007 Oct 16;25(42):7372-8
[
17868959.001
]
[Cites]
Viral Immunol. 2007 Dec;20(4):531-40
[
18158727.001
]
[Cites]
J Virol. 2008 Mar;82(5):2040-55
[
17928346.001
]
[Cites]
J Gen Virol. 2005 Jun;86(Pt 6):1645-57
[
15914842.001
]
[Cites]
Blood. 2005 Jul 1;106(1):216-23
[
15790784.001
]
[Cites]
J Virol. 2005 Jul;79(14):9315-9
[
15994826.001
]
[Cites]
J Exp Med. 2005 Sep 5;202(5):637-50
[
16129706.001
]
[Cites]
J Immunol. 2005 Nov 1;175(9):5904-11
[
16237083.001
]
[Cites]
J Immunol. 2006 Feb 1;176(3):1600-8
[
16424189.001
]
[Cites]
Blood. 2006 Feb 15;107(4):1528-36
[
16239433.001
]
[Cites]
Am J Respir Cell Mol Biol. 2006 Mar;34(3):320-9
[
16284360.001
]
[Cites]
Blood. 2006 Mar 15;107(6):2392-9
[
16293598.001
]
[Cites]
J Virol. 2006 Apr;80(7):3416-27
[
16537609.001
]
[Cites]
Int Arch Allergy Immunol. 2006;140(1):53-72
[
16534219.001
]
[Cites]
J Virol. 2006 May;80(10):5032-40
[
16641294.001
]
[Cites]
J Virol. 2006 Jun;80(12):5958-67
[
16731934.001
]
[Cites]
J Leukoc Biol. 2006 Jun;79(6):1286-94
[
16624932.001
]
[Cites]
J Virol. 2006 Jul;80(13):6295-304
[
16775317.001
]
[Cites]
J Virol. 2006 Aug;80(16):8151-7
[
16873271.001
]
[Cites]
Eur J Immunol. 2006 Jul;36(7):1827-36
[
16783851.001
]
[Cites]
Immunity. 2006 Sep;25(3):373-81
[
16979569.001
]
[Cites]
Blood. 2006 Dec 1;108(12):3792-800
[
16917011.001
]
[Cites]
J Exp Med. 2007 Jan 22;204(1):171-80
[
17190836.001
]
[Cites]
J Mol Biol. 2007 Feb 16;366(2):525-39
[
17174979.001
]
[Cites]
J Virol. 2007 Feb;81(4):1786-95
[
17151097.001
]
[Cites]
J Virol. 2007 Apr;81(7):3428-36
[
17251292.001
]
[Cites]
Arch Dermatol Res. 2007 May;299(2):59-69
[
17334966.001
]
[Cites]
Virology. 2007 Aug 15;365(1):144-56
[
17459446.001
]
[Cites]
J Virol. 2003 Aug;77(15):8426-39
[
12857912.001
]
[Cites]
J Virol. 2003 Aug;77(16):8661-8
[
12885884.001
]
[Cites]
J Virol. 2003 Sep;77(17):9156-72
[
12915532.001
]
[Cites]
J Virol. 2003 Oct;77(20):11201-11
[
14512568.001
]
[Cites]
Virology. 2003 Nov 10;316(1):41-54
[
14599789.001
]
[Cites]
J Infect Dis. 2003 Dec 1;188(11):1630-8
[
14639532.001
]
[Cites]
J Virol. 2004 Apr;78(8):4363-9
[
15047850.001
]
[Cites]
JAMA. 1999 Oct 20;282(15):1440-6
[
10535434.001
]
[Cites]
Eur J Immunol. 1999 Nov;29(11):3596-602
[
10556814.001
]
[Cites]
J Exp Med. 2000 May 15;191(10):1777-88
[
10811870.001
]
[Cites]
J Virol. 2000 Aug;74(15):7127-36
[
10888653.001
]
[Cites]
Virology. 2000 Jul 20;273(1):210-8
[
10891423.001
]
[Cites]
J Virol. 2000 Oct;74(19):9317-21
[
10982380.001
]
[Cites]
Eur J Immunol. 2000 Oct;30(10):2741-50
[
11069053.001
]
[Cites]
Nat Immunol. 2000 Nov;1(5):398-401
[
11062499.001
]
[Cites]
J Virol. 2001 Dec;75(24):12128-40
[
11711604.001
]
[Cites]
Blood. 2002 Apr 15;99(8):2913-21
[
11929782.001
]
[Cites]
Int Immunol. 2002 Apr;14(4):367-80
[
11934873.001
]
[Cites]
Cancer Immunol Immunother. 2002 May;51(3):139-44
[
11941452.001
]
[Cites]
J Virol. 2002 Oct;76(20):10109-21
[
12239285.001
]
[Cites]
Biochem J. 2002 Oct 1;367(Pt 1):145-55
[
12084011.001
]
[Cites]
J Immunol. 2003 Mar 15;170(6):2797-801
[
12626527.001
]
[Cites]
J Infect Dis. 2003 Apr 1;187(7):1126-36
[
12660927.001
]
[Cites]
Immunology. 2003 May;109(1):49-57
[
12709017.001
]
[Cites]
Eur J Immunol. 2003 Jun;33(6):1677-85
[
12778486.001
]
[Cites]
J Virol. 1997 Jul;71(7):4944-53
[
9188557.001
]
[Cites]
Mamm Genome. 1997 Aug;8(8):581-2
[
9250865.001
]
[Cites]
Nature. 1998 Mar 19;392(6673):245-52
[
9521319.001
]
[Cites]
J Immunol. 1998 May 1;160(9):4298-304
[
9574532.001
]
[Cites]
J Virol. 1998 Jun;72(6):4756-64
[
9573240.001
]
[Cites]
J Virol. 1999 Jan;73(1):466-73
[
9847352.001
]
[Cites]
Cell Death Differ. 1999 Feb;6(2):99-104
[
10200555.001
]
[Cites]
Science. 1999 Jun 11;284(5421):1835-7
[
10364556.001
]
[Cites]
Nat Med. 1999 Aug;5(8):919-23
[
10426316.001
]
[Cites]
Eur J Immunol. 1999 Sep;29(9):2769-78
[
10508251.001
]
[Cites]
J Virol. 2005 May;79(9):5353-62
[
15827150.001
]
[Cites]
J Virol. 2005 May;79(9):5507-15
[
15827165.001
]
[Cites]
N Engl J Med. 2005 Apr 28;352(17):1749-59
[
15858184.001
]
[Cites]
Leuk Lymphoma. 2004 Feb;45(2):257-64
[
15101709.001
]
(PMID = 18562519.001).
[ISSN]
1098-5514
[Journal-full-title]
Journal of virology
[ISO-abbreviation]
J. Virol.
[Language]
ENG
[Grant]
United States / Intramural NIH HHS / /
[Publication-type]
Journal Article; Research Support, N.I.H., Intramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Annexin A5; 0 / Cytokines; 0 / Viral Nonstructural Proteins; 147336-22-9 / Green Fluorescent Proteins; EC 3.4.22.- / Caspase 3
[Other-IDs]
NLM/ PMC2519638
35.
Váróczy L, Gergely L, Miltényi Z, Aleksza M, Illés A:
Can CD3+/HLA-DR+ activated T cells predict the prognosis of non-Hodgkin's lymphoma patients?
Immunol Lett
; 2005 Feb 15;97(1):155-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Can CD3+/HLA-DR+ activated T cells predict the prognosis of non-Hodgkin's
lymphoma
patients?
The immune system has several mechanisms to fight against developing malignant
cell
clones in the host, one of them is the activated T-
cell
response.
Our aim was to determine, how the ratio of activated T cells change in the peripheral blood of non-Hodgkin's
lymphoma
(NHL) patients during the periods of polychemotherapy.
We suppose that investigation of CD3+/HLA-DR+ activated T cells might be a promising method to determine the prognostics of
lymphoma
patients.
[MeSH-major]
Antigens, CD3 / immunology. HLA-DR Antigens / immunology.
Lymphoma
, Non-Hodgkin /
diagnosis
. T-Lymphocytes / immunology
[MeSH-minor]
Adult
. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Prognosis
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15626488.001).
[ISSN]
0165-2478
[Journal-full-title]
Immunology letters
[ISO-abbreviation]
Immunol. Lett.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Antigens, CD3; 0 / HLA-DR Antigens
36.
Zhou Y, Li Q, Meng HX, Wang YF, Yu Z, Qiu LG:
[The expression and clinical significance of early differentiation antigens in acute leukemia].
Zhonghua Nei Ke Za Zhi
; 2005 Jan;44(1):46-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[The expression and
clinical
significance of early differentiation antigens in
acute leukemia
].
OBJECTIVE: To evaluate the expression and
clinical
significance of early differentiation antigens of hematopoietic cells CD(34), CD(90) and CD(133) in
acute leukemia
(AL).
The expression of CD(133) antigen was highly correlated with CD(133) mRNA expression in both of the normal control donors and AL patients (r = 0.932, P < 0.01). (2) The
positive
rates of CD(34), CD(90) and CD(133) in all AL patients were 63.2%, 7.9% and 42.1%, respectively.
Positive
expression of CD(133) in AML-M(4) was significantly higher than that in other AML subtypes (P < 0.01).
The
positive
rate of CD(34) in B-ALL was much higher than that in T-ALL (P < 0.05). (3) CD(133) expression in AML was significantly correlated with the expression of CD(34) and HLA-DR (P < 0.01). (4) The expression of CD(34), CD(90) and CD(133) was not
associated
with the
clinical
prognostic factors such as cytogenetic or molecular aberrations, initial peripheral blood WBC counts, lactate dehydrogenase level, multiple drug resistant expression and age. (5) There was a trend toward lower completely remission (CR) rate and overall survival rate in CD(34), CD(90) and CD(133)
positive
cases, but only CD(34)(+)/CD(133)(+) cases had significant lower CR rate than negative ones (P < 0.05).
CD(133)/CD(34) co-expression might provide adverse prognostic stratification of
acute leukemia
.
[MeSH-major]
Antigens, CD34 / metabolism. Antigens, Thy-1 / metabolism. Glycoproteins / metabolism.
Leukemia
, Myeloid,
Acute
/ metabolism. Peptides / metabolism. Precursor
Cell
Lymphoblastic
Leukemia
-
Lymphoma
/ metabolism
[MeSH-minor]
Adolescent.
Adult
. Aged. Antigens, CD. Child. Female. Humans. Male. Middle Aged. Prognosis. RNA, Messenger / genetics
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15769398.001).
[ISSN]
0578-1426
[Journal-full-title]
Zhonghua nei ke za zhi
[ISO-abbreviation]
Zhonghua Nei Ke Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
China
[Chemical-registry-number]
0 / AC133 antigen; 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Antigens, Thy-1; 0 / Glycoproteins; 0 / Peptides; 0 / RNA, Messenger
37.
Jacyk WK, Grayson W, Dinkel JE, Requena L:
Pagetoid reticulosis with CD30 positivity and cytotoxic/suppressor cells.
J Cutan Pathol
; 2007 Aug;34(8):644-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Pagetoid reticulosis (PR) is a low-grade primary cutaneous T-
cell lymphoma
that usually presents as a solitary, slowly enlarging erythematous or hyperkeratotic plaque on the distal areas of the extremities.
Histopathologically, it is characterized by a dense, band-like infiltrate of atypical lymphocytes with prominent epidermotropism within a hyperplastic epidermis, and immunophenotypic studies show in most cases, a CD4-
positive
T-helper phenotype for the neoplastic lymphocytes.
We describe an African man with a more than 20-year history of an acral lesion of PR, which was histopathologically characterized by lymphocyte immunophenotype consisting of CD8- and CD30-
positive
cells.
We discuss the differential
diagnosis
with other primary cutaneous lymphoproliferative disorders showing similar immunophenotype.
This case shows that CD30-
positive
PR should be included as a rare variant within the spectrum of CD30-
positive
primary cutaneous lymphoproliferative disorders.
As in other primary cutaneous CD30-
positive
lymphoproliferative processes, lesions of CD30-
positive
PR show an indolent course and a benign biological behavior.
[MeSH-major]
Antigens, CD30 / metabolism. Lymphatic Diseases / pathology.
Lymphoma
, T-
Cell
, Cutaneous / pathology. Skin Neoplasms / pathology. T-Lymphocytes, Cytotoxic / pathology
[MeSH-minor]
Adult
. Biomarkers / metabolism. Biopsy. CD8-
Positive
T-Lymphocytes / metabolism. CD8-
Positive
T-Lymphocytes / pathology. Humans. Immunophenotyping. Male
MedlinePlus Health Information.
consumer health - Lymphatic Diseases
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17640236.001).
[ISSN]
0303-6987
[Journal-full-title]
Journal of cutaneous pathology
[ISO-abbreviation]
J. Cutan. Pathol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Denmark
[Chemical-registry-number]
0 / Antigens, CD30; 0 / Biomarkers
38.
Graux C, Stevens-Kroef M, Lafage M, Dastugue N, Harrison CJ, Mugneret F, Bahloula K, Struski S, Grégoire MJ, Nadal N, Lippert E, Taviaux S, Simons A, Kuiper RP, Moorman AV, Barber K, Bosly A, Michaux L, Vandenberghe P, Lahortiga I, De Keersmaecker K, Wlodarska I, Cools J, Hagemeijer A, Poirel HA, Groupe Francophone de Cytogénétique Hématologique, Belgian Cytogenetic Group for Hematology and Oncology:
Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia.
Leukemia
; 2009 Jan;23(1):125-33
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-
cell
acute
lymphoblastic
leukemia
.
In this multicentric study we collected 27 cases of NUP214-ABL1-
positive
T-ALL.
An
associated abnormality
involving TLX1 or TLX3 was found in all investigated cases.
In addition, intrachromosomal amplification (small hsr) was identified either as the only change or in association with episomes in four cases and two T-ALL
cell
lines (PEER and ALL-SIL).
[MeSH-major]
Gene Amplification.
Leukemia
-
Lymphoma
,
Adult T
-
Cell
/ genetics. Oncogene Proteins, Fusion / genetics
[MeSH-minor]
Adolescent.
Adult
.
Cell
Line, Tumor. Child. Child, Preschool. Female. Homeodomain Proteins / genetics. Humans. Male. Middle Aged. Plasmids. Proto-Oncogene Proteins / genetics. Sex Factors. Treatment Outcome. Young
Adult
Genetic Alliance.
consumer health - Acute Lymphoblastic Leukemia
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18923437.001).
[ISSN]
1476-5551
[Journal-full-title]
Leukemia
[ISO-abbreviation]
Leukemia
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Homeodomain Proteins; 0 / NUP214-ABL1 fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins; 0 / TLX3 protein, human; 143275-75-6 / TLX1 protein, human
[Investigator]
Barin C; Berger R; Bilhou-Nabera C; Cabrol C; Callet-Bauchu E; Cornillet-Lefebvre P; Laï JL; Lefebvre C; Luquet I; Perot C; Radford-Weiss I; Speleman F; Cauwelier B; Talmant P; Terré C; Tigaud I; Van DenAkker J; Viguié F
39.
Shinomiya N, Koike Y, Koyama H, Takayama E, Habu Y, Fukasawa M, Tanuma S, Seki S:
Analysis of the susceptibility of CD57 T cells to CD3-mediated apoptosis.
Clin Exp Immunol
; 2005 Feb;139(2):268-78
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
After stimulation with anti-CD3 antibody in vitro, CD57(+) T cells showed a greater susceptibility to apoptosis than CD57(-)alphabetaT
cell
receptor (TCR)(+) T cells (regular alphabeta T cells).
CD57(+) T cells display a biased expansion of a few Vbeta
T cell
fractions in individuals, but such Vbeta T cells were not specifically susceptible to CD3-mediated apoptosis.
Although the CD3epsilon expression levels were similar in both
T cell
subsets, the CD3zeta level of CD57(+) T cells was significantly higher than that of regular T cells.
[MeSH-minor]
Adult
. Antibodies / pharmacology. Antigens, CD95 / analysis. Antigens, CD95 / immunology. Apoptosis / immunology. Caspase 3. Caspases / metabolism. Cells, Cultured. Fas Ligand Protein. Humans. Immunoglobulin epsilon-Chains / analysis. Immunoglobulin gamma-Chains / analysis. Inhibitor of Apoptosis Proteins. Membrane Glycoproteins / analysis. Membrane Glycoproteins / immunology. Microtubule-
Associated
Proteins / analysis. Microtubule-
Associated
Proteins / immunology. Neoplasm Proteins. Receptors, Antigen, T-
Cell
, alpha-beta / immunology. Reverse Transcriptase Polymerase Chain Reaction
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Leuk Lymphoma. 1999 Nov;35(5-6):545-54
[
10609792.001
]
[Cites]
Int Immunol. 1998 Dec;10(12):1837-45
[
9885904.001
]
[Cites]
Immunol Rev. 2000 Apr;174:35-46
[
10807505.001
]
[Cites]
Immunol Rev. 2000 Apr;174:135-49
[
10807513.001
]
[Cites]
J Immunol. 2000 Jun 1;164(11):5652-8
[
10820240.001
]
[Cites]
Eur J Immunol. 2000 Jul;30(7):1919-28
[
10940881.001
]
[Cites]
Hepatology. 2000 Nov;32(5):962-9
[
11050046.001
]
[Cites]
Hum Immunol. 2000 Sep;61(9):908-16
[
11053634.001
]
[Cites]
Clin Cancer Res. 2001 Jan;7(1):74-80
[
11205921.001
]
[Cites]
Clin Cancer Res. 2001 Mar;7(3 Suppl):947s-957s
[
11300496.001
]
[Cites]
J Immunol. 2001 Jun 1;166(11):6578-84
[
11359810.001
]
[Cites]
Immunology. 2001 Jul;103(3):281-90
[
11454057.001
]
[Cites]
Clin Exp Immunol. 2002 Jun;128(3):453-9
[
12109440.001
]
[Cites]
Clin Exp Immunol. 2002 Oct;130(1):162-8
[
12296868.001
]
[Cites]
J Immunol. 2002 Dec 1;169(11):6127-32
[
12444115.001
]
[Cites]
Immunology. 2003 Feb;108(2):211-9
[
12562330.001
]
[Cites]
Blood. 2003 Apr 1;101(7):2711-20
[
12433688.001
]
[Cites]
J Immunol. 2003 Aug 15;171(4):1901-8
[
12902492.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10913-8
[
12960397.001
]
[Cites]
J Immunol. 2003 Oct 15;171(8):4020-7
[
14530322.001
]
[Cites]
J Immunol. 2004 Jun 1;172(11):6550-7
[
15153469.001
]
[Cites]
Immunology. 2004 Sep;113(1):35-43
[
15312134.001
]
[Cites]
J Immunol. 1981 Sep;127(3):1024-9
[
6790607.001
]
[Cites]
J Immunol. 1983 Oct;131(4):1822-6
[
6413578.001
]
[Cites]
Transplantation. 1985 Jan;39(1):25-9
[
3880961.001
]
[Cites]
J Immunol. 1986 Oct 1;137(7):2180-9
[
2944951.001
]
[Cites]
J Immunol. 1986 Nov 1;137(9):2808-13
[
2944964.001
]
[Cites]
J Immunol. 1988 Dec 1;141(11):3791-7
[
2903195.001
]
[Cites]
Annu Rev Cell Biol. 1990;6:403-31
[
2275818.001
]
[Cites]
J Immunol. 1991 Aug 15;147(4):1214-21
[
1831220.001
]
[Cites]
Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1492-6
[
1346934.001
]
[Cites]
Nature. 1992 Mar 26;356(6367):314-7
[
1372394.001
]
[Cites]
Arthritis Rheum. 1993 May;36(5):608-12
[
7683880.001
]
[Cites]
Curr Opin Immunol. 1993 Jun;5(3):324-33
[
8347295.001
]
[Cites]
Int Rev Immunol. 1994;11(1):61-102
[
8057045.001
]
[Cites]
Eur J Immunol. 1994 Nov;24(11):2882-8
[
7525310.001
]
[Cites]
Nature. 1995 Feb 2;373(6513):438-41
[
7530335.001
]
[Cites]
Nature. 1995 Feb 2;373(6513):441-4
[
7530336.001
]
[Cites]
Nature. 1995 Feb 2;373(6513):444-8
[
7530337.001
]
[Cites]
J Exp Med. 1995 Feb 1;181(2):781-6
[
7530763.001
]
[Cites]
J Immunol. 1995 Apr 15;154(8):3806-13
[
7706720.001
]
[Cites]
EMBO J. 1995 Mar 15;14(6):1129-35
[
7536672.001
]
[Cites]
J Exp Med. 1995 May 1;181(5):1881-6
[
7722462.001
]
[Cites]
J Immunol. 1995 Jun 1;154(11):6182-90
[
7538544.001
]
[Cites]
Mech Ageing Dev. 1996 Jul 5;88(1-2):25-38
[
8804091.001
]
[Cites]
Mech Ageing Dev. 1997 Mar;94(1-3):123-34
[
9147365.001
]
[Cites]
Hepatology. 1997 Aug;26(2):301-9
[
9252138.001
]
[Cites]
Nat Med. 1997 Aug;3(8):917-21
[
9256286.001
]
[Cites]
J Clin Immunol. 1997 Sep;17(5):420-9
[
9327342.001
]
[Cites]
J Immunol. 1998 Feb 15;160(4):1627-37
[
9469419.001
]
[Cites]
Clin Exp Immunol. 1998 Feb;111(2):345-52
[
9486402.001
]
[Cites]
Scand J Immunol. 1998 Mar;47(3):254-62
[
9519864.001
]
[Cites]
Br J Haematol. 1998 Mar;100(4):784-92
[
9531350.001
]
[Cites]
Clin Cancer Res. 1996 Jan;2(1):161-73
[
9816103.001
]
[Cites]
Blood. 1998 Dec 15;92(12):4771-7
[
9845544.001
]
[Cites]
Cancer Res. 1998 Dec 1;58(23):5315-20
[
9850056.001
]
[Cites]
Blood Rev. 1999 Dec;13(4):230-40
[
10741898.001
]
(PMID = 15654825.001).
[ISSN]
0009-9104
[Journal-full-title]
Clinical and experimental immunology
[ISO-abbreviation]
Clin. Exp. Immunol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antibodies; 0 / Antigens, CD3; 0 / Antigens, CD57; 0 / Antigens, CD95; 0 / BIRC5 protein, human; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Immunoglobulin epsilon-Chains; 0 / Immunoglobulin gamma-Chains; 0 / Inhibitor of Apoptosis Proteins; 0 / Membrane Glycoproteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Receptors, Antigen, T-Cell, alpha-beta; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
[Other-IDs]
NLM/ PMC1809296
40.
Couriel D, Hosing C, Saliba R, Shpall EJ, Andelini P, Popat U, Donato M, Champlin R:
Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work?
Biol Blood Marrow Transplant
; 2006 Jan;12(1 Suppl 2):37-40
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Extracorporeal photopheresis for
acute
and chronic graft-versus-host
disease
: does it work?
Acute
and chronic graft-versus-host
disease
(GVHD) continue to be major limitations to successful hematopoietic stem
cell
transplantation.
Photopheresis is currently indicated and Food and Drug Administration-approved for the treatment of skin manifestations of cutaneous T-
cell lymphoma
, where the response rate has proved to be considerably high.
Extracorporeal photochemotherapy has been evaluated in small cohorts of patients with both
acute
and chronic GVHD.
In steroid-refractory
acute
GVHD of the skin and liver, the reported response rate is more than 60%, especially in patients with less severe forms of the
disease
.
All of these results indicate activity of extracorporeal photopheresis in
acute
and chronic GVHD, which warrants further evaluation of this therapy in well-designed, prospective, controlled studies.
[MeSH-major]
Graft vs Host
Disease
/ therapy. Photopheresis
[MeSH-minor]
Acute Disease
. Adolescent.
Adult
. Aged. Child. Child, Preschool. Chronic
Disease
. Cohort Studies.
Disease
-Free Survival. Humans. Male. Middle Aged. Neoplasms / complications. Neoplasms / mortality. Neoplasms / therapy. Remission Induction. Retrospective Studies
Genetic Alliance.
consumer health - Chronic Graft versus Host Disease
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16399600.001).
[ISSN]
1083-8791
[Journal-full-title]
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
[ISO-abbreviation]
Biol. Blood Marrow Transplant.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
41.
Oba T, Suzuki R, Miyamura K, Kodera Y:
Huge mass of cutaneous-type adult T-cell leukemia which responded to interferon gamma.
Intern Med
; 2007;46(3):147
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Huge mass of cutaneous-type
adult T
-
cell
leukemia
which responded to interferon gamma.
[MeSH-major]
Leukemia
-
Lymphoma
,
Adult T
-
Cell
/ pathology. Skin Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17268135.001).
[ISSN]
1349-7235
[Journal-full-title]
Internal medicine (Tokyo, Japan)
[ISO-abbreviation]
Intern. Med.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
0 / Antineoplastic Agents; 82115-62-6 / Interferon-gamma
42.
Nakamura S, Ye H, Bacon CM, Goatly A, Liu H, Kerr L, Banham AH, Streubel B, Yao T, Tsuneyoshi M, Savio A, Takeshita M, Dartigues P, Ruskoné-Fourmestraux A, Matsumoto T, Iida M, Du MQ:
Translocations involving the immunoglobulin heavy chain gene locus predict better survival in gastric diffuse large B-cell lymphoma.
Clin Cancer Res
; 2008 May 15;14(10):3002-10
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Translocations involving the immunoglobulin heavy chain gene locus predict better survival in gastric diffuse large B-
cell lymphoma
.
PURPOSE: The pathogenesis and
clinical
heterogeneity of gastric diffuse large B-
cell lymphoma
(DLBCL) are poorly understood.
We have comprehensively investigated the incidence and
clinical
significance of
lymphoma
-
associated
chromosomal translocations, particularly those involving the immunoglobulin heavy chain (IGH) gene locus, in a large series of gastric DLBCL.
EXPERIMENTAL DESIGN: One hundred forty-one cases of primary gastric DLBCL [58 with mucosa-
associated
lymphoid tissue (MALT)
lymphoma
and 83 without MALT
lymphoma
] were enrolled.
In
positive
cases, additional fluorescence in situ hybridization was done with appropriate probes for potential partner genes.
Cases were classified into germinal center B-
cell
-like (GCB) or non-GCB subgroups by immunophenotyping with CD10, BCL6, and MUM1.
RESULTS: Translocations involving IGH were detected in 36 (32%) of 111 cases; their partner genes included BCL6 (n = 10), c-MYC (n = 5), and FOXP1 (n = 3) but remained unknown in the remaining 18 cases. t(14;18)/IGH-BCL2, t(14;18)/IGH-MALT1, and t(1;14)/BCL10-IGH were not detected in any case. t(11;18)/API2-MALT1 was detected in none of the cases, except for one case of DLBCL with MALT
lymphoma
, which showed
positive
signals only in MALT
lymphoma
cells.
IGH-involved translocation was
associated
with younger age but not with any other clinicopathologic factors including GCB or non-GCB immunophenotypes.
[MeSH-major]
Immunoglobulin Heavy Chains / genetics.
Lymphoma
, Large B-
Cell
, Diffuse / genetics. Stomach Neoplasms / genetics. Translocation, Genetic
[MeSH-minor]
Adolescent.
Adult
. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis
Genetic Alliance.
consumer health - Gastric Lymphoma
.
Genetic Alliance.
consumer health - Large B cell diffuse lymphoma
.
MedlinePlus Health Information.
consumer health - Stomach Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18445693.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
eng
[Grant]
United Kingdom / Wellcome Trust / /
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Immunoglobulin Heavy Chains
43.
Dietel V, Bührdel P, Hirsch W, Körholz D, Kiess W:
Cerebral sinus occlusion in a boy presenting with asparaginase-induced hypertriglyceridemia.
Klin Padiatr
; 2007 Mar-Apr;219(2):95-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Cerebral sinus thrombosis is a rare but severe complication during treatment for
acute
lymphoblastic
leukaemia
(ALL).
Hypertriglyceridemia has - albeit very rarely - also been
associated
with asparaginase therapy.
Here we describe a 15-year-old boy who presented with
clinical
symptoms and radiologic findings of a cerebral sinus thrombosis.
[MeSH-major]
Antineoplastic Agents / toxicity. Antineoplastic Combined Chemotherapy Protocols / toxicity. Asparaginase / toxicity. Hypertriglyceridemia / chemically induced.
Leukemia
-
Lymphoma
,
Adult T
-
Cell
/ drug therapy. Polyethylene Glycols / toxicity. Sinus Thrombosis, Intracranial / chemically induced
MedlinePlus Health Information.
consumer health - Triglycerides
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17405075.001).
[ISSN]
0300-8630
[Journal-full-title]
Klinische Pädiatrie
[ISO-abbreviation]
Klin Padiatr
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Anticoagulants; 0 / Antineoplastic Agents; 0 / Heparin, Low-Molecular-Weight; 0 / Hypolipidemic Agents; 0 / pegaspargase; 30IQX730WE / Polyethylene Glycols; EC 3.5.1.1 / Asparaginase; Y9449Q51XH / Bezafibrate
44.
Kletting P, Kull T, Reske SN, Glatting G:
Comparing time activity curves using the Akaike information criterion.
Phys Med Biol
; 2009 Nov 7;54(21):N501-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[MeSH-minor]
Adult
. Aged. Antigens, CD / chemistry.
Cell
Adhesion Molecules / chemistry. Female. Humans. Indium Radioisotopes / pharmacokinetics. Kinetics.
Leukemia
, Myeloid,
Acute
/ radiotherapy. Male. Middle Aged. Models, Statistical. Precursor
Cell
Lymphoblastic
Leukemia
-
Lymphoma
/ radiotherapy. Radiopharmaceuticals / pharmacokinetics. Yttrium Radioisotopes / pharmacokinetics
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19820266.001).
[ISSN]
1361-6560
[Journal-full-title]
Physics in medicine and biology
[ISO-abbreviation]
Phys Med Biol
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antigens, CD; 0 / CD66 antigens; 0 / Cell Adhesion Molecules; 0 / Indium Radioisotopes; 0 / Radiopharmaceuticals; 0 / Yttrium Radioisotopes
45.
Tsartsidze E, Betaneli M:
Prognostic significance of immunophenotype in aggressive non-Hodgkin's lymphoma.
Georgian Med News
; 2006 May;(134):107-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prognostic significance of immunophenotype in aggressive non-Hodgkin's
lymphoma
.
The purpose of the study was to evaluate prognostic value of immunophenotype in aggressive Non-Hodgkin's
lymphoma
.
87 patients with immunohistologically confirmed
diagnosis
of aggressive Non-Hodgkin's
lymphoma
according to the WHO classification (2001) were under observation.
Overall survival was calculated from the date of
diagnosis
to the last follow-up or death regardless of the cause.
17 patients out of 87 were diagnosed as T-
cell
lymphomas
.
Overall survival in patients with IPI greater than 2 (poor prognosis) was shorter for T-
cell
lymphomas
(7,6 months) in comparison with B-
cell
lymphomas
(17,3 months) (p<0,001).
T-
cell
phenotype should be considered as an independent factor that strongly influences the survival for patients with
diagnosis
of aggressive non-Hodgkin's
lymphomas
.
Besides petipherial T-
cell
lymphomas
occurs more frequently in the elderly, with advanced stage, frequent extranodal site involvement, and often detected high level of LDH compared with B-
cell
lymphomas
.
[MeSH-major]
B-Lymphocytes / immunology. Immunophenotyping.
Lymphoma
, Non-Hodgkin /
diagnosis
.
Lymphoma
, Non-Hodgkin / mortality. T-Lymphocytes / immunology
[MeSH-minor]
Adult
. Humans. Middle Aged. Prognosis
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16783081.001).
[ISSN]
1512-0112
[Journal-full-title]
Georgian medical news
[ISO-abbreviation]
Georgian Med News
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Georgia (Republic)
46.
Ständer H, Neugebauer F, Schneider SW, Luger TA, Schiller M:
Extracorporeal photopheresis with permanent subcutaneous right atrial catheters.
J Dtsch Dermatol Ges
; 2007 Dec;5(12):1112-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
As this approach is not always feasible in older patients and patients with graft-versus-host
disease
, central venous catheters play an increasing role in providing long-term vascular access for ECP.However, not all catheters are able to deliver the minimum flow rate of 7 ml/min for ECP.
[MeSH-minor]
Adolescent.
Adult
. Aged. Aged, 80 and over. Blood Flow Velocity. Equipment Design. Equipment Failure Analysis. Female. Graft vs Host
Disease
/ drug therapy. Humans. Hydrostatic Pressure. In Vitro Techniques.
Lymphoma
, T-
Cell
, Cutaneous / drug therapy. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Retrospective Studies
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17888008.001).
[ISSN]
1610-0387
[Journal-full-title]
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
[ISO-abbreviation]
J Dtsch Dermatol Ges
[Language]
eng; ger
[Publication-type]
Journal Article
[Publication-country]
Germany
47.
Demirkan F, Alacacioglu I, Piskin O, Ozsan HG, Akinci B, Ozcan AM, Yavuzsen T, Yuksel E, Undar B:
The clinical, haematological and morphological profile of patients with myelodysplastic syndromes: a single institution experience from Turkey.
Leuk Lymphoma
; 2007 Jul;48(7):1372-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The
clinical
, haematological and morphological profile of patients with myelodysplastic syndromes: a single institution experience from Turkey.
In a retrospective analysis of 113 patients with primary myelodysplastic syndromes (MDS) diagnosed according to French-American-British (FAB) classification, we evaluated the prognostic impact of FAB and World Health Organisation (WHO) classifications, International Prognostic Scoring System (IPSS), and other
clinical
and laboratory variables.
At a median follow-up of 24 months, 22 patients (19.5 %) transformed to
acute
myelogenous
leukaemia
(AML).
In WHO classification, significant differences were observed in both OS and
leukaemia
free survival (LFS) between patients with RA/RARS and refractory cytopenia with multi-lineage dysplasia/refractory cytopenia with multi-lineage dysplasia and ringed sideroblasts (RCMD/RS-RCMD) (p = 0.0001).
[MeSH-minor]
Adult
. Aged. Aged, 80 and over.
Cell
Transformation, Neoplastic. Classification. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Retrospective Studies. Survival Analysis. Turkey / epidemiology. World Health Organization
Genetic Alliance.
consumer health - Myelodysplastic syndromes
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17613766.001).
[ISSN]
1042-8194
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
48.
Jeang KT:
Progress, challenges, and responsibilities in retrovirology.
Retrovirology
; 2005;2:1
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
In this editorial, Retrovirology's choice for best basic science "retrovirus paper of the year" and a perspective on challenges and responsibilities facing HIV-1 and
HTLV
-I research are presented.
[MeSH-major]
Leukemia
-
Lymphoma
,
Adult T
-
Cell
. Research
[MeSH-minor]
Animals.
Disease
Models, Animal. HIV Infections / drug therapy. HIV Infections / epidemiology. HIV Infections / prevention & control. HIV-1 / pathogenicity.
Human
T-
lymphotropic virus
1. Humans. Proteins / metabolism. Proteins / therapeutic use
HIV InSite.
treatment guidelines - Human Herpesvirus-8
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Nature. 2004 Feb 26;427(6977):848-53
[
14985764.001
]
[Cites]
J Biol Chem. 2004 Jul 30;279(31):31991-4
[
15090550.001
]
[Cites]
Retrovirology. 2004;1:9
[
15169567.001
]
[Cites]
Retrovirology. 2004;1:2
[
15169555.001
]
[Cites]
Retrovirology. 2004;1:46
[
15620346.001
]
(PMID = 15644139.001).
[ISSN]
1742-4690
[Journal-full-title]
Retrovirology
[ISO-abbreviation]
Retrovirology
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Proteins; 0 / TRIM5(alpha) protein, rhesus monkey
[Other-IDs]
NLM/ PMC544867
49.
Lee Y, Lee KW, Kim JH, Bang SM, Lee JS, Park BB, Kim WS, Suh C, Kang JH, Ryoo BY, Lee JH, Shin DB:
Epstein-Barr virus-positivity in tumor has no correlation with the clinical outcomes of patients with angioimmunoblastic T-cell lymphoma.
Korean J Intern Med
; 2008 Mar;23(1):30-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Epstein-Barr
virus
-positivity in tumor has no correlation with the
clinical
outcomes of patients with angioimmunoblastic T-
cell lymphoma
.
BACKGROUND/AIMS: Epstein-Barr
virus
(EBV) is involved in the pathogenesis of angioimmunoblastic T-
cell lymphoma
(AILT), but its precise role and prognostic impact are not clear.
This study aimed to evaluate the incidence of EBV-postitivity in the tumor and bone marrow (BM) samples from AILT patients, and their correlations with the
clinical
variables and patient survival.
RESULTS: Among the 27 tumor specimens, ten (37%) were EBV-
positive
.
In 13 (48%) patients, gross tumor involvement was recognized by hematoxylin-eosin staining at the time of
diagnosis
.
Among the 10 patients who had additional BM slides available, there were 3 with BM involvement, and none showed EBV
positive
results on ISH.
EBV PCR of the BM mononuclear cells revealed one-
positive
case among 8 patients.
[MeSH-major]
Herpesvirus 4,
Human
/ isolation & purification. Immunoblastic Lymphadenopathy / virology.
Lymphoma
, T-
Cell
/ virology
[MeSH-minor]
Adolescent.
Adult
. Aged. Bone Marrow / virology. DNA, Viral / isolation & purification. Female. Humans. In Situ Hybridization. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Survival Analysis
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Am J Pathol. 2000 Feb;156(2):661-9
[
10666395.001
]
[Cites]
Am J Clin Pathol. 2007 Jun;127(6):860-8
[
17509983.001
]
[Cites]
Am J Clin Pathol. 2000 Aug;114(2):236-47
[
10941339.001
]
[Cites]
Am J Clin Pathol. 2002 Mar;117(3):368-79
[
11888076.001
]
[Cites]
Leuk Lymphoma. 2002 Apr;43(4):805-11
[
12153168.001
]
[Cites]
Int J Cancer. 2003 Jan 1;103(1):12-20
[
12455048.001
]
[Cites]
Lancet Infect Dis. 2003 Mar;3(3):131-40
[
12614729.001
]
[Cites]
N Engl J Med. 2004 Mar 25;350(13):1328-37
[
15044644.001
]
[Cites]
J Korean Med Sci. 2004 Apr;19(2):229-33
[
15082896.001
]
[Cites]
Ann Oncol. 2004 Oct;15(10):1467-75
[
15367405.001
]
[Cites]
Int J Cancer. 1976 Feb 15;17(2):177-81
[
175027.001
]
[Cites]
Blood. 1991 Feb 15;77(4):799-808
[
1847084.001
]
[Cites]
Blood. 1992 Apr 1;79(7):1789-95
[
1373088.001
]
[Cites]
Blood. 1992 Jul 15;80(2):484-91
[
1320954.001
]
[Cites]
Blood. 1992 Oct 1;80(7):1804-12
[
1327284.001
]
[Cites]
Histopathology. 1993 Feb;22(2):145-9
[
8384155.001
]
[Cites]
Ann Oncol. 1995 Sep;6(7):659-64
[
8664186.001
]
[Cites]
Haematologica. 2005 Aug;90(8):1063-9
[
16079105.001
]
[Cites]
Haematologica. 2005 Sep;90(9):1192-6
[
16154842.001
]
[Cites]
Hematology Am Soc Hematol Educ Program. 2005;:260-6
[
16304390.001
]
[Cites]
J Mol Diagn. 2006 Sep;8(4):466-75; quiz 527
[
16931587.001
]
[Cites]
Leuk Lymphoma. 2007 Apr;48(4):716-22
[
17454629.001
]
[Cites]
N Engl J Med. 2000 Aug 17;343(7):481-92
[
10944566.001
]
(PMID = 18363277.001).
[ISSN]
1226-3303
[Journal-full-title]
The Korean journal of internal medicine
[ISO-abbreviation]
Korean J. Intern. Med.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Korea (South)
[Chemical-registry-number]
0 / DNA, Viral
[Other-IDs]
NLM/ PMC2686953
50.
Khositseth S, Matas A, Cook ME, Gillingham KJ, Chavers BM:
Thymoglobulin versus ATGAM induction therapy in pediatric kidney transplant recipients: a single-center report.
Transplantation
; 2005 Apr 27;79(8):958-63
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: Induction immunosuppressive therapy with the anti-T-
cell
antibody Thymoglobulin decreases the incidence of
acute
rejection in
adult
kidney transplant (KTx) recipients, but limited data are available for pediatric KTx recipients.
RESULTS: Overall, the incidence of
acute
rejection was lower in Thymoglobulin recipients versus ATGAM recipients (33% vs. 50%, P=0.02).
Epstein-Barr
virus
(EBV) infection was higher in Thymoglobulin recipients versus ATGAM recipients (8% vs. 3%, P=0.002).
But the two groups did not significantly differ in patient and graft survival rates, incidence of chronic rejection, EBV
lymphoma
, or other infection.
CONCLUSIONS: Thus, Thymoglobulin induction was
associated
with a decreased incidence of
acute
rejection and an increased incidence of EBV infection in pediatric KTx recipients.
MedlinePlus Health Information.
consumer health - Kidney Transplantation
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15849550.001).
[ISSN]
0041-1337
[Journal-full-title]
Transplantation
[ISO-abbreviation]
Transplantation
[Language]
eng
[Grant]
United States / NIDDK NIH HHS / DK / DK13083
[Publication-type]
Clinical Trial; Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / Antilymphocyte Serum
51.
Tardío JC, Moreno A, Pérez C, Hernández-Rivas JA, López-Carreira M:
Primary laryngeal T/NK-cell lymphoma, nasal-type: an unusual location for an aggressive subtype of extranodal lymphoma.
Eur Arch Otorhinolaryngol
; 2008 Jun;265(6):705-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary laryngeal T/NK-
cell lymphoma
, nasal-type: an unusual location for an aggressive subtype of extranodal
lymphoma
.
Most of them are extramedullary plasmocytomas, diffuse large B-
cell
lymphomas
, or MALT-type marginal zone B-
cell
lymphomas
.
T- or NK-
cell
lymphomas
have rarely been reported in this location.
The
diagnosis
of laryngeal
lymphomas
is a challenge, due to the absence of
clinical
and gross differential criteria.
We present hereby a primary laryngeal T/NK-
cell lymphoma
, nasal-type.
Polychemotherapy was administrated with initial partial response, but rapid local progression and exitus followed six months after the
diagnosis
.
The extranodal T/NK-
cell lymphoma
, nasal-type is a very aggressive subtype of extranodal
lymphoma
, usually located in the nasal cavity or in nearby sites.
The prognosis of extranasal cases of this type of
lymphoma
is poor, even when they are diagnosed in localized stages.
[MeSH-major]
Killer Cells, Natural / pathology. Laryngeal Neoplasms /
diagnosis
.
Lymphoma
, T-
Cell
, Peripheral /
diagnosis
[MeSH-minor]
Adult
. Antineoplastic Agents / therapeutic use. Biopsy.
Diagnosis
, Differential. Fatal Outcome. Humans. Laryngoscopy. Male. Severity of Illness Index. Tomography, X-Ray Computed
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Am J Otolaryngol. 1996 Sep-Oct;17(5):332-4
[
8870939.001
]
[Cites]
Pathol Res Pract. 1995 Mar;191(2):130-8
[
7567682.001
]
[Cites]
Cancer. 1996 May 15;77(10):2137-49
[
8640683.001
]
[Cites]
Blood. 1997 Jun 15;89(12):4501-13
[
9192774.001
]
[Cites]
Cancer. 1979 Apr;43(4):1527-32
[
445348.001
]
[Cites]
Am J Surg Pathol. 1996 Jan;20(1):103-11
[
8540601.001
]
[Cites]
Otolaryngol Head Neck Surg. 1999 Sep;121(3):335-6
[
10471889.001
]
[Cites]
Arch Otolaryngol Head Neck Surg. 1998 Sep;124(9):1037-40
[
9738818.001
]
[Cites]
Leuk Lymphoma. 1999 Oct;35(3-4):397-401
[
10706465.001
]
[Cites]
Hematology Am Soc Hematol Educ Program. 2005;:267-77
[
16304391.001
]
[Cites]
Leuk Lymphoma. 2003 Jun;44(6):1053-7
[
12854909.001
]
[Cites]
Laryngoscope. 1997 Nov;107(11 Pt 1):1502-6
[
9369397.001
]
[Cites]
Hematology Am Soc Hematol Educ Program. 2006;:331-7
[
17124080.001
]
[Cites]
J Laryngol Otol. 1989 Oct;103(10):955-60
[
2685150.001
]
[Cites]
Br J Haematol. 1997 Jun;97(4):821-9
[
9217183.001
]
[Cites]
Blood. 1998 Mar 1;91(5):1723-31
[
9473239.001
]
[Cites]
Hum Pathol. 1990 Oct;21(10):1041-50
[
2210727.001
]
[Cites]
Head Neck. 2001 Aug;23(8):625-8
[
11443744.001
]
(PMID = 17955253.001).
[ISSN]
0937-4477
[Journal-full-title]
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
[ISO-abbreviation]
Eur Arch Otorhinolaryngol
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Antineoplastic Agents
52.
Rymkiewicz G, Ptaszyński K, Walewski J, Błachnio K, Swoboda P, Gos M, Paszkiewicz-Kozik E, Woroniecka R, Pieńkowska-Grela B, Czarnocka M, Janik P:
Unusual cyclin D1 positive marginal zone lymphoma of mediastinum.
Med Oncol
; 2006;23(3):423-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Unusual cyclin D1
positive
marginal zone
lymphoma
of mediastinum.
We report a case of 43-yr-old Caucasian female with an unusual, cyclin D1
positive
marginal zone
lymphoma
(MZL) of mucosa-
associated
lymphoid tissue (MALT) type of the mediastinum.
They occur mainly in Asian females with a history of coexisting autoimmune
disease
.
The
diagnosis
was based on histopathological examination only.
Our final
diagnosis
of MZL was made by combined evaluation of histopathology (HP), immunohistochemistry (IH), flow cytometry (FCM), fluorescence in situ hybridization (FISH), and molecular biology studies.
We found
a positive
cyclin D1 reaction by IH and cyclin D1 mRNA (CCND1) overexpression by reverse transcription polymerase chain reaction (RT-PCR).
Very high cyclin D1 to beta-actin mRNA ratio in this case was comparable with the ratio, characteristic for mantle
cell lymphoma
(MCL).
However, there was no translocation t(11;14) found by FISH and an immunophenotype by IH and FCM was consistent with MZL ruling out MCL
diagnosis
.
In addition, our case differs from other, previously reported thymic MZL
lymphoma
cases by no autoimmune
disease
association, Caucasian origin, and the absence of the plasmacytic differentiation on both HP/IH.
[MeSH-major]
Cyclin D1 / biosynthesis. Gene Expression Regulation, Neoplastic.
Lymphoma
, B-
Cell
, Marginal Zone / metabolism. Mediastinal Neoplasms / metabolism
[MeSH-minor]
Adult
. Female. Flow Cytometry / methods. Humans. Immunohistochemistry / methods. Immunophenotyping. In Situ Hybridization, Fluorescence / methods.
Lymphoma
, Mantle-
Cell
/ genetics.
Lymphoma
, Mantle-
Cell
/ pathology. Models, Biological. Translocation, Genetic
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer. 1992 Mar 15;69(6):1347-55
[
1540872.001
]
[Cites]
Arch Pathol Lab Med. 2003 Feb;127(2):E76-9
[
12562258.001
]
[Cites]
Semin Diagn Pathol. 1991 Feb;8(1):2-13
[
2047614.001
]
[Cites]
Blood. 1997 Oct 15;90(8):2863-92
[
9376567.001
]
[Cites]
Med Oncol. 2005;22(3):319-23
[
16110143.001
]
[Cites]
J Mol Diagn. 2004 May;6(2):84-9
[
15096562.001
]
[Cites]
Am J Pathol. 1998 Dec;153(6):1969-76
[
9846986.001
]
[Cites]
Am J Pathol. 2002 Apr;160(4):1435-43
[
11943727.001
]
[Cites]
Am J Pathol. 1994 Jul;145(1):86-96
[
7518196.001
]
[Cites]
J Clin Oncol. 1993 Oct;11(10):1985-9
[
8410123.001
]
[Cites]
Lancet Oncol. 2004 Feb;5(2):107-18
[
14761815.001
]
[Cites]
Blood. 1987 Apr;69(4):1087-95
[
3103712.001
]
[Cites]
Am J Pathol. 1991 Mar;138(3):591-9
[
1900388.001
]
[Cites]
Ann Oncol. 1996 Mar;7(3):251-6
[
8740788.001
]
[Cites]
J Exp Med. 1980 Nov 1;152(5):1430-5
[
6968814.001
]
[Cites]
J Appl Genet. 2002;43(4):545-53
[
12441639.001
]
[Cites]
J Clin Oncol. 1987 Mar;5(3):407-12
[
3819806.001
]
[Cites]
Blood. 2000 Apr 1;95(7):2253-61
[
10733493.001
]
[Cites]
Am J Surg Pathol. 1990 Apr;14(4):342-51
[
1690952.001
]
[Cites]
Am J Clin Pathol. 2000 Jun;113(6):784-91
[
10874878.001
]
[Cites]
Genes Chromosomes Cancer. 1993 Oct;8(2):80-7
[
7504521.001
]
[Cites]
Mod Pathol. 2002 May;15(5):556-64
[
12011261.001
]
[Cites]
Am J Med. 1980 Apr;68(4):509-14
[
6892753.001
]
(PMID = 17018901.001).
[ISSN]
1559-131X
[Journal-full-title]
Medical oncology (Northwood, London, England)
[ISO-abbreviation]
Med. Oncol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
136601-57-5 / Cyclin D1
53.
Hui D, Proctor B, Donaldson J, Shenkier T, Hoskins P, Klasa R, Savage K, Chhanabhai M, Gascoyne RD, Connors JM, Sehn LH:
Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone.
Leuk Lymphoma
; 2010 Sep;51(9):1658-67
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prognostic implications of extranodal involvement in patients with diffuse large B-
cell lymphoma
treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone.
We sought to
re
-examine the prognostic utility of (1) the number of extranodal sites of
disease
involvement, and (2) a primary extranodal presentation in patients with DLBCL treated with immunochemotherapy.
In the R-CHOP group, extranodal involvement as defined by the International Prognostic Index (>or=2 sites) was not prognostic on multivariate analysis, but the presence of any extranodal involvement (>or=1 site) was
associated
with decreased progression-free survival (HR 1.6, 95% CI 1.1-2.4, p = 0.024) and overall survival (HR 1.8, 95% CI 1.1-2.7, p = 0.011).
There was no difference in outcome between patients with primary extranodal and nodal DLBCL, and no primary site of involvement was
associated
with an inferior outcome.
In patients with DLBCL treated with R-CHOP, the presence of extranodal
disease
remains prognostic, whereas a primary extranodal presentation did not affect outcome.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymph Nodes / pathology.
Lymphoma
, Large B-
Cell
, Diffuse / drug therapy
[MeSH-minor]
Adult
. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-
Derived
/ administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prednisone / administration & dosage. Prognosis. Rituximab. Survival Rate. Tissue Distribution. Vincristine / administration & dosage. Young
Adult
Genetic Alliance.
consumer health - Large B cell diffuse lymphoma
.
Hazardous Substances Data Bank.
RITUXIMAB
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20795790.001).
[ISSN]
1029-2403
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
54.
Kress AK, Schneider G, Pichler K, Kalmer M, Fleckenstein B, Grassmann R:
Elevated cyclic AMP levels in T lymphocytes transformed by human T-cell lymphotropic virus type 1.
J Virol
; 2010 Sep;84(17):8732-42
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Elevated cyclic AMP levels in T lymphocytes transformed by
human
T-
cell
lymphotropic virus
type 1.
Human
T-
cell
lymphotropic virus
type 1 (
HTLV
-1), the cause of
adult T
-
cell
leukemia
/
lymphoma
(
ATLL
), transforms CD4(+) T cells to permanent growth through its transactivator Tax.
HTLV
-1-transformed cells share phenotypic properties with memory and regulatory T cells (T-reg).
This led us to determine cAMP levels in
HTLV
-1-transformed cells.
We found elevated cAMP concentrations as a consistent feature of
all HTLV
-1-transformed
cell
lines, including in vitro-
HTLV
-1-transformed, Tax-transformed, and patient-
derived
cells.
We found specific downregulation of the cAMP-degrading phosphodiesterase 3B (PDE3B) in
HTLV
-1-transformed cells, which was independent of Tax in transient expression experiments.
Overexpression of PDE3B led to a decrease of cAMP in
HTLV
-1-transformed cells.
Decreased expression of PDE3B was
associated
with inhibitory histone modifications at the PDE3B promoter and the PDE3B locus.
This shows that
HTLV
-1-transformed cells assume biological features of long-lived T-
cell
populations that potentially contribute to viral persistence.
[MeSH-major]
Cell
Transformation, Viral. Cyclic AMP / metabolism.
HTLV
-I Infections / metabolism.
Human
T-
lymphotropic virus
1 / physiology.
Leukemia
-
Lymphoma
,
Adult T
-
Cell
/ metabolism
[MeSH-minor]
Cell
Line, Transformed. Cells, Cultured. Cyclic Nucleotide Phosphodiesterases, Type 3 / genetics. Cyclic Nucleotide Phosphodiesterases, Type 3 / metabolism. Gene Products, tax / genetics. Gene Products, tax / metabolism. Humans. T-Lymphocytes / metabolism. T-Lymphocytes / virology
SciCrunch.
ArrayExpress: Data: Microarray
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Biochem Pharmacol. 1999 Sep 15;58(6):935-50
[
10509746.001
]
[Cites]
Cancer Res. 1986 Sep;46(9):4458-62
[
2873886.001
]
[Cites]
Cancer Sci. 2005 Aug;96(8):527-33
[
16108835.001
]
[Cites]
Oncogene. 2005 Sep 5;24(39):5938-51
[
16155601.001
]
[Cites]
Oncogene. 2005 Sep 5;24(39):5976-85
[
16155604.001
]
[Cites]
Oncogene. 2005 Sep 5;24(39):6026-34
[
16155609.001
]
[Cites]
Oncogene. 2005 Sep 5;24(39):6035-46
[
16155610.001
]
[Cites]
Int Immunol. 2006 Feb;18(2):269-77
[
16361311.001
]
[Cites]
Nat Med. 2006 Apr;12(4):466-72
[
16550188.001
]
[Cites]
Blood. 2006 Jun 1;107(11):4491-9
[
16467195.001
]
[Cites]
Pharmacol Rev. 2006 Sep;58(3):488-520
[
16968949.001
]
[Cites]
J Leukoc Biol. 2006 Oct;80(4):880-8
[
16888088.001
]
[Cites]
Blood. 2006 Dec 15;108(13):3979-82
[
16917009.001
]
[Cites]
J Virol. 2007 Mar;81(5):2524-30
[
17151105.001
]
[Cites]
Nature. 2007 Feb 15;445(7129):771-5
[
17220874.001
]
[Cites]
Nature. 2007 Feb 22;445(7130):936-40
[
17237761.001
]
[Cites]
Cell. 2007 Feb 23;128(4):669-81
[
17320505.001
]
[Cites]
Nat Rev Cancer. 2007 Apr;7(4):270-80
[
17384582.001
]
[Cites]
J Exp Med. 2007 Jun 11;204(6):1303-10
[
17502663.001
]
[Cites]
J Biol Chem. 2007 Jun 29;282(26):18750-7
[
17449469.001
]
[Cites]
J Immunol. 2008 Jan 15;180(2):931-9
[
18178833.001
]
[Cites]
J Gen Physiol. 2008 Apr;131(4):293-305
[
18378798.001
]
[Cites]
Blood. 2008 May 1;111(9):4741-51
[
18276843.001
]
[Cites]
Blood. 2000 Jan 1;95(1):30-8
[
10607681.001
]
[Cites]
FEBS Lett. 2001 Sep 7;505(1):136-40
[
11557056.001
]
[Cites]
Nucleic Acids Res. 2002 Jan 1;30(1):207-10
[
11752295.001
]
[Cites]
Mol Cell Biol. 1985 Dec;5(12):3610-6
[
3915782.001
]
[Cites]
Nature. 1988 Oct 20;335(6192):738-40
[
3262832.001
]
[Cites]
J Virol. 1989 Apr;63(4):1604-11
[
2538645.001
]
[Cites]
J Virol. 1989 Aug;63(8):3220-6
[
2501514.001
]
[Cites]
J Virol. 1992 Jul;66(7):4570-5
[
1351105.001
]
[Cites]
AIDS Res Hum Retroviruses. 1994 Oct;10(10):1259-68
[
7531462.001
]
[Cites]
J Exp Med. 1995 Mar 1;181(3):985-92
[
7532686.001
]
[Cites]
Clin Diagn Lab Immunol. 1995 May;2(3):349-55
[
7545080.001
]
[Cites]
J Virol. 1998 Jan;72(1):633-40
[
9420268.001
]
[Cites]
Retrovirology. 2008;5:76
[
18702816.001
]
[Cites]
FEBS Lett. 2008 Oct 29;582(25-26):3614-8
[
18835269.001
]
[Cites]
Blood. 2008 Nov 1;112(9):3788-97
[
18689544.001
]
[Cites]
Retrovirology. 2008;5:100
[
19014482.001
]
[Cites]
Int J Cancer. 2009 Nov 15;125(10):2375-82
[
19544530.001
]
[Cites]
Virus Genes. 2001 Dec;23(3):263-71
[
11778694.001
]
[Cites]
Blood. 2002 May 1;99(9):3383-9
[
11964307.001
]
[Cites]
Nat Rev Mol Cell Biol. 2002 Sep;3(9):710-8
[
12209131.001
]
[Cites]
Virology. 2003 Dec 5;317(1):136-45
[
14675632.001
]
[Cites]
Cancer Res. 2004 Mar 15;64(6):2039-46
[
15026341.001
]
[Cites]
J Virol. 2004 Sep;78(18):9814-9
[
15331715.001
]
[Cites]
J Immunol. 1971 Nov;107(5):1489-92
[
4330163.001
]
[Cites]
Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9
[
6261256.001
]
[Cites]
Proc Natl Acad Sci U S A. 1984 Apr;81(8):2534-7
[
6326131.001
]
[Cites]
Gan. 1984 Sep;75(9):752-5
[
6094296.001
]
[Cites]
J Gen Virol. 1985 Aug;66 ( Pt 8):1825-9
[
2991447.001
]
[Cites]
Lancet. 1985 Aug 24;2(8452):407-10
[
2863442.001
]
[Cites]
Lancet. 1986 May 3;1(8488):1031-2
[
2871307.001
]
[Cites]
Biochem Biophys Res Commun. 2005 Jul 1;332(2):569-84
[
15896717.001
]
(PMID = 20573814.001).
[ISSN]
1098-5514
[Journal-full-title]
Journal of virology
[ISO-abbreviation]
J. Virol.
[Language]
eng
[Databank-accession-numbers]
GEO/ GSE17718
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Gene Products, tax; 0 / tax protein, Human T-lymphotrophic virus 1; E0399OZS9N / Cyclic AMP; EC 3.1.4.17 / Cyclic Nucleotide Phosphodiesterases, Type 3; EC 3.1.4.17 / PDE3B protein, human
[Other-IDs]
NLM/ PMC2918996
55.
Dulai MS, Park CY, Howell WD, Smyth LT, Desai M, Carter DM, Vogel H:
CNS T-cell lymphoma: an under-recognized entity?
Acta Neuropathol
; 2008 Mar;115(3):345-56
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
CNS T-
cell lymphoma
: an under-recognized entity?
The incidence of CNS
lymphoma
has increased significantly in the past 30 years, primarily in the elderly and immunocompromised.
While T-
cell
lymphomas
comprise 15-20% of systemic
lymphomas
, they comprise less than 4% of primary CNS
lymphomas
, suggesting that they may be under-recognized compared to their systemic counterparts.
To investigate this, we studied brain biopsies from three patients who were diagnosed with T-
cell lymphoma
confined to the brain.
We compared these to biopsies from three patients who had reactive lymphoid infiltrates and who had
clinical
signs/symptoms and radiographic findings that were indistinguishable from the
lymphoma
group.
Biopsies from both the
lymphoma
group and reactive group showed considerable cytomorphologic heterogeneity.
Although one
lymphoma
case contained large atypical cells, the other two contained small, mature lymphocytes within a heterogeneous infiltrate of neoplastic and reactive inflammatory cells.
Surface marker aberrancies were present in two
lymphoma
cases, but this alone could not reliably diagnose T-
cell lymphoma
.
The proliferation index was not useful for differentiating
lymphoma
from reactive infiltrates.
In five of the six cases the
diagnosis
was most influenced by clonality studies for T-
cell
receptor-gamma gene rearrangements.
We conclude that because of the high degree of overlap in cytomorphologic and immunophenotypic features between T-
cell lymphoma
and reactive infiltrates, T-
cell lymphoma
may not be recognized unless studies for T-
cell
receptor gene rearrangements are performed for CNS lesions composed of a polymorphous but predominantly T-
cell
infiltrate.
[MeSH-major]
Brain Diseases / pathology. Central Nervous System Neoplasms / pathology.
Lymphoma
, T-
Cell
/ pathology
[MeSH-minor]
Adult
.
Diagnosis
, Differential. Female. Gene Rearrangement, gamma-Chain T-
Cell
Antigen Receptor. Humans. Immunohistochemistry. In Situ Hybridization. Magnetic Resonance Imaging. Male. Middle Aged. Polymerase Chain Reaction
MedlinePlus Health Information.
consumer health - Brain Diseases
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18196250.001).
[ISSN]
0001-6322
[Journal-full-title]
Acta neuropathologica
[ISO-abbreviation]
Acta Neuropathol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Germany
56.
Uphoff CC, Denkmann SA, Steube KG, Drexler HG:
Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.
J Biomed Biotechnol
; 2010;2010:904767
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Detection of EBV, HBV, HCV, HIV-1,
HTLV
-I and -II, and SMRV in
human
and other primate
cell
lines.
The high prevalence of contaminated
cell
cultures suggests that viral contaminations might be distributed among cultures.
We investigated more than 460 primate
cell
lines for Epstein-Barr (EBV), hepatitis B (HBV), hepatitis C (HCV),
human
immunodeficiency
virus
type 1 (HIV-1),
human
T-
cell
leukemia
/
lymphoma
virus I
and II (
HTLV
-I/-II), and squirrel monkey retrovirus (SMRV) infections for risk assessment.
None of the
cell
lines were infected with HCV, HIV-1, or
HTLV
-I/-II.
However, one
cell
line displayed reverse transcriptase activity.
Thirty-nine
cell
lines harbored EBV DNA sequences.
Studies on the lytic phase of EBV revealed that five
cell
lines produce EBV particles and six further
cell
lines produced EBV upon stimulation.
One
cell
line contained an integrated HBV genome fragment but showed
no virus
production.
Six
cell
lines were SMRV-infected.
Newly established
cell
lines should be tested for EBV infections to detect B-lymphoblastoid
cell
lines (B-LCL).
B-LCLs established with EBV from
cell
line B95-8 should be tested for SMRV infections.
[MeSH-major]
Primates / virology.
Viruses
/ genetics.
Viruses
/ isolation & purification
[MeSH-minor]
Animals. Blotting, Southern.
Cell
Line. DNA, Circular / analysis. HIV-1 / genetics. HIV-1 / isolation & purification. Hepacivirus / genetics. Hepacivirus / isolation & purification. Hepatitis B
virus
/ genetics. Hepatitis B
virus
/ isolation & purification. Herpesvirus 4,
Human
/ genetics. Herpesvirus 4,
Human
/ isolation & purification.
Human
T-
lymphotropic virus
1 / genetics.
Human
T-
lymphotropic virus
1 / isolation & purification.
Human
T-
lymphotropic virus
2 / genetics.
Human
T-
lymphotropic virus
2 / isolation & purification. Humans. In Situ Hybridization, Fluorescence. Polymerase Chain Reaction. Retroviruses, Simian / genetics. Retroviruses, Simian / isolation & purification. Saimiri / virology. Viral Proteins / analysis
Genetic Alliance.
consumer health - HIV
.
Cellosaurus - a cell line knowledge resource.
culture/stock collections - Cell lines described in this publication
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Genes Chromosomes Cancer. 1992 Apr;4(3):205-10
[
1382560.001
]
[Cites]
ALTEX. 2005;22(2):103-9
[
15953965.001
]
[Cites]
J Virol Methods. 1992 Sep;39(3):259-68
[
1430070.001
]
[Cites]
J Virol Methods. 1992 Dec 1;40(3):347-56
[
1282132.001
]
[Cites]
Gastroenterology. 1993 Nov;105(5):1529-33
[
8224658.001
]
[Cites]
Leukemia. 1994 Apr;8(4):652-8
[
8152260.001
]
[Cites]
Leukemia. 1994 Aug;8(8):1385-91
[
8057678.001
]
[Cites]
Leukemia. 1994 Sep;8(9):1510-26
[
8090031.001
]
[Cites]
Int J Cancer. 1997 Nov 14;73(4):562-9
[
9389573.001
]
[Cites]
J Hepatol. 1998 Mar;28(3):396-403
[
9551676.001
]
[Cites]
DNA Cell Biol. 1998 May;17(5):415-25
[
9628585.001
]
[Cites]
Br J Haematol. 1998 Sep;102(4):1081-9
[
9734661.001
]
[Cites]
Leukemia. 1998 Nov;12(11):1806-9
[
9823957.001
]
[Cites]
Eur J Haematol. 1999 Jan;62(1):1-18
[
9918306.001
]
[Cites]
Biochem Biophys Res Commun. 1999 Oct 14;264(1):33-6
[
10527836.001
]
[Cites]
J Hepatol. 1999 Nov;31(5):967-8
[
10580600.001
]
[Cites]
Eur J Cancer. 1999 Dec;35(14):1878-85
[
10711230.001
]
[Cites]
Leuk Res. 2002 Apr;26(4):329-33
[
11839374.001
]
[Cites]
In Vitro Cell Dev Biol Anim. 2002 Feb;38(2):79-85
[
11928999.001
]
[Cites]
J Virol. 2002 Jun;76(11):5612-26
[
11991990.001
]
[Cites]
Haemophilia. 2002 May;8(3):236-43
[
12010417.001
]
[Cites]
Leuk Lymphoma. 2004 Mar;45(3):567-74
[
15160920.001
]
[Cites]
Nature. 1973 Mar 2;242(5392):44-7
[
4348458.001
]
[Cites]
Int J Cancer. 1974 Mar 15;13(3):363-76
[
4362611.001
]
[Cites]
Neoplasma. 1974;21(6):619-27
[
4141066.001
]
[Cites]
J Virol Methods. 2006 Sep;136(1-2):193-9
[
16806502.001
]
[Cites]
Adv Cancer Res. 2007;97:81-109
[
17419942.001
]
[Cites]
Beitr Pathol. 1975 May;155(1):72-8
[
168861.001
]
[Cites]
Science. 1977 Jan 21;195(4275):289-92
[
63993.001
]
[Cites]
Virology. 1980 Mar;101(2):553-7
[
6244705.001
]
[Cites]
Nature. 1981 Dec 24;294(5843):770-1
[
6275274.001
]
[Cites]
Int J Cancer. 1982 Jul 15;30(1):93-9
[
6288581.001
]
[Cites]
Proc Natl Acad Sci U S A. 1983 Apr;80(7):1987-91
[
6300885.001
]
[Cites]
J Virol. 1984 Apr;50(1):248-54
[
6321792.001
]
[Cites]
Gene. 1984 Mar;27(3):279-88
[
6329907.001
]
[Cites]
Cell Mol Biol. 1986;32(3):343-50
[
3017561.001
]
[Cites]
Int J Cancer. 1987 Jan 15;39(1):89-93
[
3098690.001
]
[Cites]
Proc Natl Acad Sci U S A. 1987 Feb;84(4):1005-9
[
3029758.001
]
[Cites]
Proc Natl Acad Sci U S A. 1987 Mar;84(5):1332-6
[
3029778.001
]
[Cites]
Eur J Biochem. 1987 Jun 1;165(2):393-401
[
2439332.001
]
[Cites]
Blood. 1987 Nov;70(5):1665-72
[
3478106.001
]
[Cites]
Clin Exp Immunol. 1988 Jul;73(1):23-8
[
3262465.001
]
[Cites]
J Infect Dis. 1988 Dec;158(6):1193-7
[
3198935.001
]
[Cites]
Virology. 1988 Dec;167(2):468-76
[
3201749.001
]
[Cites]
J Exp Med. 1989 Jun 1;169(6):2191-8
[
2543732.001
]
[Cites]
J Virol. 1990 Mar;64(3):1143-55
[
2154599.001
]
[Cites]
Leuk Res. 1990;14(4):381-7
[
2159091.001
]
[Cites]
J Med Virol. 1990 Apr;30(4):266-71
[
2164560.001
]
[Cites]
Leukemia. 1991 Mar;5(3):221-4
[
1849602.001
]
[Cites]
Leukemia. 1991 May;5(5):399-407
[
1851909.001
]
[Cites]
Braz J Med Biol Res. 2004 Nov;37(11):1707-12
[
15517087.001
]
[Cites]
Int J Cancer. 1992 Sep 30;52(3):451-4
[
1339415.001
]
(PMID = 20454443.001).
[ISSN]
1110-7251
[Journal-full-title]
Journal of biomedicine & biotechnology
[ISO-abbreviation]
J. Biomed. Biotechnol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / DNA, Circular; 0 / Viral Proteins
[Other-IDs]
NLM/ PMC2861168
57.
Halfdanarson TR, Rubio-Tapia A, Ristow KM, Habermann TM, Murray JA, Inwards DJ:
Patients with celiac disease and B-cell lymphoma have a better prognosis than those with T-cell lymphoma.
Clin Gastroenterol Hepatol
; 2010 Dec;8(12):1042-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Patients with celiac
disease
and B-
cell lymphoma
have a better prognosis than those with T-
cell lymphoma
.
BACKGROUND & AIMS: Celiac
disease
(CD) is
associated
with an increased risk of
lymphoma
.
However, relatively few studies have assessed the outcome of patients diagnosed with both CD and
lymphoma
.
We evaluated the temporal association between
lymphoma
and CD, along with
clinical
presentation, response to therapy, and prognosis.
METHODS: Patients diagnosed with both CD and
lymphoma
were identified retrospectively in a tertiary referral center.
Clinical
characteristics and survival were analyzed.
RESULTS: Sixty-three patients (36 men) were identified who had been diagnosed with
lymphoma
and CD.
Thirty-six (57%) were diagnosed with CD before they were diagnosed with
lymphoma
.
The most common histologic entity was diffuse, large, B-
cell lymphoma
, which affected 18 (29%) patients.
Complete information for staging was available in 59 patients; 24 (38%) had stage IV
disease
.
Survival of patients with T-
cell lymphoma
was shorter than for all other
lymphomas
(119.4 vs 22.8 mo; P = .02).
CONCLUSIONS: CD is
associated
with B- and T-
cell
lymphomas
.
Patients with B-
cell
lymphomas
had a better prognosis than those with T-
cell lymphoma
.
Therapy is unsatisfactory for enteropathy-type T-
cell lymphoma
.
Genetic Alliance.
consumer health - Celiac Disease
.
MedlinePlus Health Information.
consumer health - Celiac Disease
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright © 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
[Cites]
Lancet. 2000 Jul 15;356(9225):203-8
[
10963198.001
]
[Cites]
Am J Gastroenterol. 2010 Jun;105(6):1412-20
[
20145607.001
]
[Cites]
Am J Pathol. 2002 Nov;161(5):1635-45
[
12414511.001
]
[Cites]
Arch Intern Med. 2003 Feb 10;163(3):286-92
[
12578508.001
]
[Cites]
N Engl J Med. 2003 Jun 19;348(25):2517-24
[
12815137.001
]
[Cites]
Gastroenterology. 2003 Jul;125(1):40-6
[
12851869.001
]
[Cites]
Gastroenterology. 2003 Sep;125(3):730-45
[
12949719.001
]
[Cites]
Clin Gastroenterol Hepatol. 2003 Jan;1(1):19-27
[
15017513.001
]
[Cites]
Lancet. 1978 Jan 14;1(8055):67-70
[
74567.001
]
[Cites]
J Clin Oncol. 2000 Feb;18(4):795-803
[
10673521.001
]
[Cites]
Digestion. 2000;62(1):60-5
[
10899727.001
]
[Cites]
Br Med J (Clin Res Ed). 1983 Jan 1;286(6358):16-8
[
6401441.001
]
[Cites]
Am J Clin Oncol. 1982 Dec;5(6):649-55
[
7165009.001
]
[Cites]
Gut. 1989 Mar;30(3):333-8
[
2707633.001
]
[Cites]
N Engl J Med. 1993 Sep 30;329(14):987-94
[
8141877.001
]
[Cites]
BMJ. 1994 Jan 1;308(6920):13-5
[
8298344.001
]
[Cites]
Gut. 1994 Sep;35(9):1215-8
[
7959226.001
]
[Cites]
J Clin Gastroenterol. 1995 Sep;21(2):123-9
[
8583077.001
]
[Cites]
Gut. 1996 Apr;38(4):528-30
[
8707082.001
]
[Cites]
Gastroenterology. 1998 Mar;114(3):471-81
[
9496937.001
]
[Cites]
Gut. 2005 Jan;54(1):54-9
[
15591504.001
]
[Cites]
Gastroenterology. 2005 Apr;128(4 Suppl 1):S79-86
[
15825131.001
]
[Cites]
CA Cancer J Clin. 2005 Nov-Dec;55(6):368-76
[
16282281.001
]
[Cites]
Blood. 2006 Jan 1;107(1):265-76
[
16150940.001
]
[Cites]
J Natl Cancer Inst. 2006 Jan 4;98(1):51-60
[
16391371.001
]
[Cites]
Eur J Gastroenterol Hepatol. 2006 Feb;18(2):187-94
[
16394801.001
]
[Cites]
Clin Gastroenterol Hepatol. 2006 Mar;4(3):315-9
[
16527694.001
]
[Cites]
Clin Gastroenterol Hepatol. 2006 Nov;4(11):1320-1
[
17110301.001
]
[Cites]
Gastroenterology. 2006 Dec;131(6):1981-2002
[
17087937.001
]
[Cites]
Blood. 2007 Jan 15;109(2):412-21
[
16973955.001
]
[Cites]
Br J Haematol. 2007 Jan;136(1):111-3
[
17116129.001
]
[Cites]
Br J Haematol. 2007 Apr;137(2):170; author reply 171
[
17391498.001
]
[Cites]
Aliment Pharmacol Ther. 2007 May 15;25(10):1237-45
[
17451570.001
]
[Cites]
Gastroenterology. 2007 May;132(5):1902-11
[
17484883.001
]
[Cites]
Dig Liver Dis. 2007 Jul;39(7):634-41
[
17531561.001
]
[Cites]
Gut. 2007 Oct;56(10):1373-8
[
17470479.001
]
[Cites]
N Engl J Med. 2007 Oct 25;357(17):1731-43
[
17960014.001
]
[Cites]
Clin Gastroenterol Hepatol. 2007 Dec;5(12):1399-405, 1405.e1-2
[
17967566.001
]
[Cites]
Scand J Gastroenterol. 2008;43(11):1322-8
[
18618372.001
]
[Cites]
Eur J Gastroenterol Hepatol. 2009 Jan;21(1):66-70
[
19011576.001
]
[Cites]
Gastroenterology. 2009 Jan;136(1):91-8
[
18950631.001
]
[Cites]
Gastroenterology. 2009 Jan;136(1):99-107; quiz 352-3
[
18996383.001
]
[Cites]
Gastroenterology. 2009 Jan;136(1):81-90
[
19014942.001
]
[Cites]
Gastroenterology. 2009 Jul;137(1):88-93
[
19362553.001
]
[Cites]
Gut. 2010 Apr;59(4):547-57
[
20332526.001
]
[Cites]
Blood. 2010 May 6;115(18):3664-70
[
20197551.001
]
[Cites]
JAMA. 2002 Mar 20;287(11):1413-9
[
11903028.001
]
(PMID = 20851210.001).
[ISSN]
1542-7714
[Journal-full-title]
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
[ISO-abbreviation]
Clin. Gastroenterol. Hepatol.
[Language]
ENG
[Grant]
United States / NIDDK NIH HHS / DK / R01 DK057892; United States / NIAID NIH HHS / AI / T32 AI007047; United States / NIDDK NIH HHS / DK / DK-57892; United States / NIAID NIH HHS / AI / T32 AI-07047
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Other-IDs]
NLM/ NIHMS237618; NLM/ PMC3594736
58.
Persico M, Capasso M, Persico E, Masarone M, Renzo Ad, Spano D, Bruno S, Iolascon A:
Interleukin-10 - 1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection.
J Hepatol
; 2006 Dec;45(6):779-85
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Interleukin-10 - 1082 GG polymorphism influences the occurrence and the
clinical
characteristics of hepatitis
C virus
infection.
BACKGROUND/AIMS: In this study, we determined the genotypic and allelic frequencies of the Interleukin (IL)-10(-1082G/A) IL-10(-592A/C), and IL-10(-819C/T) polymorphisms, and their association with the risk to develop B
cell
Non Hodgkin
Lymphoma
(NHL) in hepatitis
virus C
(HCV) carriers.
RESULTS: Genetic polymorphisms in the IL-10 gene promoter were studied in 250 consecutive patients with B-
cell
NHL with
no clinical
and/or laboratory findings of cryoglobulinemia, 142 NHL/HCV- and 108 NHL/HCV+ with chronic hepatitis (
CH
), 120 consecutive subjects with HCV-related
CH
, and 110 age, sex-matched healthy blood donors.
The frequency of the IL-10(-1082GG) genotype vs remaining genotypes (IL-10(-1082GA/AA)) was higher in NHL/HCV+ patients than HCV-related
CH
patients (P=0.0002, OR=2.89, CI: 1.62-5.15) and in NHL/HCV+ than NHL/HCV- patients (P=0.0001, OR=2.99, CI: 1.72-5.19).
Finally, we confirmed that IL-10(-1082GG) genotype is
associated
with higher IL-10 production compared to AA homozygous (P=0.037).
CONCLUSIONS: The high IL-10 production, due to IL-10(-1082GG) genotype, influences the
clinical
expression of the HCV infection by increasing susceptibility to develop NHL and might contribute to the indolent form of the
disease
.
[MeSH-minor]
Adult
. Aged. Alleles. Female. Gene Frequency. Genetic Predisposition to
Disease
. Genotype. Humans.
Lymphoma
, B-
Cell
/ epidemiology.
Lymphoma
, B-
Cell
/ etiology.
Lymphoma
, B-
Cell
/ genetics. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. RNA, Viral / analysis. Retrospective Studies. Risk Factors
Genetic Alliance.
consumer health - Hepatitis
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17049666.001).
[ISSN]
0168-8278
[Journal-full-title]
Journal of hepatology
[ISO-abbreviation]
J. Hepatol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / RNA, Viral; 130068-27-8 / Interleukin-10; 9007-49-2 / DNA
59.
Dögel D, Beuing O, Koenigsmann M, Diete S:
[Paraneoplastic limbic encephalitis resulting from non-Hodgkin-lymphoma: two case reports].
Fortschr Neurol Psychiatr
; 2008 Jan;76(1):41-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Paraneoplastic limbic encephalitis resulting from non-Hodgkin-
lymphoma
: two case reports].
Paraneoplastic limbic encephalitis (PLE) is a rare
disease
that is probably caused by an immunological reaction against CNS-structures.
Besides treatment of the underlying neoplastic
disease
, there is no generally applicable evidence-based treatment.
PLE is most frequently
associated
with certain carcinomas, but its occurrence with Hodgkin
lymphoma
has also been recognized.
Association with non-Hodgkin
lymphoma
has only been occasionally reported in single cases.
We report two additional patients, in whom malignant non-Hodgkin
lymphomas
of the B- and T-
cell
lines were detected.
Treatment with corticosteroids in one and chemotherapy in the other case were
associated
with
clinical
improvement.
[MeSH-major]
Limbic Encephalitis / etiology.
Lymphoma
, Non-Hodgkin / complications
[MeSH-minor]
Adrenal Cortex Hormones / therapeutic use.
Adult
. Aged. Anti-Inflammatory Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Electroencephalography. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed
Genetic Alliance.
consumer health - Hodgkin lymphoma
.
Genetic Alliance.
consumer health - Limbic encephalitis
.
Genetic Alliance.
consumer health - Non-Hodgkin Lymphoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18189222.001).
[ISSN]
0720-4299
[Journal-full-title]
Fortschritte der Neurologie-Psychiatrie
[ISO-abbreviation]
Fortschr Neurol Psychiatr
[Language]
ger
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Adrenal Cortex Hormones; 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents
60.
Hara S, Yokote T, Oka S, Akioka T, Kobayashi K, Hirata Y, Miyoshi T, Tsuji M, Hanafusa T:
Endophthalmitis due to Trichosporon beigelii in acute leukemia.
Int J Hematol
; 2007 Jun;85(5):415-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Endophthalmitis due to Trichosporon beigelii in
acute leukemia
.
The administration of AMPH-B is likely to be more effective in treating endophthalmitis due to trichosporonosis when the
disease
is at an early stage.
[MeSH-major]
Endophthalmitis / complications. Endophthalmitis / microbiology.
Leukemia
, Myeloid / complications. Mycoses / complications. Precursor
Cell
Lymphoblastic
Leukemia
-
Lymphoma
/ complications. Trichosporon
[MeSH-minor]
Acute Disease
.
Adult
. Amphotericin B / administration & dosage. Antifungal Agents / administration & dosage. Drug Resistance, Fungal. Female. Fluconazole / administration & dosage. Flucytosine / administration & dosage. Humans. Male. Middle Aged
MedlinePlus Health Information.
consumer health - Fungal Infections
.
Hazardous Substances Data Bank.
AMPHOTERICIN B
.
Hazardous Substances Data Bank.
FLUCYTOSINE
.
Hazardous Substances Data Bank.
FLUCONAZOLE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Rocz Panstw Zakl Hig. 1994;45(4):337-46
[
7792523.001
]
[Cites]
Medicine (Baltimore). 1986 Jul;65(4):268-79
[
3523114.001
]
[Cites]
Cancer. 1975 Sep;36(3):1106-10
[
52400.001
]
[Cites]
J Clin Oncol. 1991 Jul;9(7):1210-4
[
2045861.001
]
[Cites]
Antimicrob Agents Chemother. 2000 Jan;44(1):57-62
[
10602723.001
]
[Cites]
N Engl J Med. 1999 Mar 11;340(10):764-71
[
10072411.001
]
[Cites]
Curr Top Med Mycol. 1993;5:79-113
[
8242806.001
]
[Cites]
Ann Intern Med. 1985 Oct;103(4):620-5
[
3862359.001
]
[Cites]
Antimicrob Agents Chemother. 2002 Jun;46(6):1857-69
[
12019101.001
]
[Cites]
Ophthalmology. 1982 Feb;89(2):152-6
[
6951137.001
]
[Cites]
Infect Dis Clin North Am. 1989 Mar;3(1):43-52
[
2647833.001
]
[Cites]
Cancer. 1981 Nov 1;48(9):2107-11
[
6945903.001
]
[Cites]
Retina. 2003 Jun;23(3):404-5
[
12824845.001
]
[Cites]
Med Mycol. 2000 Feb;38(1):27-30
[
10746224.001
]
[Cites]
Cancer. 1980 Jan 15;45(2):367-71
[
6927961.001
]
[Cites]
Br J Ophthalmol. 1974 Jun;58(6):591-4
[
4425639.001
]
[Cites]
Clin Infect Dis. 1992 Mar;14 Suppl 1:S161-9
[
1314105.001
]
[Cites]
Clin Microbiol Infect. 2001;7 Suppl 2:8-24
[
11525222.001
]
[Cites]
Rev Infect Dis. 1989 May-Jun;11(3):369-78
[
2749101.001
]
[Cites]
Scand J Infect Dis. 1978;10(3):225-6
[
715385.001
]
[Cites]
Am J Ophthalmol. 2005 Jan;139(1):135-40
[
15652837.001
]
[Cites]
J Med Microbiol. 1970 Feb;3(1):191-3
[
5448879.001
]
[Cites]
Blood. 2004 Sep 15;104(6):1624-30
[
15178574.001
]
[Cites]
Chemotherapy. 1998 Jan-Feb;44(1):55-62
[
9444410.001
]
[Cites]
Eur J Clin Chem Clin Biochem. 1997 Jul;35(7):553-60
[
9263735.001
]
[Cites]
J Clin Lab Anal. 1995;9(5):334-9
[
8531015.001
]
[Cites]
Clin Infect Dis. 1992 Nov;15(5):781-7
[
1445976.001
]
[Cites]
Clin Infect Dis. 2003 Mar 1;36(5):630-7
[
12594645.001
]
[Cites]
J Clin Microbiol. 1998 Oct;36(10 ):2950-6
[
9738049.001
]
[Cites]
Mycoses. 1994 Jan-Feb;37(1-2):3-10
[
7935589.001
]
(PMID = 17562617.001).
[ISSN]
0925-5710
[Journal-full-title]
International journal of hematology
[ISO-abbreviation]
Int. J. Hematol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
0 / Antifungal Agents; 7XU7A7DROE / Amphotericin B; 8VZV102JFY / Fluconazole; D83282DT06 / Flucytosine
61.
Peloponese JM, Yeung ML, Jeang KT:
Modulation of nuclear factor-kappaB by human T cell leukemia virus type 1 Tax protein: implications for oncogenesis and inflammation.
Immunol Res
; 2006;34(1):1-12
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Modulation of nuclear factor-kappaB by
human
T cell
leukemia virus
type 1 Tax protein: implications for oncogenesis and inflammation.
Human
T cell
leukemia virus
type 1 (
HTLV
-1) is the causative agent of a fatal malignancy known as
adult T cell
leukemia
(
ATL
) and an inflammatory
disease
named tropical spastic paraparesis/
HTLV
-
1 associated
myelopathy (TSP/HAM).
HTLV
-1 encodes an oncoprotein, Tax, which plays a significant role in the initiation of cellular transformation and the elicitation of the host's inflammatory responses.
[MeSH-major]
Cell
Transformation, Neoplastic / immunology. Gene Products, tax / immunology.
HTLV
-I Infections / immunology.
Human
T-
lymphotropic virus
1 / immunology. Inflammation / immunology. NF-kappa B / immunology
Genetic Alliance.
consumer health - Human T-cell leukemia virus type 1
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16720895.001).
[ISSN]
0257-277X
[Journal-full-title]
Immunologic research
[ISO-abbreviation]
Immunol. Res.
[Language]
eng
[Grant]
United States / Intramural NIH HHS / /
[Publication-type]
Journal Article; Research Support, N.I.H., Intramural; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Gene Products, tax; 0 / NF-kappa B
[Number-of-references]
102
62.
Miyano-Kurosaki N, Kira J, Barnor JS, Maeda N, Misawa N, Kawano Y, Tanaka Y, Yamamoto N, Koyanagi Y:
Autonomous proliferation of HTLV-CD4+ T cell clones derived from human T cell leukemia virus type I (HTLV-I)-associated myelopathy patients.
Microbiol Immunol
; 2007;51(2):235-42
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Autonomous proliferation of
HTLV
-CD4+
T cell
clones
derived
from
human
T cell
leukemia virus
type I (
HTLV
-I)-
associated
myelopathy patients.
That
HTLV
-I infects CD4(+) T cells and enhances their
cell
growth has been shown as successful long-term in vitro proliferation in the presence of IL-2.
It is known that T cells isolated from HAM patients possess strong ability for
cell
proliferation in vitro and mRNA of various cytokines are abundantly expressed in CNS tissues of HAM patients.
In this study, we examined the relationship between
cell
proliferation and ability of in vitro cytokine production of CD4(+)
T cell
clones isolated from HAM patients.
We started a culture from a single
cell
to isolate
cell
clones immediately after drawing blood from the patients using limiting dilution method, which could allow the
cell
to avoid in vitro
HTLV
-I infection after initiation of culture.
Many
cell
clones were obtained and the rate of proliferation efficiency from a single
cell
was as high as 80%, especially in the 4 weeks' culture cells from HAM patients.
Our results indicate that the ability of
cell
proliferation in HAM patients is not restricted in
HTLV
-I-infected T cells.
HTLV
-Iuninfected CD4(+) T cells, mainly Th0 cells, also have a strong ability to respond to IL-2-stimulation, showing that unusual immune activation on T cells has been observed in HAM patients.
[MeSH-major]
CD4-
Positive
T-Lymphocytes / immunology. CD4-
Positive
T-Lymphocytes / virology.
Human
T-
lymphotropic virus
1 / immunology. Paraparesis, Tropical Spastic / immunology
[MeSH-minor]
Adult
. Aged. Clone Cells. Cytokines / genetics. Cytokines / immunology. DNA, Viral / chemistry. DNA, Viral / genetics. Female. Humans. Lymphocyte Activation. Male. Middle Aged. Polymerase Chain Reaction. Receptors, Antigen, T-
Cell
/ immunology
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17310092.001).
[ISSN]
0385-5600
[Journal-full-title]
Microbiology and immunology
[ISO-abbreviation]
Microbiol. Immunol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Japan
[Chemical-registry-number]
0 / Cytokines; 0 / DNA, Viral; 0 / Receptors, Antigen, T-Cell
63.
Olsen M, Madsen HO, Hjalgrim H, Gregers J, Rostgaard K, Schmiegelow K:
Preleukemic TEL-AML1-positive clones at cell level of 10(-3) to 10(-4) do not persist into adulthood.
J Pediatr Hematol Oncol
; 2006 Nov;28(11):734-40
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Preleukemic TEL-AML1-
positive
clones at
cell
level of 10(-3) to 10(-4) do not persist into adulthood.
The TEL-AML1 translocation, t(12;21)(p13;q22), is one of the most frequent genetic aberrations in childhood B-
cell
precursor
acute
lymphoblastic
leukemia
(ALL), where it occurs in 25% of all cases.
In contrast, the translocation is seen in only 3% of
adult
ALL cases.
Evidence suggests that the TEL-AML1 translocation occurs in utero in 1% of all newborn children at
cell
levels of 10 to 10.
In this study, we explore the prevalence of TEL-AML1-
positive
cells in 2 cohorts of healthy blood donors by real-time and nested reverse transcription-polymerase chain reaction.
Overall, TEL-AML1-
positive
cells were demonstrated in 10 of 2005 healthy donors, that is, a prevalence of 0.5% (95% confidence interval, 0.2-0.3%).
The level of TEL-AML1-
positive
cells was estimated to 10 to 10.
The observed prevalence of TEL-AML1-
positive
cells in healthy adults is of the same order of magnitude as the prevalence reported in healthy newborns, but the observed
cell
level of 10 to 10 is much lower.
These data indicates that prenatal TEL-AML1 subclones does not persist throughout
adult
life at
cell
levels of 10 to 10.
The findings are compatible with the risk of t(12;21)(p13;q22) ALL correlating with the total number of TEL-AML1-
positive
cells in peripheral blood in both childhood and adulthood.
[MeSH-major]
Burkitt
Lymphoma
/ genetics. Core Binding Factor Alpha 2 Subunit / genetics. Oncogene Proteins, Fusion / genetics. Preleukemia / genetics. Translocation, Genetic
[MeSH-minor]
Adult
. Blood Donors. Child. Female. Humans. Male. Middle Aged. Nucleic Acid Hybridization / methods. Precursor
Cell
Lymphoblastic
Leukemia
-
Lymphoma
/ genetics. Reverse Transcriptase Polymerase Chain Reaction
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17114960.001).
[ISSN]
1077-4114
[Journal-full-title]
Journal of pediatric hematology/oncology
[ISO-abbreviation]
J. Pediatr. Hematol. Oncol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
64.
Mandelli F, Vignetti M, Suciu S, Stasi R, Petti MC, Meloni G, Muus P, Marmont F, Marie JP, Labar B, Thomas X, Di Raimondo F, Willemze R, Liso V, Ferrara F, Baila L, Fazi P, Zittoun R, Amadori S, de Witte T:
Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.
J Clin Oncol
; 2009 Nov 10;27(32):5397-403
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with
acute
myeloid
leukemia
: the EORTC and GIMEMA Groups Study AML-10.
PURPOSE: To compare the antitumor efficacy of three different anthracyclines in combination with cytarabine and etoposide in
adult
patients with newly diagnosed
acute
myeloid
leukemia
(AML).
After achieving complete remission (CR), patients were assigned to undergo either allogeneic or autologous stem-
cell
transplantation (SCT), depending on the availability of a sibling donor.
However, the
disease
-free survival (DFS) and survival from CR were significantly shorter in the daunorubicin arm: the 5-year DFS was 29% versus 37% and 37% in mitoxantrone and idarubicin, respectively.
CONCLUSION: In
adult
patients with AML who do not receive an allogeneic SCT, the use of mitoxantrone or idarubicin instead of daunorubicin enhances the long-term efficacy of chemotherapy.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Leukemia
, Myeloid / drug therapy
[MeSH-minor]
Acute Disease
. Adolescent.
Adult
. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Idarubicin / administration & dosage. Male. Middle Aged. Mitoxantrone / administration & dosage. Remission Induction. Survival Analysis. Survival Rate. Treatment Outcome. Young
Adult
Genetic Alliance.
consumer health - Acute Myelocytic Leukemia
.
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
CYTARABINE
.
Hazardous Substances Data Bank.
DAUNORUBICIN
.
Hazardous Substances Data Bank.
ETOPOSIDE
.
Hazardous Substances Data Bank.
NOVANTRONE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Acta Oncol. 2001;40(2-3):231-52
[
11441935.001
]
[Cites]
N Engl J Med. 1999 Sep 30;341(14):1051-62
[
10502596.001
]
[Cites]
Blood. 2001 Sep 1;98(5):1302-11
[
11520775.001
]
[Cites]
Leukemia. 2003 Jan;17(1):60-7
[
12529661.001
]
[Cites]
Blood. 2004 Jan 15;103(2):479-85
[
14512295.001
]
[Cites]
Blood. 1982 Aug;60(2):454-62
[
6953986.001
]
[Cites]
Cancer Chemother Pharmacol. 1982;8(2):157-62
[
7105379.001
]
[Cites]
Ann Intern Med. 1985 Oct;103(4):620-5
[
3862359.001
]
[Cites]
Blood. 1990 Jan 1;75(1):27-32
[
2403818.001
]
[Cites]
Leukemia. 1990 Mar;4(3):177-83
[
2179638.001
]
[Cites]
Blood. 1991 Apr 15;77(8):1666-74
[
2015395.001
]
[Cites]
Br J Haematol. 1991 Jul;78(3):325-9
[
1651754.001
]
[Cites]
Cancer Chemother Pharmacol. 1991;28(6):480-3
[
1934252.001
]
[Cites]
Blood. 1992 Jan 15;79(2):313-9
[
1730080.001
]
[Cites]
Blood. 1992 Jun 15;79(12):3267-73
[
1596567.001
]
[Cites]
J Clin Oncol. 1992 Jul;10(7):1103-11
[
1607916.001
]
[Cites]
Ann Hematol. 1994 Jul;69(1):11-5
[
8061102.001
]
[Cites]
N Engl J Med. 1995 Jan 26;332(4):217-23
[
7808487.001
]
[Cites]
Lancet. 1998 Mar 7;351(9104):700-8
[
9504514.001
]
[Cites]
J Clin Oncol. 1998 Mar;16(3):872-81
[
9508168.001
]
[Cites]
Leuk Lymphoma. 1998 Jan;28(3-4):315-27
[
9517503.001
]
[Cites]
Br J Haematol. 1998 Oct;103(1):100-9
[
9792296.001
]
[ErratumIn]
J Clin Oncol. 2010 Mar 10;28(8):1438
(PMID = 19826132.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / U10 CA011488; United States / NCI NIH HHS / CA / 2U10-CA11488-36; United States / NCI NIH HHS / CA / CA11488-23
[Publication-type]
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone; ZRP63D75JW / Idarubicin; ZS7284E0ZP / Daunorubicin
[Other-IDs]
NLM/ PMC2773224
65.
Rollinson S, Kesby H, Morgan GJ:
Haplotypic variation in MRE11, RAD50 and NBS1 and risk of non-Hodgkin's lymphoma.
Leuk Lymphoma
; 2006 Dec;47(12):2567-83
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Haplotypic variation in MRE11, RAD50 and NBS1 and risk of non-Hodgkin's
lymphoma
.
The MRE11-RAD50-NBS1 tri-complex is involved in the cellular response to DNA double strand breaks, detecting DNA damage, activating
cell
cycle checkpoints and apoptosis.
Defects in members of the tri-complex are linked to increased chromosomal instability and in
lymphoma
predisposition.
Using genotyping data from six intronic or gene flanking variants in MRE11, five in NBS1 and six in RAD50 in 461 non-Hodgkin's
lymphoma
cases and 461 age, sex matched controls, Phase 2.1 was used to impute haplotypes for each of these genes.
A protective effect against follicular
lymphoma
was seen for the MRE11 rs601341 variant, the homozygous T allele being
associated
with an odds ratio (OR) of 0.50, 95% confidence interval (95% CI) 0.26 - 0.97, while a protective effect was seen for the MRE11 haplotype GCTCA (OR 0.72, 95% CI 0.53 - 0.97) for diffuse large B-
cell lymphoma
.
While reproduction of this data in other datasets is indicated, the results are indicative for a role for MRE11 in non-Hodgkin's
lymphoma
.
[MeSH-major]
Cell
Cycle Proteins / genetics. DNA Repair Enzymes / genetics. DNA-Binding Proteins / genetics. Haplotypes.
Lymphoma
, Non-Hodgkin /
diagnosis
.
Lymphoma
, Non-Hodgkin / genetics. Nuclear Proteins / genetics
[MeSH-minor]
Adolescent.
Adult
. DNA Repair. Female. Genotype. Humans. Linkage Disequilibrium. Male. Middle Aged. Risk
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17169801.001).
[ISSN]
1042-8194
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / MRE11A protein, human; 0 / NBN protein, human; 0 / Nuclear Proteins; 0 / Rad50 protein, human; EC 6.5.1.- / DNA Repair Enzymes
66.
Cheadle EJ, Gilham DE, Thistlethwaite FC, Radford JA, Hawkins RE:
Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells.
Br J Haematol
; 2005 May;129(3):322-32
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Killing of non-Hodgkin
lymphoma
cells by autologous CD19 engineered T cells.
However, tumours can avoid
T cell
-mediated attack through multiple mechanisms including downregulation of major histocompatability complex (MHC).
Consequently, engineering T cells to target intact protein antigen directly, thus bypassing the need for MHC presentation, can facilitate
T cell
targeting of tumour cells.
Peripheral blood lymphocytes from nine of nine patients with non-Hodgkin
lymphoma
(NHL) were successfully gene-modified to express a receptor consisting of a CD19 single chain variable fragment (scFv) fused to the
T cell
CD3zeta signalling molecule.
These T cells were functionally active against the CD19(+) Raji Burkitt's
lymphoma cell
line.
These results demonstrate that patients with CD19(+) NHL would be suitable candidates for this form of therapy in the setting of a phase
I clinical
trial.
[MeSH-major]
Antigens, CD19 / analysis. Lymphocyte Transfusion / methods.
Lymphoma
, Non-Hodgkin / pathology. T-Lymphocyte Subsets / immunology
[MeSH-minor]
Adult
. Aged. Antigens, CD3 / immunology. Biopsy. Cytotoxicity, Immunologic. Female. Genetic Vectors. Humans. Immunotherapy, Adoptive / methods. Interferon-gamma / biosynthesis. Lymphocyte Activation. Male. Middle Aged. Retroviridae / genetics. Transduction, Genetic. Tumor Cells, Cultured
Genetic Alliance.
consumer health - Hodgkin lymphoma
.
Genetic Alliance.
consumer health - Non-Hodgkin Lymphoma
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15842655.001).
[ISSN]
0007-1048
[Journal-full-title]
British journal of haematology
[ISO-abbreviation]
Br. J. Haematol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antigens, CD19; 0 / Antigens, CD3; 0 / CD3 antigen, zeta chain; 82115-62-6 / Interferon-gamma
67.
Salem HK, Thiemermann C:
Mesenchymal stromal cells: current understanding and clinical status.
Stem Cells
; 2010 Mar 31;28(3):585-96
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Mesenchymal stromal cells: current understanding and
clinical
status.
Multipotent mesenchymal stromal cells (MSCs) represent a rare heterogeneous subset of pluripotent stromal cells that can be isolated from many different
adult
tissues that exhibit the potential to give rise to cells of diverse lineages.
In addition, MSCs possess remarkable immunosuppressive properties, suppressing T-
cell
, NK
cell
functions, and also modulating dentritic
cell
activities.
Tremendous progress has been made in preclinical studies using MSCs, including the ability to use allogeneic cells, which has driven the application of MSCs toward the
clinical
setting.
This review highlights our current understanding into the biology of MSCs with particular emphasis on the cardiovascular and renal applications, and provides a brief update on the
clinical
status of MSC-based therapy.
[MeSH-major]
Immune Tolerance / physiology. Mesenchymal Stem
Cell
Transplantation / methods. Mesenchymal Stromal Cells / immunology. Stromal Cells / immunology
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Scand J Immunol. 2003 Jan;57(1):11-20
[
12542793.001
]
[Cites]
Transplantation. 2003 Feb 15;75(3):389-97
[
12589164.001
]
[Cites]
J Biomed Sci. 2003 Mar-Apr;10(2):228-41
[
12595759.001
]
[Cites]
Biochem Soc Symp. 2002;(69):33-45
[
12655772.001
]
[Cites]
J Cell Sci. 2003 May 1;116(Pt 9):1827-35
[
12665563.001
]
[Cites]
Zhonghua Er Bi Yan Hou Ke Za Zhi. 2002 Apr;37(2):137-9
[
12768728.001
]
[Cites]
Cardiovasc Res. 2003 Jul 1;59(1):132-42
[
12829184.001
]
[Cites]
Transplantation. 2003 Oct 27;76(8):1208-13
[
14578755.001
]
[Cites]
J Gene Med. 2003 Dec;5(12):1028-38
[
14661178.001
]
[Cites]
Am J Obstet Gynecol. 2004 Jan;190(1):239-45
[
14749666.001
]
[Cites]
Blood. 2004 Mar 1;103(5):1662-8
[
14592819.001
]
[Cites]
Circ Res. 2004 Mar 19;94(5):678-85
[
14739163.001
]
[Cites]
Blood. 2004 May 1;103(9):3313-9
[
14715641.001
]
[Cites]
Nat Rev Immunol. 2004 Jun;4(6):432-44
[
15173832.001
]
[Cites]
Blood. 2004 Jun 15;103(12):4619-21
[
15001472.001
]
[Cites]
Stem Cells Dev. 2004 Jun;13(3):263-71
[
15186722.001
]
[Cites]
J Am Soc Nephrol. 2004 Jul;15(7):1794-804
[
15213267.001
]
[Cites]
Am J Cardiol. 2004 Jul 1;94(1):92-5
[
15219514.001
]
[Cites]
Exp Biol Med (Maywood). 2004 Jul;229(7):623-31
[
15229356.001
]
[Cites]
Lancet. 2004 Jul 10-16;364(9429):141-8
[
15246726.001
]
[Cites]
Biorheology. 2004;41(3-4):469-76
[
15299278.001
]
[Cites]
Blood. 2004 Nov 1;104(9):2643-5
[
15251986.001
]
[Cites]
Chin Med J (Engl). 2004 Oct;117(10):1443-8
[
15498362.001
]
[Cites]
Transplantation. 1968 Mar;6(2):230-47
[
5654088.001
]
[Cites]
Am J Cardiol. 1991 Nov 18;68(14):1D-6D
[
1836091.001
]
[Cites]
Ann N Y Acad Sci. 1995 Mar 27;752:72-9
[
7755297.001
]
[Cites]
Proc Natl Acad Sci U S A. 1995 May 23;92(11):4857-61
[
7761413.001
]
[Cites]
Muscle Nerve. 1995 Dec;18(12):1417-26
[
7477065.001
]
[Cites]
J Biol Chem. 1995 Dec 8;270(49):29439-46
[
7493982.001
]
[Cites]
Am J Pathol. 1996 Jan;148(1):165-75
[
8546203.001
]
[Cites]
Lab Invest. 1996 Jan;74(1):86-107
[
8569201.001
]
[Cites]
Exp Cell Res. 1996 Aug 1;226(2):316-27
[
8806435.001
]
[Cites]
Blood. 1996 Nov 1;88(9):3259-87
[
8896391.001
]
[Cites]
Science. 1997 Apr 4;276(5309):71-4
[
9082988.001
]
[Cites]
Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8801-5
[
9671759.001
]
[Cites]
Ageing Res Rev. 2006 Feb;5(1):91-116
[
16310414.001
]
[Cites]
Stem Cells. 2006 Jan;24(1):74-85
[
16099998.001
]
[Cites]
Stem Cells. 2006 Feb;24(2):386-98
[
16123384.001
]
[Cites]
Cardiovasc Revasc Med. 2006 Jan-Mar;7(1):19-24
[
16513519.001
]
[Cites]
Blood. 2006 Mar 15;107(6):2570-7
[
16293599.001
]
[Cites]
Stem Cells. 2006 Apr;24(4):1030-41
[
16253981.001
]
[Cites]
Stem Cells. 2006 Apr;24(4):1095-103
[
16282438.001
]
[Cites]
Stem Cells. 2006 May;24(5):1254-64
[
16410389.001
]
[Cites]
J Am Soc Nephrol. 2006 Jun;17(6):1503-20
[
16707563.001
]
[Cites]
J Cell Sci. 2006 Jun 1;119(Pt 11):2204-13
[
16684817.001
]
[Cites]
J Am Soc Nephrol. 2006 Aug;17(8):2202-12
[
16790513.001
]
[Cites]
Int J Cardiol. 2006 Aug 10;111(2):231-9
[
16246440.001
]
[Cites]
Stem Cells. 2006 Oct;24(10):2202-8
[
16778152.001
]
[Cites]
Blood. 2006 Dec 1;108(12):3938-44
[
16896152.001
]
[Cites]
Mol Ther. 2006 Dec;14(6):840-50
[
16965940.001
]
[Cites]
Stem Cells. 2006 Dec;24(12):2810-6
[
16931770.001
]
[Cites]
Exp Cell Res. 2006 Nov 15;312(19):3711-27
[
17026998.001
]
[Cites]
Blood. 2007 Jan 1;109(1):228-34
[
16985180.001
]
[Cites]
Stem Cells. 2007 Jan;25(1):69-77
[
16973831.001
]
[Cites]
J Interferon Cytokine Res. 2007 Jan;27(1):53-64
[
17266444.001
]
[Cites]
Clin Immunol. 2007 Apr;123(1):7-13
[
17064966.001
]
[Cites]
Biochem Biophys Res Commun. 2007 May 11;356(3):780-4
[
17382293.001
]
[Cites]
J Cell Biochem. 2007 May 1;101(1):135-46
[
17295203.001
]
[Cites]
Blood. 2007 May 1;109(9):4055-63
[
17197427.001
]
[Cites]
Haematologica. 2007 Apr;92(4):440-9
[
17488654.001
]
[Cites]
Arch Intern Med. 2007 May 28;167(10):989-97
[
17533201.001
]
[Cites]
Stem Cells. 2007 Jul;25(7):1761-8
[
17395769.001
]
[Cites]
Leukemia. 2007 Aug;21(8):1733-8
[
17541394.001
]
[Cites]
Leuk Lymphoma. 2005 Nov;46(11):1531-44
[
16236607.001
]
[Cites]
Ann N Y Acad Sci. 2007 Jun;1106:262-71
[
17395729.001
]
[Cites]
Mol Biol Cell. 2007 Aug;18(8):2873-82
[
17507648.001
]
[Cites]
Blood. 2007 Aug 15;110(4):1362-9
[
17483296.001
]
[Cites]
Nat Rev Immunol. 2007 Sep;7(9):678-89
[
17717539.001
]
[Cites]
Stem Cells. 2007 Sep;25(9):2363-70
[
17540857.001
]
[Cites]
Stem Cells. 2007 Nov;25(11):2739-49
[
17656645.001
]
[Cites]
Blood. 2000 Jun 1;95(11):3289-96
[
10828007.001
]
[Cites]
J Clin Invest. 2000 Jun;105(12):1663-8
[
10862779.001
]
[Cites]
Exp Hematol. 2000 Aug;28(8):875-84
[
10989188.001
]
[Cites]
J Clin Invest. 2000 Dec;106(11):1331-9
[
11104786.001
]
[Cites]
N Engl J Med. 2001 Jun 7;344(23):1750-7
[
11396441.001
]
[Cites]
Ann N Y Acad Sci. 2001 Jun;938:83-95
[
11458529.001
]
[Cites]
Stem Cells. 2001;19(6):477-82
[
11713338.001
]
[Cites]
J Am Soc Nephrol. 2001 Dec;12(12):2625-35
[
11729231.001
]
[Cites]
J Clin Invest. 2002 Feb;109(3):337-46
[
11827993.001
]
[Cites]
Ann Thorac Surg. 2002 Jun;73(6):1919-25; discussion 1926
[
12078791.001
]
[Cites]
J Exp Med. 2002 Aug 19;196(4):459-68
[
12186838.001
]
[Cites]
Heart. 2002 Oct;88 Suppl 2:ii15-22
[
12213795.001
]
[Cites]
Ann Thorac Surg. 2002 Oct;74(4):1154-9; discussion 1159-60
[
12400761.001
]
[Cites]
J Clin Invest. 1999 Mar;103(5):697-705
[
10074487.001
]
[Cites]
Science. 1999 Apr 2;284(5411):143-7
[
10102814.001
]
[Cites]
J Exp Med. 1999 May 3;189(9):1363-72
[
10224276.001
]
[Cites]
J Cell Physiol. 1999 Oct;181(1):67-73
[
10457354.001
]
[Cites]
Immunol Today. 1999 Oct;20(10):469-73
[
10500295.001
]
[Cites]
Int J Mol Med. 2004 Dec;14(6):1035-41
[
15547670.001
]
[Cites]
Circulation. 2004 Nov 23;110(21):3300-5
[
15533866.001
]
[Cites]
Stem Cells. 2005;23(1):44-54
[
15625121.001
]
[Cites]
Lancet. 2005 Jan 29-Feb 4;365(9457):417-30
[
15680458.001
]
[Cites]
Blood. 2005 Feb 15;105(4):1815-22
[
15494428.001
]
[Cites]
Blood. 2005 Mar 1;105(5):2214-9
[
15514012.001
]
[Cites]
J Cell Biochem. 2005 Mar 1;94(4):645-55
[
15547939.001
]
[Cites]
Cancer Res. 2005 Apr 15;65(8):3035-9
[
15833829.001
]
[Cites]
Biol Blood Marrow Transplant. 2005 May;11(5):389-98
[
15846293.001
]
[Cites]
Eur J Immunol. 2005 May;35(5):1482-90
[
15827960.001
]
[Cites]
Blood. 2005 May 15;105(10):4120-6
[
15692068.001
]
[Cites]
Am J Physiol Renal Physiol. 2005 Jul;289(1):F31-42
[
15713913.001
]
[Cites]
Blood. 2005 Jul 15;106(2):419-27
[
15784733.001
]
[Cites]
Catheter Cardiovasc Interv. 2005 Jul;65(3):321-9
[
15954106.001
]
[Cites]
Circulation. 2005 Jul 12;112(2):214-23
[
15998673.001
]
[Cites]
Circulation. 2005 Jul 26;112(4):521-6
[
16027258.001
]
[Cites]
Circulation. 2005 Aug 23;112(8):1128-35
[
16103243.001
]
[Cites]
Blood. 2005 Sep 15;106(6):1901-10
[
15890683.001
]
[Cites]
Kidney Int. 2005 Oct;68(4):1613-7
[
16164638.001
]
[Cites]
Cytotherapy. 2005;7(5):393-5
[
16236628.001
]
[Cites]
Mol Ther. 2006 Jan;13(1):49-58
[
16216560.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18111-6
[
16326806.001
]
[Cites]
Nat Immunol. 2005 Dec;6(12):1182-90
[
16369557.001
]
[Cites]
Handb Exp Pharmacol. 2006;(174):249-82
[
16370331.001
]
[Cites]
Cell. 2007 Nov 30;131(5):861-72
[
18035408.001
]
[Cites]
PLoS One. 2008;3(1):e1398
[
18167557.001
]
[Cites]
J Immunol. 2008 Feb 1;180(3):1598-608
[
18209056.001
]
[Cites]
Cardiovasc Res. 2008 Feb 1;77(3):515-24
[
18006453.001
]
[Cites]
J Immunol. 2008 Feb 15;180(4):2581-7
[
18250469.001
]
[Cites]
J Mol Cell Cardiol. 2008 Mar;44(3):486-95
[
18061611.001
]
[Cites]
J Mol Cell Cardiol. 2008 Jun;44(6):1072-84
[
18462748.001
]
[Cites]
Adv Cancer Res. 2008;100:133-58
[
18620095.001
]
[Cites]
J Zhejiang Univ Sci B. 2008 Aug;9(8):630-7
[
18763313.001
]
[Cites]
Blood. 2009 Jan 22;113(4):816-26
[
18818395.001
]
[Cites]
Can J Physiol Pharmacol. 2009 Feb;87(2):143-50
[
19234578.001
]
[Cites]
Transplantation. 2009 Mar 27;87(6):896-906
[
19300194.001
]
[Cites]
Bone Marrow Transplant. 2009 Mar;43(6):447-54
[
18955980.001
]
[Cites]
Stem Cells. 2009 Apr;27(4):961-70
[
19353524.001
]
[Cites]
Cytotherapy. 2009;11(3):278-88
[
19308773.001
]
(PMID = 19967788.001).
[ISSN]
1549-4918
[Journal-full-title]
Stem cells (Dayton, Ohio)
[ISO-abbreviation]
Stem Cells
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Cytokines
[Number-of-references]
127
[Other-IDs]
NLM/ PMC2962904
68.
Amit BH, Gil-Ad I, Taler M, Bar M, Zolokov A, Weizman A:
Proapoptotic and chemosensitizing effects of selective serotonin reuptake inhibitors on T cell lymphoma/leukemia (Jurkat) in vitro.
Eur Neuropsychopharmacol
; 2009 Oct;19(10):726-34
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Proapoptotic and chemosensitizing effects of selective serotonin reuptake inhibitors on
T cell lymphoma
/
leukemia
(Jurkat) in vitro.
We evaluated such in vitro effects in malignant T cells (Jurkat),
finding
that exposure to high concentrations of sertraline (IC(50)=9.5 microM) or paroxetine (IC(50)=18 microM) yielded a considerable reduction in cellular viability, exceeding equimolar doses of the chemotherapeutics vincristine and cyclophosphamide (P<0.015).
[MeSH-major]
Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Drug Interactions.
Leukemia
-
Lymphoma
,
Adult T
-
Cell
/ drug therapy. Serotonin Uptake Inhibitors / pharmacology
[MeSH-minor]
Cell
Proliferation / drug effects.
Cell
Survival / drug effects. Chemotherapy, Adjuvant. Doxorubicin / pharmacology. Humans. Jurkat Cells. Mitogen-Activated Protein Kinases / metabolism. Paroxetine / pharmacology. Sertraline / pharmacology. Vincristine / pharmacology
MedlinePlus Health Information.
consumer health - Drug Reactions
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
VINCRISTINE
.
Hazardous Substances Data Bank.
PAROXETINE HYDROCHLORIDE
.
Hazardous Substances Data Bank.
SERTRALINE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19631512.001).
[ISSN]
1873-7862
[Journal-full-title]
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
[ISO-abbreviation]
Eur Neuropsychopharmacol
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Serotonin Uptake Inhibitors; 41VRH5220H / Paroxetine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; QUC7NX6WMB / Sertraline
69.
Burgoyne LL, Anghelescu DL, Tamburro RF, De Armendi AJ:
A pediatric patient with a mediastinal mass and pulmonary embolus.
Paediatr Anaesth
; 2006 Apr;16(4):487-91
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
We suggest that pulmonary embolism should be considered in the differential
diagnosis
when a patient with a mediastinal mass develops perioperative hypoxaemia, cardiovascular collapse, or both.
[MeSH-minor]
Anoxia / etiology. Cardiovascular Diseases / etiology. Cardiovascular Diseases / pathology. Child. Fatal Outcome. Humans.
Leukemia
-
Lymphoma
,
Adult T
-
Cell
/
diagnosis
.
Leukemia
-
Lymphoma
,
Adult T
-
Cell
/ pathology. Male. Pulmonary Artery / pathology. Tomography, X-Ray Computed. Ventilation-Perfusion Ratio / physiology
MedlinePlus Health Information.
consumer health - Pulmonary Embolism
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16618309.001).
[ISSN]
1155-5645
[Journal-full-title]
Paediatric anaesthesia
[ISO-abbreviation]
Paediatr Anaesth
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
France
70.
Watanabe T, Terui S, Itoh K, Terauchi T, Igarashi T, Usubuchi N, Nakata M, Nawano S, Sekiguchi N, Kusumoto S, Tanimoto K, Kobayashi Y, Endo K, Seriu T, Hayashi M, Tobinai K:
Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate ((90)Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma.
Cancer Sci
; 2005 Dec;96(12):903-10
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate ((90)Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-
cell lymphoma
.
We conducted a phase I study to evaluate the safety and efficacy of radioimmunotherapy with yttrium-90-ibritumomab tiuxetan (Y2B8) in Japanese patients with relapsed or refractory indolent B-
cell lymphoma
.
[MeSH-major]
Antibodies, Monoclonal / toxicity.
Lymphoma
, B-
Cell
/ radiotherapy. Radioimmunotherapy / adverse effects. Yttrium Radioisotopes / toxicity
[MeSH-minor]
Adult
. Aged. Dose-Response Relationship, Radiation. Female. Humans. Male. Middle Aged. Neoplasm Staging. Recurrence. Reproducibility of Results. Tissue Distribution
Genetic Alliance.
consumer health - Indolent B cell lymphoma
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(Cancer Sci 2005; 96: 903-910).
(PMID = 16367911.001).
[ISSN]
1347-9032
[Journal-full-title]
Cancer science
[ISO-abbreviation]
Cancer Sci.
[Language]
eng
[Publication-type]
Clinical Trial, Phase I; Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan
71.
Aifantis I, Raetz E, Buonamici S:
Molecular pathogenesis of T-cell leukaemia and lymphoma.
Nat Rev Immunol
; 2008 May;8(5):380-90
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Molecular pathogenesis of T-
cell
leukaemia
and
lymphoma
.
T-
cell
acute
lymphoblastic
leukaemia
(T-ALL) is induced by the transformation of T-
cell
progenitors and mainly occurs in children and adolescents.
Although treatment outcome in patients with T-ALL has improved in recent years, patients with relapsed
disease
continue to have a poor prognosis.
It is therefore important to understand the molecular pathways that control both the induction of transformation and the treatment of relapsed
disease
.
In this Review, we focus on the molecular mechanisms responsible for
disease
induction and maintenance.
We also compare the physiological progression of T-
cell
differentiation with T-
cell
transformation, highlighting the close relationship between these two processes.
MedlinePlus Health Information.
consumer health - Lymphoma
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18421304.001).
[ISSN]
1474-1741
[Journal-full-title]
Nature reviews. Immunology
[ISO-abbreviation]
Nat. Rev. Immunol.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / R01 CA105129; United States / NCI NIH HHS / CA / R01CA105129; United States / NCI NIH HHS / CA / T32 CA-09161
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Cell Cycle Proteins; 0 / F-Box Proteins; 0 / Homeodomain Proteins; 0 / NF-kappa B; 0 / Receptor, Notch1; 0 / Transcription Factors; EC 6.3.2.19 / FBXW7 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
[Number-of-references]
101
72.
Satoh J, Nakanishi M, Koike F, Miyake S, Yamamoto T, Kawai M, Kikuchi S, Nomura K, Yokoyama K, Ota K, Kanda T, Fukazawa T, Yamamura T:
Microarray analysis identifies an aberrant expression of apoptosis and DNA damage-regulatory genes in multiple sclerosis.
Neurobiol Dis
; 2005 Apr;18(3):537-50
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
To clarify the molecular mechanisms underlying multiple sclerosis (MS)-promoting autoimmune process, we have investigated a comprehensive gene expression profile of
T cell
and non-
T cell
fractions of peripheral blood mononuclear cells (PBMC) isolated from 72 MS patients and 22 age- and sex-matched healthy control (CN) subjects by using a cDNA microarray.
They included upregulation in MS of orphan nuclear receptor Nurr1 (NR4A2), receptor-interacting serine/threonine kinase 2 (RIPK2), and silencer of death domains (SODD), and downregulation in MS of TNF-related apoptosis-inducing ligand (TRAIL), B-
cell
CLL/
lymphoma
2 (BCL2), and death-
associated
protein 6 (DAXX).
[MeSH-minor]
Adult
. Down-Regulation / genetics. Female. Humans. Male. Middle Aged. Up-Regulation / genetics
Genetic Alliance.
consumer health - Multiple Sclerosis
.
MedlinePlus Health Information.
consumer health - Multiple Sclerosis
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15755681.001).
[ISSN]
0969-9961
[Journal-full-title]
Neurobiology of disease
[ISO-abbreviation]
Neurobiol. Dis.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
73.
Hiraga J, Tomita A, Sugimoto T, Shimada K, Ito M, Nakamura S, Kiyoi H, Kinoshita T, Naoe T:
Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance.
Blood
; 2009 May 14;113(20):4885-93
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Down-regulation of CD20 expression in B-
cell lymphoma
cells after treatment with rituximab-containing combination chemotherapies: its prevalence and
clinical
significance.
Although rituximab is a key molecular targeting drug for CD20-
positive
B-
cell
lymphomas
, resistance to rituximab has recently been recognized as a considerable problem.
Here, we report that a CD20-negative phenotypic change after chemotherapies with rituximab occurs in a certain number of CD20-
positive
B-
cell lymphoma
patients.
For 5 years, 124 patients with B-
cell
malignancies were treated with rituximab-containing chemotherapies in Nagoya University Hospital.
Of those 19, 5 (26.3%; diffuse large B-
cell lymphoma
[DLBCL], 3 cases; DLBCL transformed from follicular
lymphoma
, 2 cases) indicated CD20 protein-negative transformation.
Quantitative reverse-transcription-polymerase chain reaction (RT-PCR) showed that CD20 mRNA expression was significantly lower in CD20-negative cells than in CD20-
positive
cells obtained from the same patient.
Interestingly, when CD20-negative cells were treated with 5-aza-2'-deoxycytidine in vitro, the expression of CD20 mRNA was stimulated within 3 days, resulting in the restoration of both
cell
surface expression of the CD20 protein and rituximab sensitivity.
[MeSH-major]
Antibodies, Monoclonal / administration & dosage. Antigens, CD20 / genetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Lymphoma
, B-
Cell
/ drug therapy.
Lymphoma
, B-
Cell
/ genetics
[MeSH-minor]
Adolescent.
Adult
. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-
Derived
. Down-Regulation / drug effects. Epigenesis, Genetic / drug effects. Epigenesis, Genetic / physiology. Follow-Up Studies. Gene Expression Regulation, Neoplastic / drug effects. Humans. Middle Aged. Mutation. Phenotype. Prognosis. RNA, Messenger / metabolism. Rituximab. Young
Adult
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
Hazardous Substances Data Bank.
RITUXIMAB
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19246561.001).
[ISSN]
1528-0020
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / RNA, Messenger; 4F4X42SYQ6 / Rituximab
74.
Yasuda I, Tsurumi H, Omar S, Iwashita T, Kojima Y, Yamada T, Sawada M, Takami T, Moriwaki H, Soehendra N:
Endoscopic ultrasound-guided fine-needle aspiration biopsy for lymphadenopathy of unknown origin.
Endoscopy
; 2006 Sep;38(9):919-24
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND AND STUDY AIMS: The
diagnosis
of mediastinal and intra-abdominal lymphadenopathy is sometimes difficult, especially in patients who have no other primary lesions.
Lymphoma
is one of the main causes of this condition.
However, diagnosing
lymphoma
using the EUS-FNA technique remains a diagnostic challenge, due to limitations in the amount of material sampled.
The aim of the present study was to evaluate the yield of EUS-FNA biopsy (EUS-FNAB) using a large-gauge needle in patients with mediastinal and intra-abdominal lymphadenopathy of unknown origin, especially in relation to subclassification of the
lymphomas
.
The diagnoses made using EUS-FNAB were
lymphoma
(n = 48), metastasis (n = 16), and benign/reactive (n = 40).
The overall accuracy of EUS-FNAB for unknown lymphadenopathy was 98 %, and it was possible to classify the
lymphomas
in accordance with the World Health Organization classifications in 88 % of cases.
CONCLUSIONS: Open thoracic surgery, laparotomy, and other invasive diagnostic procedures such as mediastinoscopy and laparoscopy can now be avoided, as EUS-FNAB is potentially a safe and accurate tool for diagnosing unknown lymphadenopathy, including
lymphoma
.
[MeSH-major]
Biopsy, Fine-Needle / methods. Endosonography. Lymphatic Diseases /
diagnosis
.
Lymphoma
/
diagnosis
[MeSH-minor]
Adult
. Aged. Aged, 80 and over. Female. Humans.
Lymphoma
, B-
Cell
/
diagnosis
.
Lymphoma
, T-
Cell
/
diagnosis
. Male. Middle Aged. Prospective Studies. Sensitivity and Specificity
MedlinePlus Health Information.
consumer health - Lymphatic Diseases
.
MedlinePlus Health Information.
consumer health - Lymphoma
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Nat Clin Pract Gastroenterol Hepatol. 2007 Apr;4(4):198-9
[
17342065.001
]
(PMID = 16981110.001).
[ISSN]
0013-726X
[Journal-full-title]
Endoscopy
[ISO-abbreviation]
Endoscopy
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
75.
Harting R, Venugopal P, Gregory SA, O'brien T, Bogdanova E:
Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Clin Lymphoma Myeloma
; 2007 May;7(6):406-12
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-
cell
non-Hodgkin
lymphoma
.
BACKGROUND: We evaluated the efficacy and safety of adding rituximab to nonanthracycline ESHAP (etoposide/methylprednisolone/cytarabine/cisplatin) chemotherapy for relapsed/refractory aggressive non-Hodgkin
lymphoma
(NHL).
Thirteen patients were enrolled (median age, 56 years); all had previously treated NHL, 12 (92%) had diffuse large B-
cell lymphoma
, 10 (77%) had stage III/IV
disease
, and 2 (15%) had chemotherapy-refractory
disease
.
Among 6 patients completing all 6 cycles, 4 (67%) had a CR, 1 had a partial response, and 1 had progressive
disease
.
CONCLUSION: Rituximab plus ESHAP led to durable responses with acceptable toxicity in patients with relapsed/refractory aggressive NHL, most of whom had advanced
disease
.
[MeSH-major]
Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Lymphoma
, B-
Cell
/ drug therapy. Neoplasm Recurrence, Local / drug therapy
[MeSH-minor]
Adult
. Aged. Aged, 80 and over. Anemia / chemically induced. Antibodies, Monoclonal, Murine-
Derived
. Cisplatin / adverse effects. Cisplatin / therapeutic use. Creatinine / urine. Cytarabine / adverse effects. Cytarabine / therapeutic use. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Humans. Male. Methylprednisolone / adverse effects. Methylprednisolone / therapeutic use. Middle Aged. Nausea / chemically induced. Neutropenia / chemically induced. Platelet Count. Prospective Studies. Rituximab. Thrombocytopenia / chemically induced. Treatment Outcome
Genetic Alliance.
consumer health - Hodgkin lymphoma
.
Genetic Alliance.
consumer health - Non-Hodgkin Lymphoma
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
CYTARABINE
.
Hazardous Substances Data Bank.
CIS-DIAMINEDICHLOROPLATINUM
.
Hazardous Substances Data Bank.
RITUXIMAB
.
Hazardous Substances Data Bank.
ETOPOSIDE
.
Hazardous Substances Data Bank.
METHYLPREDNISOLONE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17621406.001).
[ISSN]
1557-9190
[Journal-full-title]
Clinical lymphoma & myeloma
[ISO-abbreviation]
Clin Lymphoma Myeloma
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 6PLQ3CP4P3 / Etoposide; AYI8EX34EU / Creatinine; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone; ESAP protocol
76.
Dewan MZ, Uchihara JN, Terashima K, Honda M, Sata T, Ito M, Fujii N, Uozumi K, Tsukasaki K, Tomonaga M, Kubuki Y, Okayama A, Toi M, Mori N, Yamamoto N:
Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir.
Blood
; 2006 Jan 15;107(2):716-24
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Efficient intervention of growth and infiltration of primary
adult T
-
cell
leukemia
cells by an HIV protease inhibitor, ritonavir.
Adult T
-
cell
leukemia
(
ATL
), an aggressive malignancy of CD4+ T cells
associated
with
human
T-
cell
leukemia virus
type I (
HTLV
-I) infection, carries a very poor prognosis because of the resistance of leukemic cells to any conventional regimen, including chemotherapy.
We examined the effect of ritonavir, an HIV protease inhibitor, on
HTLV
-I-infected T-
cell
lines and primary
ATL
cells and found that it induced apoptosis and inhibited transcriptional activation of NF-kappaB in these cells.
Our data indicate that ritonavir has potent anti-NF-kappaB and antitumor effects and might be clinically applicable for treatment of
ATL
.
These results would provide a new concept and novel platform for new drug development of
leukemia
and solid cancer as well.
[MeSH-minor]
Adult
. Aged. Aged, 80 and over. Animals. Cyclin D2. Cyclins / metabolism.
Disease
Models, Animal. Female.
Human
T-
lymphotropic virus
1 / physiology. Humans. Inhibitor of Apoptosis Proteins.
Leukemia
-
Lymphoma
,
Adult T
-
Cell
/ drug therapy.
Leukemia
-
Lymphoma
,
Adult T
-
Cell
/ pathology.
Leukemia
-
Lymphoma
,
Adult T
-
Cell
/ virology. Male. Mice. Mice, Inbred NOD. Mice, SCID. Microtubule-
Associated
Proteins / metabolism. Middle Aged. Neoplasm Proteins / metabolism. Proto-Oncogene Proteins c-myc / metabolism. bcl-X Protein / metabolism
Genetic Alliance.
consumer health - HIV
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16174765.001).
[ISSN]
0006-4971
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / BIRC5 protein, human; 0 / CCND2 protein, human; 0 / Cyclin D2; 0 / Cyclins; 0 / HIV Protease Inhibitors; 0 / Inhibitor of Apoptosis Proteins; 0 / MYC protein, human; 0 / Microtubule-Associated Proteins; 0 / NF-kappa B; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-myc; 0 / bcl-X Protein; O3J8G9O825 / Ritonavir
77.
Yamada Y, Kamihira S:
Inactivation of tumor suppressor genes and the progression of adult T-cell leukemia-lymphoma.
Leuk Lymphoma
; 2005 Nov;46(11):1553-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Inactivation of tumor suppressor genes and the progression of
adult T
-
cell
leukemia
-
lymphoma
.
Almost three decades have passed since
adult T
-
cell
leukemia
-
lymphoma
(
ATLL
) was proposed as a new
disease
entity.
During this period, its causative agent,
human
T-
cell
leukemia virus
type-1 (
HTLV
-1), was found and a crucial role of the viral product Tax in the development of
ATLL
was disclosed.
However, the long latent period after infection with
HTLV
-1 indicates the need for additional factors for full-blown
ATLL
, most of which are supposed to be provided by somatic mutations of cellular genes.
Recent progress in
cell
-cycle research has revealed that the uncontrolled and superior proliferative activity of malignant cells is mainly caused by the breakdown of
cell
-cycle regulation and that most malignancies carry aberrations in p16-pRB and/or p53 pathways.
ATLL
is not an exception, despite the consistent association of
HTLV
-1 in primary
leukemia
cells, and accumulating evidence indicates that the breakdown of these pathways is indeed involved in the leukemogenesis of
ATLL
, especially in its later steps, which serve as the key events for promotion of indolent
ATLL
to aggressive
ATLL
.
[MeSH-major]
Gene Silencing. Genes, Tumor Suppressor.
Leukemia
-
Lymphoma
,
Adult T
-
Cell
/ etiology
[MeSH-minor]
Disease
Progression. Genes, cdc. Humans
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16236609.001).
[ISSN]
1042-8194
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Number-of-references]
47
78.
Prochazka V, Trneny M, Pytlik R, Vasova I, Kral Z, Belada D, Kozak T, Kubackova K, Siffnerova H, Matuska M, Lysy M, Bolomska I, Petrakova K, Otavova B, Pribylova J, Svecova J, Papajik T, Hamouzova M, Petrova M, Zapletalova J, Langova K:
Peripheral T-cell lymphoma, unspecified--the analysis of the data from the Czech Lymphoma Study Group (CLSG) registry.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
; 2007 Jun;151(1):103-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Peripheral T-
cell lymphoma
, unspecified--the analysis of the data from the Czech
Lymphoma
Study Group (CLSG) registry.
BACKGROUND: Peripheral T-
cell lymphoma
, unspecified (PTCL-US) is one of the entities from the infrequent family of nodal mature T-
cell
lymphomas
.
The
clinical
course is aggressive, and despite multiagent chemotherapy, the median survival is about 2 years.
Published data are limited to retrospective, mostly single-center studies or reviews and usually include more
lymphoma
subtypes.
AIM: To evaluate the current treatment modalities,
clinical
outcome and prognostic factors in unselected, new diagnosed patients with PTCL-US in the population of the central european region (Czech Republic).
METHOD: Czech
Lymphoma
Study Group is a national scientific organization which provides an on-line database registry which collects a data about almost all new diagnosed
lymphoma
patients since year 2000.
RESULTS: We analyzed 63 patients with new
diagnosis
of PTCL-US.
After a median follow-up of 19.6 months, 41% of the patients were in CR, 3.4% in PR or stable
disease
and 55% of the patients died.
Clinical
stage (IV) and CR achievement were found to be independent survival predictors in a multivariate analysis.
[MeSH-major]
Lymphoma
, T-
Cell
, Peripheral
[MeSH-minor]
Adult
. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Survival Rate
Genetic Alliance.
consumer health - Peripheral T-cell lymphoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17690750.001).
[ISSN]
1213-8118
[Journal-full-title]
Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia
[ISO-abbreviation]
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Czech Republic
79.
Murata K, Hayashibara T, Sugahara K, Uemura A, Yamaguchi T, Harasawa H, Hasegawa H, Tsuruda K, Okazaki T, Koji T, Miyanishi T, Yamada Y, Kamihira S:
A novel alternative splicing isoform of human T-cell leukemia virus type 1 bZIP factor (HBZ-SI) targets distinct subnuclear localization.
J Virol
; 2006 Mar;80(5):2495-505
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A novel alternative splicing isoform of
human
T-
cell
leukemia virus
type 1 bZIP factor (HBZ-SI) targets distinct subnuclear localization.
Adult T
-
cell
leukemia
(
ATL
) is
associated
with prior infection with
human
T-
cell
leukemia virus
type 1 (
HTLV
-1); however, the mechanism by which
HTLV
-1 causes
adult T
-
cell
leukemia
has not been fully elucidated.
Recently, a functional basic leucine zipper (bZIP) protein coded in the minus strand of
HTLV
-1 genome (HBZ) was identified.
We report here a novel isoform of the
HTLV
-1 bZIP factor (HBZ), HBZ-SI, identified by means of reverse transcription-PCR (RT-PCR) in conjunction with 5' and 3' rapid amplification of cDNA ends (RACE).
HBZ-SI is a 206-amino-acid-long protein and is generated by alternative splicing between part of the HBZ gene and a novel exon located in the 3' long terminal repeat of the
HTLV
-1 genome.
Duplex RT-PCR and real-time quantitative RT-PCR analyses showed that the mRNAs of these isoforms were expressed at equivalent levels in
all ATL
cell
samples examined.
Nonetheless, we found by Western blotting that the HBZ-SI protein was preferentially expressed in some
ATL
cell
lines examined.
A key
finding
was obtained from the subcellular localization analyses of these isoforms.
These data show the presence of a novel isoform of HBZ in
ATL
cells, and in addition, shed new light on the possibility that each isoform may play a unique role in distinct regions in the
cell
nucleus.
[MeSH-major]
Alternative Splicing. Basic-Leucine Zipper Transcription Factors / genetics. Basic-Leucine Zipper Transcription Factors / metabolism.
Cell
Nucleus / metabolism.
Human
T-
lymphotropic virus
1 / genetics. RNA Processing, Post-Transcriptional. RNA, Messenger / metabolism. RNA, Viral / metabolism. Viral Proteins / genetics. Viral Proteins / metabolism
[MeSH-minor]
Amino Acid Sequence. Artificial Gene Fusion. Base Sequence. Biological Transport. Blotting, Western.
Cell
Line, Tumor. Green Fluorescent Proteins / analysis. Green Fluorescent Proteins / genetics. Humans. Microscopy, Fluorescence. Molecular Sequence Data. Protein Isoforms / chemistry. Protein Isoforms / genetics. Protein Isoforms / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sequence Analysis, DNA
Genetic Alliance.
consumer health - Human T-cell leukemia virus type 1
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Blood. 2001 Feb 15;97(4):987-93
[
11159527.001
]
[Cites]
J Cell Sci. 2005 Apr 1;118(Pt 7):1355-62
[
15755797.001
]
[Cites]
Virus Genes. 2001;23(2):123-35
[
11724264.001
]
[Cites]
J Virol. 2002 Dec;76(24):12813-22
[
12438606.001
]
[Cites]
Nutr Cancer. 2002;44(2):193-201
[
12734068.001
]
[Cites]
Oncogene. 2003 Aug 11;22(33):5131-40
[
12910250.001
]
[Cites]
J Biol Chem. 2003 Oct 31;278(44):43620-7
[
12937177.001
]
[Cites]
FEBS Lett. 2004 Mar 26;562(1-3):165-70
[
15044019.001
]
[Cites]
J Biol Chem. 2004 Jul 30;279(31):31991-4
[
15090550.001
]
[Cites]
J Biol Chem. 2004 Oct 15;279(42):43998-4004
[
15308664.001
]
[Cites]
Proc Natl Acad Sci U S A. 1981 Mar;78(3):1887-91
[
6262827.001
]
[Cites]
Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80
[
7031654.001
]
[Cites]
Crit Rev Microbiol. 1986;12(4):293-320
[
3007026.001
]
[Cites]
Adv Virus Res. 1985;30:225-77
[
3008524.001
]
[Cites]
Cell. 1987 Jan 30;48(2):343-50
[
3026643.001
]
[Cites]
Proc Natl Acad Sci U S A. 1987 Aug;84(15):5389-93
[
3037548.001
]
[Cites]
Biochem Biophys Res Commun. 1989 Sep 15;163(2):1006-13
[
2476979.001
]
[Cites]
Br J Haematol. 1991 Nov;79(3):428-37
[
1751370.001
]
[Cites]
Biochim Biophys Acta. 1991 Dec 10;1072(2-3):129-57
[
1751545.001
]
[Cites]
Proc Natl Acad Sci U S A. 1992 May 1;89(9):4042-6
[
1315048.001
]
[Cites]
J Virol. 1992 Jul;66(7):4570-5
[
1351105.001
]
[Cites]
Jpn J Cancer Res. 1993 Jan;84(1):4-8
[
8449826.001
]
[Cites]
Br J Haematol. 1994 Oct;88(2):234-41
[
7803265.001
]
[Cites]
Blood. 1995 May 15;85(10):2699-704
[
7742529.001
]
[Cites]
Blood. 1996 Sep 1;88(5):1551-60
[
8781409.001
]
[Cites]
Leuk Lymphoma. 1996 May;21(5-6):443-7
[
9172809.001
]
[Cites]
Int J Cancer. 1996 Sep 27;68(1):102-8
[
8895548.001
]
[Cites]
J Virol. 1997 Apr;71(4):3188-96
[
9060682.001
]
[Cites]
J Virol. 1998 Jan;72(1):388-95
[
9420237.001
]
[Cites]
EMBO J. 1998 Mar 2;17(5):1476-86
[
9482744.001
]
[Cites]
Cell. 1998 Apr 3;93(1):81-91
[
9546394.001
]
[Cites]
Mol Cell Biol. 1998 Jun;18(6):3620-32
[
9584203.001
]
[Cites]
Oncogene. 2005 Feb 3;24(6):1001-10
[
15592508.001
]
[Cites]
J Biol Chem. 2001 May 25;276(21):17920-31
[
11279020.001
]
(PMID = 16474156.001).
[ISSN]
0022-538X
[Journal-full-title]
Journal of virology
[ISO-abbreviation]
J. Virol.
[Language]
eng
[Databank-accession-numbers]
GENBANK/ AB219938
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Basic-Leucine Zipper Transcription Factors; 0 / HBZ protein, human T-cell leukemia virus type I; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / RNA, Viral; 0 / Viral Proteins; 0 / enhanced green fluorescent protein; 147336-22-9 / Green Fluorescent Proteins
[Other-IDs]
NLM/ PMC1395368
80.
Lévy M, Copie-Bergman C, Molinier-Frenkel V, Riou A, Haioun C, Gaulard P, Delfau-Larue MH, Sobhani I, Leroy K, Delchier JC:
Treatment of t(11;18)-positive gastric mucosa-associated lymphoid tissue lymphoma with rituximab and chlorambucil: clinical, histological, and molecular follow-up.
Leuk Lymphoma
; 2010 Feb;51(2):284-90
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Treatment of t(11;18)-
positive
gastric mucosa-
associated
lymphoid tissue
lymphoma
with rituximab and chlorambucil:
clinical
, histological, and molecular follow-up.
Translocation t(11;18) is a factor predictive of poor response to treatment of gastric marginal zone
lymphoma
of mucosa-
associated
lymphoid tissue (MALT).
We treated 13 patients with t(11;18)-
positive
gastric MALT
lymphoma
with the combination of rituximab and chlorambucil (nine patients as first treatment and four as second line therapy).
At week 25, B
cell
monoclonality and t(11;18)-
positive
tumor cells were still detected in 77% and 73%, respectively.
However, at long term follow-up, the tumor B
cell
clone was present in only 30% whereas the t(11;18) was still detected in 70%.
The combination of rituximab - chlorambucil is highly effective in t(11;18)-
positive
gastric MALT
lymphoma
.
Molecular
disease
persists despite histological remission. t(11;18) is more sensitive than B
cell
clonality for the monitoring of residual molecular
disease
.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastric Mucosa / drug effects.
Lymphoma
, B-
Cell
, Marginal Zone / drug therapy. Translocation, Genetic
[MeSH-minor]
Adult
. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-
Derived
. Chlorambucil / administration & dosage. Chromosomes,
Human
, Pair 11 / genetics. Chromosomes,
Human
, Pair 18 / genetics. Female. Follow-Up Studies. Helicobacter Infections / drug therapy. Helicobacter Infections / genetics. Helicobacter Infections / microbiology. Helicobacter pylori / drug effects. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Male. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / analysis. Rituximab. Treatment Outcome
Genetic Alliance.
consumer health - Gastric Lymphoma
.
Hazardous Substances Data Bank.
RITUXIMAB
.
Hazardous Substances Data Bank.
CHLORAMBUCIL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20038225.001).
[ISSN]
1029-2403
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 18D0SL7309 / Chlorambucil; 4F4X42SYQ6 / Rituximab
81.
Li B, Shi YK, He XH, Zou SM, Zhou SY, Dong M, Yang JL, Liu P, Xue LY:
Primary non-Hodgkin lymphomas in the small and large intestine: clinicopathological characteristics and management of 40 patients.
Int J Hematol
; 2008 May;87(4):375-81
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary non-Hodgkin
lymphomas
in the small and large intestine: clinicopathological characteristics and management of 40 patients.
To investigate the clinicopathological characteristics and optimal treatment modalities of primary non-Hodgkin
lymphoma
(NHL) in the small and large intestine.
All cases were reclassified according to the World Health Organization (WHO) classification of
lymphoma
in 2001.
Fourteen patients had primary
disease
in the small intestine, which were all of B-
cell
origin with diffuse large B-
cell lymphoma
(DLBCL) diagnosed in 5 of 14 (35.7%) patients and mucosa-
associated
lymphoid tissue (MALT)
lymphoma
in 8 of 14 (57.1%) patients.
Twenty-five patients had primary colorectal
lymphoma
, with B-
cell
origin accounting for 92.0% and T-
cell
origin for 8.0% of these patients.
However, no post-operation treatment modality can improve OS or EFS for patients with MALT
lymphoma
.
B-
cell lymphoma
is the most common pathological type of intestinal
lymphomas
.
Chemotherapy-containing treatment modality is an effective way to improve intestinal
lymphoma
patients' EFS, especially for those with DLBCL subtype.
[MeSH-major]
Intestinal Neoplasms / pathology. Intestinal Neoplasms / therapy. Intestine, Large / pathology. Intestine, Small / pathology.
Lymphoma
, Non-Hodgkin / pathology.
Lymphoma
, Non-Hodgkin / therapy
[MeSH-minor]
Adolescent.
Adult
. Aged. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Zhonghua Wei Chang Wai Ke Za Zhi. 2006 Nov;9(6):502-5
[
17143795.001
]
[Cites]
Histopathology. 2003 Aug;43(2):135-43
[
12877728.001
]
[Cites]
Am Surg. 1988 May;54(5):262-6
[
3364860.001
]
[Cites]
Med Oncol. 2005;22(1):57-62
[
15750197.001
]
[Cites]
Cancer. 1985 Mar 1;55(5):1060-73
[
3881161.001
]
[Cites]
Cancer Causes Control. 2005 Sep;16(7):781-7
[
16132788.001
]
[Cites]
Gastroenterol Jpn. 1976;11(2):141-7
[
789171.001
]
[Cites]
Dig Dis Sci. 2005 Dec;50(12):2243-7
[
16416168.001
]
[Cites]
J Clin Oncol. 2005 Oct 1;23(28):7050-9
[
16129843.001
]
[Cites]
Gastroenterology. 2000 Nov;119(5):1191-202
[
11054376.001
]
[Cites]
Am J Med. 1991 Jan;90(1):77-84
[
1702581.001
]
[Cites]
Cancer. 2003 May 15;97(10):2462-73
[
12733145.001
]
[Cites]
J Clin Oncol. 2001 Sep 15;19(18):3861-73
[
11559724.001
]
[Cites]
Rofo. 1983 Mar;138(3):283-7
[
6403420.001
]
[Cites]
Eur J Surg. 1997 Nov;163(11):803-13
[
9414040.001
]
[Cites]
Ann Surg. 2004 Jul;240(1):44-50
[
15213617.001
]
[Cites]
Leuk Lymphoma. 2004 Sep;45(9):1847-52
[
15223645.001
]
[Cites]
Br J Cancer. 1993 Apr;67(4):776-82
[
8471435.001
]
[Cites]
Gastroenterology. 1994 Apr;106(4):846-58
[
8143991.001
]
[Cites]
Isr Med Assoc J. 2006 Dec;8(12):832-5
[
17214096.001
]
[Cites]
Cancer. 1989 Sep 15;64(6):1208-17
[
2670184.001
]
[Cites]
Br J Cancer. 1989 Aug;60(2):244-8
[
2765374.001
]
[Cites]
Ann Oncol. 2001 Jan;12(1):53-8
[
11249049.001
]
[Cites]
Leuk Lymphoma. 2006 Jul;47(7):1253-9
[
16923554.001
]
[Cites]
Acta Oncol. 1988;27(1):51-5
[
3284553.001
]
[Cites]
Semin Oncol. 1999 Jun;26(3):324-37
[
10375089.001
]
[Cites]
Zhonghua Zhong Liu Za Zhi. 2006 Feb;28(2):142-4
[
16750023.001
]
[Cites]
Dis Colon Rectum. 2000 Sep;43(9):1277-82
[
11005497.001
]
[Cites]
Am J Surg Pathol. 2000 May;24(5):688-93
[
10800987.001
]
[Cites]
Med Oncol. 2006;23(2):225-35
[
16720923.001
]
[Cites]
Cancer. 2005 Aug 1;104(3):532-40
[
15937928.001
]
[Cites]
Cancer. 1978 Aug;42(2):693-707
[
354774.001
]
[Cites]
Ann Oncol. 1997 Aug;8(8):727-37
[
9332679.001
]
[Cites]
Colorectal Dis. 2006 Sep;8(7):586-91
[
16919111.001
]
[Cites]
Cancer. 2000 Jan 15;88(2):286-94
[
10640959.001
]
(PMID = 18409078.001).
[ISSN]
0925-5710
[Journal-full-title]
International journal of hematology
[ISO-abbreviation]
Int. J. Hematol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Japan
82.
Lee J, Kim WS, Park YH, Park SH, Park KW, Kang JH, Lee SS, Lee SI, Lee SH, Kim K, Jung CW, Ahn YC, Ko YH, Park K:
Nasal-type NK/T cell lymphoma: clinical features and treatment outcome.
Br J Cancer
; 2005 Apr 11;92(7):1226-30
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Nasal-type NK/
T cell lymphoma
:
clinical
features and treatment outcome.
Nasal-type NK/
T cell lymphoma
is an increasingly recognised
disease
entity of aggressive
clinical
behaviour.
The objective of this study was to investigate
clinical
features and treatment outcomes in patients with nasal-type NK/
T cell lymphoma
.
From January 1991 to December 2003, 26 patients diagnosed as nasal-type NK/
T cell lymphoma
were included in the analysis.
The median survival for 26 patients with nasal-type NK/
T cell lymphoma
was 7.4 months (95% CI, 0.1, 16.9).
The treatment outcome of primary anthracycline-based chemotherapy was poor: 60% CR rate in localised
disease
and 0% CR rate in advanced
disease
.
After a median follow-up of 24.4 months (range 3.1-99.0) in patients with localised
disease
who had achieved a CR (range 29.6-165.7), three patients (50.0%) developed
disease
recurrence at 6.1, 21.8, and 52.1 months, respectively, and all patients presented with locoregional failure.
In conclusion, Nasal-type NK/
T cell
lymphomas
showed a poor response to the conventional anthracycline-based chemotherapy, and thus an investigation for an innovative therapy is urgently needed to improve survival in these patients.
[MeSH-minor]
Adult
. Aged. Aged, 80 and over. Anthracyclines / therapeutic use. Antineoplastic Agents / therapeutic use. Female. Health Status. Humans. Killer Cells, Natural.
Lymphoma
, T-
Cell
. Male. Middle Aged. Multivariate Analysis. Prognosis. Retrospective Studies. Survival Analysis
MedlinePlus Health Information.
consumer health - Nasal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Ann Oncol. 2001 Mar;12(3):349-52
[
11332147.001
]
[Cites]
J Clin Oncol. 2001 Apr 15;19(8):2179-88
[
11304770.001
]
[Cites]
Int J Hematol. 2003 Oct;78(3):248-50
[
14604284.001
]
[Cites]
Acta Oncol. 2003;42(7):779-83
[
14690165.001
]
[Cites]
Histopathology. 2004 May;44(5):480-9
[
15139996.001
]
[Cites]
Blood. 1992 May 1;79(9):2432-7
[
1373974.001
]
[Cites]
Hum Pathol. 1992 Jul;23(7):798-804
[
1377163.001
]
[Cites]
Blood. 1993 Aug 1;82(3):687-8
[
8393351.001
]
[Cites]
Blood. 1994 Sep 1;84(5):1361-92
[
8068936.001
]
[Cites]
Am J Surg Pathol. 1995 Mar;19(3):284-96
[
7532919.001
]
[Cites]
J Clin Oncol. 1995 Mar;13(3):666-70
[
7884427.001
]
[Cites]
Am J Surg Pathol. 1996 Jan;20(1):103-11
[
8540601.001
]
[Cites]
Blood. 1996 Feb 15;87(4):1207-10
[
8608206.001
]
[Cites]
Histopathology. 1996 Feb;28(2):111-20
[
8834518.001
]
[Cites]
Blood. 1997 Jun 15;89(12):4501-13
[
9192774.001
]
[Cites]
Am J Clin Pathol. 1999 Jan;111(1 Suppl 1):S46-55
[
9894469.001
]
[Cites]
J Am Acad Dermatol. 1999 Feb;40(2 Pt 1):268-72
[
10025761.001
]
[Cites]
Ann Oncol. 2004 Jul;15(7):1097-108
[
15205205.001
]
[Cites]
J Clin Oncol. 1999 Apr;17(4):1244
[
10561185.001
]
[Cites]
J Clin Oncol. 1999 Dec;17(12):3835-49
[
10577857.001
]
[Cites]
J Clin Oncol. 2000 Jan;18(1):54-63
[
10623693.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):182-90
[
12182990.001
]
(PMID = 15798768.001).
[ISSN]
0007-0920
[Journal-full-title]
British journal of cancer
[ISO-abbreviation]
Br. J. Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Anthracyclines; 0 / Antineoplastic Agents
[Other-IDs]
NLM/ PMC2361983
83.
De Re V, Simula MP, Caggiari L, Ortz N, Spina M, Da Ponte A, De Appolonia L, Dolcetti R, Canzonieri V, Cannizzaro R:
Protein expression profile of celiac disease patient with aberrant T cell by two-dimensional difference gel electrophoresis.
Ann N Y Acad Sci
; 2007 Aug;1109:429-40
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Protein expression profile of celiac
disease
patient with aberrant
T cell
by two-dimensional difference gel electrophoresis.
One complication of celiac
disease
(CD) is refractory CD.
These patients frequently show aberrant intraepithelial
T cell
clones and an increasing risk of evolution into enteropathy-
associated
T cell lymphoma
(EATL).
There is debate in the literature whether these cases are actually a smoldering
lymphoma
from the outset.
The mechanism inducing
T cell
proliferation and prognosis remains unknown.
Only few single cases have been tested presently, nevertheless, in all of them
a clinical
improvement has been observed, while intraepithelial lymphocytes (IELs) effectively targeted by alemtuzumab are still a debated issue.
Using 2D-DIGE, we found hyperexpressed proteins specifically
associated
with aberrant
T cell
in a patient with CD by comparing the protein expression with that of patients with CD and polyclonal
T cell
or with that of control subjects (patients with polyclonal
T cell
and no CD).
Proteins with a higher expression in duodenal biopsy of the patient with aberrant
T cell
were identified as IgM, apolipoprotein C-III, and Charcot-Leyden crystal proteins.
These preliminary data allow hypothesizing different
clinical
effects of alemtuzumab in patients with CD, since besides the probable effect of alemtuzumab on
T cell
, it could effect inflammatory-
associated
CD52(+) IgM(+)B
cell
and eosinophils cells, known to produce IgM and Charcot-Leyden crystal proteins, which we demonstrated to be altered in this patient.
Results also emphasize the possible association of apolipoprotein with aberrant
T cell
proliferation.
[MeSH-major]
Celiac
Disease
/ metabolism. Electrophoresis, Gel, Two-Dimensional / methods. Proteomics / methods. T-Lymphocytes / metabolism
[MeSH-minor]
Adult
. Aged. Apolipoprotein C-III / metabolism. B-Lymphocytes / immunology. B-Lymphocytes / metabolism. Female. Glycoproteins / metabolism. Humans. Immunoglobulin M / immunology. Immunoglobulin M / metabolism. Lysophospholipase / metabolism. Male. Middle Aged. Receptors, Antigen, T-
Cell
, gamma-delta / genetics
Genetic Alliance.
consumer health - Celiac Disease
.
MedlinePlus Health Information.
consumer health - Celiac Disease
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17785332.001).
[ISSN]
0077-8923
[Journal-full-title]
Annals of the New York Academy of Sciences
[ISO-abbreviation]
Ann. N. Y. Acad. Sci.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Apolipoprotein C-III; 0 / Glycoproteins; 0 / Immunoglobulin M; 0 / Receptors, Antigen, T-Cell, gamma-delta; 0 / lysolecithin acylhydrolase; EC 3.1.1.5 / Lysophospholipase
84.
Oka K, Nagayama R, Mori N:
Epstein-Barr virus-associated proliferative disorder presenting as Hodgkin's lymphoma and developing as aggressive natural killer-cell leukemia 19 years later: a case report of composite lymphoma.
Pathol Res Pract
; 2009;205(10):730-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Epstein-Barr
virus
-
associated
proliferative
disorder
presenting as Hodgkin's
lymphoma
and developing as aggressive natural killer-
cell
leukemia
19 years later: a case report of composite
lymphoma
.
We describe a patient who was diagnosed as having classic Hodgkin's
lymphoma
at 29 years of age, and aggressive natural killer-
cell
leukemia
at 48 years.
Hodgkin and Reed-Sternberg cells in the lymph node expressed CD30, CD15, T-
cell
intracellular antigen-1 (TIA-1), perforin, granzyme B, and Epstein-Barr
virus
-encoded RNA (EBER).
Natural killer-
cell
leukemia
cells in the bone marrow expressed cytoplasmic CD3epsilon, TIA-1, perforin, granzyme B, and EBER, and some neoplastic cells expressed CD56 (123C3).
Fluorescence-activated
cell
sorter (FACS) analysis showed that neoplastic cells expressed CD56.
Neither a rearrangement band of the T-
cell
receptor gene nor that of the immunoglobulin heavy chain gene was detected.
[MeSH-major]
Epstein-Barr
Virus
Infections / complications. Hodgkin
Disease
/ pathology.
Leukemia
, Large Granular Lymphocytic / pathology. Neoplasms, Second Primary / pathology
[MeSH-minor]
Adult
. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fatal Outcome. Flow Cytometry. Herpesvirus 4,
Human
. Humans. Immunohistochemistry. Male. Middle Aged
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19269751.001).
[ISSN]
1618-0631
[Journal-full-title]
Pathology, research and practice
[ISO-abbreviation]
Pathol. Res. Pract.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Germany
85.
Arellano ML, Langston A, Winton E, Flowers CR, Waller EK:
Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience.
Biol Blood Marrow Transplant
; 2007 Jan;13(1):116-23
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Treatment of relapsed
acute leukemia
after allogeneic transplantation: a single center experience.
Relapsed
acute leukemia
after allogeneic transplantation has a poor prognosis and most reports have focused on the role of second transplantations in relapsed patients.
We report our single-institution experience on the management of relapsed
acute leukemia
after allogeneic transplantation.
We aimed to describe the outcome of relapsed
acute leukemia
after allogeneic transplantation at our institution and investigate whether maneuvers intended to augment donor
T cell
allogeneic reactivity were
associated
with durable graft-versus-
leukemia
effects.
We analyzed 310 patients with
acute leukemia
who received allogeneic hematopoietic progenitor
cell
transplants from HLA-matched donors between 1982 and 2005 (229 with
acute
myelogenous
leukemia
, 81 with
acute
lymphoblastic
leukemia
).
Factors
associated
with relapse incidence, therapy for relapse, response to treatment, and post-relapse survival were assessed.
One hundred of 310 patients (32%) with
acute leukemia
relapsed after transplantation, including 28 of 81 patients (35%) with
acute
lymphoblastic
leukemia
and 72 of 229 (31%) with
acute
myelogenous
leukemia
at a median of 136 days after transplantation.
A multivariable Cox regression analysis indicated that a longer time to relapse after transplantation, peripheral blood as source of stem cells, and initial post-relapse therapy with cytokines, donor lymphocyte infusions, or second transplants were
associated
with improved post-relapse survival (P <.001, <.001, and .025).
The outlook for patients with post-transplant relapse of
acute leukemia
is extremely poor; currently, no single therapy consistently results in durable remissions.
Our study highlights the need for
clinical
trials in this area.
[MeSH-major]
Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use. Hematopoietic Stem
Cell
Transplantation. Interferon-alpha / therapeutic use.
Leukemia
, Myeloid,
Acute
/ therapy. Neoplasm Recurrence, Local / therapy. Precursor
Cell
Lymphoblastic
Leukemia
-
Lymphoma
/ therapy
[MeSH-minor]
Adolescent.
Adult
. Female. Humans. Immunotherapy / methods. Kaplan-Meier Estimate. Male. Middle Aged. Mortality. Prognosis. Retrospective Studies. Salvage Therapy / methods. Transplantation, Homologous / adverse effects
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17222760.001).
[ISSN]
1083-8791
[Journal-full-title]
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
[ISO-abbreviation]
Biol. Blood Marrow Transplant.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Interferon-alpha; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
86.
Kannangara AP, Levitan D, Fleischer AB Jr:
Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
J Dermatolog Treat
; 2009;20(3):169-76
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-
cell lymphoma
.
BACKGROUND: Various combination therapies are used in refractory cutaneous T-
cell lymphoma
(CTCL).
RESULTS: Twelve patients with CTCL stage IA-IIB
disease
who received a combination of bexarotene and methotrexate were identified.
Tolerance to the treatment was good and commonly observed side effects were hyperlipidemia, elevated liver transaminases and a decreased white blood
cell
count.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / administration & dosage.
Lymphoma
, T-
Cell
, Cutaneous / drug therapy.
Lymphoma
, T-
Cell
, Cutaneous / pathology. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology
[MeSH-minor]
Administration, Oral.
Adult
. Age Factors. Aged. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Middle Aged. Mycosis Fungoides / drug therapy. Mycosis Fungoides / mortality. Mycosis Fungoides / pathology. Neoplasm Staging. Retrospective Studies. Risk Assessment. Sex Factors. Survival Rate. Tetrahydronaphthalenes / administration & dosage. Tetrahydronaphthalenes / adverse effects. Treatment Outcome
Genetic Alliance.
consumer health - Cutaneous T-Cell Lymphoma
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
METHOTREXATE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19016373.001).
[ISSN]
1471-1753
[Journal-full-title]
The Journal of dermatological treatment
[ISO-abbreviation]
J Dermatolog Treat
[Language]
eng
[Publication-type]
Comparative Study; Evaluation Studies; Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Tetrahydronaphthalenes; A61RXM4375 / bexarotene; YL5FZ2Y5U1 / Methotrexate
87.
Tözsér J, Weber IT:
The protease of human T-cell leukemia virus type-1 is a potential therapeutic target.
Curr Pharm Des
; 2007;13(12):1285-94
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The protease of
human
T-
cell
leukemia virus
type-1 is a potential therapeutic target.
Human
T-
cell
leukemia virus
type-1 (
HTLV
-1) is
associated
with a number of
human
diseases.
Although the mechanism by which the
virus
causes diseases is still not known, studies indicate that viral replication is critical for the development of
HTLV
-
1 associated
myelopathy, and initial studies suggested that blocking replication with reverse transcriptase inhibitors had a therapeutic effect.
Therefore, based on the success of HIV-1 protease inhibitors, the
HTLV
-1 protease is also a potential target for chemotherapy.
Furthermore, mutated residues in HIV-1 protease that confer drug resistance are frequently seen in equivalent positions of other retroviral proteases, like
HTLV
-1 protease.
Therefore, comparison of
HTLV
-1 and HIV-1 proteases is expected to aid the rational design of broad spectrum inhibitors effective against various retroviral proteases, including the mutant HIV-1 enzymes appearing in drug resistance.
This review describes the characteristics of
HTLV
-1 protease, makes comparison with HIV-1 protease, and discusses the status of inhibitor development for the
HTLV
-1 protease.
Genetic Alliance.
consumer health - Human T-cell leukemia virus type 1
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17504236.001).
[ISSN]
1873-4286
[Journal-full-title]
Current pharmaceutical design
[ISO-abbreviation]
Curr. Pharm. Des.
[Language]
ENG
[Grant]
United States / NIGMS NIH HHS / GM / R01 GM062920; United States / NIGMS NIH HHS / GM / GM 062920; United States / FIC NIH HHS / TW / TW01001
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Protease Inhibitors; EC 3.4.23.- / Aspartic Acid Endopeptidases; EC 3.4.23.- / HTLV-1 protease
[Number-of-references]
45
88.
Okayama A:
[Natural history of human T-lymphotropic virus type 1 (HTLV-1) infection].
Rinsho Byori
; 2005 Sep;53(9):837-44
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Natural history of
human
T-
lymphotropic virus
type 1 (
HTLV
-1) infection].
The natural history of
human
T-
lymphotropic virus
type-1 (
HTLV
-1) infection has been difficult to be clarified, because only a small proportion of
HTLV
-1 carriers develop
adult T
-
cell
leukemia
(
ATL
) after a long incubation period.
We have performed a long-term follow-up study of
HTLV
-1 carriers for 17 years.
Based on the findings of this study and other studies, the natural history of
HTLV
-1 carriers is hypothesized as follows.
The major routes of infection of this
virus
are from mother to child, between spouses, and through blood products.
The target of
HTLV
-1 infection is CD4
positive
peripheral blood mononuclear cells (PBMCs).
Clonal expansion of infected cells is likely to be contributing to the maintenance of the
HTLV
-1 infection.
Finally, some of these clones, which acquired the accumulation of genomic
abnormality
, develop the pre-leukemic state.
The increased number of certain T-cells due to
HTLV
-1 infection may also cause imbalance of the immune system, resulting in immune dysfunction or inflammatory diseases like myelopathy and uveitis.
Therefore, it seems to be important to find ways to prevent
HTLV
-
1 associated
diseases among the carriers especially those with many infected cells.
[MeSH-major]
HTLV
-I Infections / virology
[MeSH-minor]
Adult
. Carrier State. Female. Humans.
Leukemia
-
Lymphoma
,
Adult T
-
Cell
/ virology. Male. Paraparesis, Tropical Spastic / virology
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16235837.001).
[ISSN]
0047-1860
[Journal-full-title]
Rinsho byori. The Japanese journal of clinical pathology
[ISO-abbreviation]
Rinsho Byori
[Language]
jpn
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
Japan
[Number-of-references]
26
89.
Yu Y, Yuan F, Li X, Lin D, Lan Z, Rao CV, Lei Z:
Luteinizing hormone receptor deficiency increases the susceptibility to alkylating agent-induced lymphomagenesis in mice.
Horm Cancer
; 2010 Oct;1(5):256-64
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Previous studies have revealed a close link between luteinizing hormone (LH)/
human
chorionic gonadotropin (hCG) signaling and oncogenesis in gonadal and nongonadal tissues.
To investigate whether genetic ablation of LH receptor (Lhr) affects the animal's oncogenic susceptibility,
adult
female wild-type (wt), heterozygous, and homozygous Lhr knockout (LhrKO) mice were intraperitoneally injected with an alkylating agent, N-methyl-N-nitrosourea (MNU, 50 mg/kg of body weight).
The results showed that MNU induced non-Hodgkin's thymic and lymphonodus
lymphomas
in 70.6% and 100% of heterozygous and homozygous animals, respectively, compared with 35.7% in wt siblings.
All tumors were immunostained-
positive
for a T-
cell
specific marker, CD3, but not for a B-
cell
marker, CD22, suggesting that all the
lymphomas
arose from T-cells, which are known to be LH/hCG receptor-
positive
.
There was no rearrangement of the Lhr gene locus or differences in thymic
cell
proliferation among the genotypes.
In conclusion, MNU induced a higher incidence and an earlier onset of aggressive
lymphomas
in LhrKO animals, which may be
associated
with a reduction in apoptosis of thymocytes.
Hazardous Substances Data Bank.
N-NITROSO-N-METHYLUREA
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
© Springer Science+Business Media, LLC 2010
[Cites]
Nature. 1994 Jun 9;369(6480):455-61
[
8202136.001
]
[Cites]
Carcinogenesis. 2003 Mar;24(3):541-6
[
12663516.001
]
[Cites]
Nature. 1995 May 4;375(6526):64-8
[
7723844.001
]
[Cites]
Mol Cell Endocrinol. 1995 Apr 28;111(1):R13-7
[
7544304.001
]
[Cites]
Growth Dev Aging. 1995 Fall;59(3):139-48
[
8675368.001
]
[Cites]
Carcinogenesis. 1996 Apr;17(4):771-7
[
8625490.001
]
[Cites]
Immunol Cell Biol. 1996 Apr;74(2):134-43
[
8724000.001
]
[Cites]
Eur J Cancer Prev. 1996 Sep;5 Suppl 1:11-7
[
8972287.001
]
[Cites]
Biol Reprod. 1997 Jan;56(1):67-72
[
9002634.001
]
[Cites]
Leuk Res. 1997 Mar;21(3):189-98
[
9111162.001
]
[Cites]
Arch Histol Cytol. 1997 Mar;60(1):29-38
[
9161687.001
]
[Cites]
Exp Gerontol. 1997 Jul-Oct;32(4-5):415-29
[
9315446.001
]
[Cites]
Oncogene. 1997 Oct 23;15(17):2127-32
[
9366529.001
]
[Cites]
Neuroimmunomodulation. 1999 Jan-Apr;6(1-2):126-36
[
9876243.001
]
[Cites]
Neuroimmunomodulation. 1999 Jan-Apr;6(1-2):137-42
[
9876244.001
]
[Cites]
Mol Cell Endocrinol. 2005 Apr 29;234(1-2):117-26
[
15836960.001
]
[Cites]
Biol Reprod. 2005 Nov;73(5):860-5
[
16033998.001
]
[Cites]
Hum Reprod. 2006 Apr;21(4):936-42
[
16361283.001
]
[Cites]
Cell Death Differ. 2006 Sep;13(9):1495-505
[
16341126.001
]
[Cites]
Mol Cell Endocrinol. 2007 Apr 15;269(1-2):51-60
[
17367919.001
]
[Cites]
Mol Cell Endocrinol. 2007 Apr 15;269(1-2):26-33
[
17382461.001
]
[Cites]
Mol Cell Endocrinol. 2007 Apr 15;269(1-2):2-8
[
17382462.001
]
[Cites]
Blood. 2007 Apr 1;109(7):2700-7
[
17119127.001
]
[Cites]
Blood. 2007 Oct 1;110(7):2650-8
[
17585052.001
]
[Cites]
Int Immunopharmacol. 2008 Jan;8(1):71-9
[
18068102.001
]
[Cites]
Nat Rev Mol Cell Biol. 2008 Jan;9(1):47-59
[
18097445.001
]
[Cites]
Mol Hum Reprod. 2009 Nov;15(11):703-11
[
19710244.001
]
[Cites]
Front Biosci. 2000 Mar 1;5:D343-52
[
10704433.001
]
[Cites]
J Biol Chem. 2000 May 5;275(18):13307-14
[
10788437.001
]
[Cites]
Gynecol Oncol. 2000 Nov;79(2):158-68
[
11063638.001
]
[Cites]
Mol Endocrinol. 2001 Jan;15(1):184-200
[
11145749.001
]
[Cites]
Oncogene. 2001 Aug 30;20(38):5258-63
[
11536039.001
]
[Cites]
EMBO J. 2003 May 1;22(9):2255-63
[
12727891.001
]
[Cites]
Biol Reprod. 2003 Jul;69(1):338-46
[
12672665.001
]
[Cites]
Cancer Sci. 2003 Mar;94(3):240-3
[
12824916.001
]
[Cites]
Cancer Res. 2003 Jul 15;63(14):4281-6
[
12874038.001
]
[Cites]
Cancer Sci. 2003 Aug;94(8):668-71
[
12901790.001
]
[Cites]
Endocrinology. 2003 Sep;144(9):4123-33
[
12933687.001
]
[Cites]
Horm Metab Res. 2003 Aug;35(8):502-5
[
12953169.001
]
[Cites]
J Biol Chem. 2004 Jun 11;279(24):25503-10
[
15044447.001
]
[Cites]
CA Cancer J Clin. 2004 Sep-Oct;54(5):260-72
[
15371284.001
]
[Cites]
Boll Soc Ital Biol Sper. 1986 Jun 30;62(6):763-70
[
3024676.001
]
[Cites]
J Endocrinol. 1987 Mar;112(3):345-50
[
2951474.001
]
[Cites]
J Reprod Immunol. 1988 Aug;13(3):263-75
[
3139875.001
]
[Cites]
J Cell Biol. 1989 Jun;108(6):2423-34
[
2472407.001
]
[Cites]
Acta Endocrinol (Copenh). 1989 Dec;121(6):833-40
[
2532849.001
]
[Cites]
Jpn J Cancer Res. 1991 Dec;82(12):1397-405
[
1778764.001
]
[Cites]
Nature. 1993 Apr 29;362(6423):849-52
[
8479523.001
]
[Cites]
Chem Res Toxicol. 1993 Nov-Dec;6(6):771-85
[
8117915.001
]
[Cites]
Endocr Rev. 2002 Apr;23(2):141-74
[
11943741.001
]
[Cites]
Peptides. 2002 May;23(5):1011-4
[
12084534.001
]
[Cites]
Endocrinology. 2002 Aug;143(8):3114-21
[
12130577.001
]
[Cites]
Carcinogenesis. 2002 Oct;23(10):1701-11
[
12376480.001
]
[Cites]
J Exp Ther Oncol. 2002 May-Jun;2(3):133-45
[
12415629.001
]
[Cites]
Breast Cancer Res Treat. 2003 Feb;77(3):253-64
[
12602925.001
]
[Cites]
Biol Reprod. 2003 Mar;68(3):888-95
[
12604639.001
]
[Cites]
Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1322-6
[
7877975.001
]
(PMID = 21666843.001).
[ISSN]
1868-8500
[Journal-full-title]
Hormones & cancer
[ISO-abbreviation]
Horm Cancer
[Language]
ENG
[Grant]
United States / NICHD NIH HHS / HD / HD057501-01; United States / NICHD NIH HHS / HD / R01 HD057501; United States / NICHD NIH HHS / HD / R01 HD057501-01; United States / NICHD NIH HHS / HD / R01-HD057501
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Alkylating Agents; 0 / Receptors, LH; 684-93-5 / Methylnitrosourea
[Other-IDs]
NLM/ NIHMS280254; NLM/ PMC3110697
[Keywords]
NOTNLM ; Apoptosis / Gene knockout / LH/hCG receptor / Lymphoma / MNU / Thymus
90.
Shimizu Y, Takamori A, Utsunomiya A, Kurimura M, Yamano Y, Hishizawa M, Hasegawa A, Kondo F, Kurihara K, Harashima N, Watanabe T, Okamura J, Masuda T, Kannagi M:
Impaired Tax-specific T-cell responses with insufficient control of HTLV-1 in a subgroup of individuals at asymptomatic and smoldering stages.
Cancer Sci
; 2009 Mar;100(3):481-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Impaired Tax-specific T-
cell
responses with insufficient control of
HTLV
-1 in a subgroup of individuals at asymptomatic and smoldering stages.
Human
T-
cell
leukemia virus
type-1 (
HTLV
-1)-specific T-
cell
immunity, a potential antitumor surveillance system in vivo, is impaired in
adult T
-
cell
leukemia
(
ATL
).
In this study, we aimed to clarify whether the T-
cell
insufficiency in
ATL
is present before the
disease
onset or occurs as a consequence of the
disease
.
We investigated T-
cell
responses against Tax protein in peripheral blood mononuclear cells (PBMCs) from individuals at earlier stages of
HTLV
-1-infection, including 21 asymptomatic
HTLV
-1 carriers (ACs) and four patients with smoldering-type
ATL
(sATL), whose peripheral lymphocyte count was in normal range.
The latter group was further divided to two subgroups with or without emergence of Tax-specific responses following depletion of CC chemokine receptor 4 (CCR4)(+) cells that contained
HTLV
-1-infected cells.
In the PBMCs with Tax-specific responses, CD8(+) cells efficiently suppressed
HTLV
-1 p19 production in culture.
The remaining group without the emergence of Tax-specific response after CCR4(+)
cell
-depletion included at least two sATL and one AC samples, which spontaneously produced
HTLV
-1 p19 in culture, where tetramer-binding, Tax-specific cytotoxic T-lymphocytes were either undetectable or unresponsive.
Our results indicated that
HTLV
-1-specific T-
cell
responsiveness widely differed among
HTLV
-1 carriers, and that impairment of
HTLV
-1-specific T-
cell
responses was observed not only in advanced
ATL
patients but also in a subpopulation at earlier stages, which was
associated
with insufficient control of
HTLV
-1.
[MeSH-major]
Gene Products, tax / immunology.
HTLV
-I Infections / immunology.
Leukemia
-
Lymphoma
,
Adult T
-
Cell
/ immunology. T-Lymphocytes, Cytotoxic / immunology
[MeSH-minor]
Adult
. Aged. Enzyme-Linked Immunosorbent Assay. Female. Flow Cytometry.
Human
T-
lymphotropic virus
1 / immunology. Humans. Immunologic Surveillance. Male. Middle Aged. Receptors, CCR4 / metabolism
Immune Epitope Database and Analysis Resource.
gene/protein/disease-specific - Related Immune Epitope Information
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19154412.001).
[ISSN]
1349-7006
[Journal-full-title]
Cancer science
[ISO-abbreviation]
Cancer Sci.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / CCR4 protein, human; 0 / Gene Products, tax; 0 / Receptors, CCR4
91.
Edinger JT, Clark BZ, Pucevich BE, Geskin LJ, Swerdlow SH:
CD30 expression and proliferative fraction in nontransformed mycosis fungoides.
Am J Surg Pathol
; 2009 Dec;33(12):1860-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The major differential
diagnosis
for a primary cutaneous T-
cell
lymphoproliferative
disorder
with CD30 (Ki-1) positivity includes primary cutaneous anaplastic large
cell lymphoma
, lymphomatoid papulosis, pagetoid reticulosis and transformed mycosis fungoides (MF).
The proportions of
positive
cells were determined and correlated with each other as well as with age, stage at
diagnosis
, maximum stage and survival.
All cases had at least rare dermal CD30-
positive
cells.
Higher percentages of dermal CD30 and Ki-67-
positive
cells were
associated
with a higher stage at
diagnosis
, and together with epidermal CD30,
associated
with a higher maximum stage.
The proportion of CD30 and Ki-67-
positive
cells did not correlate with each other.
Genetic Alliance.
consumer health - Mycosis fungoides
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Blood. 2000 Apr 1;95(7):2212-8
[
10733487.001
]
[Cites]
Cell Prolif. 1997 Jan;30(1):37-47
[
9332493.001
]
[Cites]
Blood. 1998 Aug 15;92(4):1150-9
[
9694702.001
]
[Cites]
Leuk Lymphoma. 1998 Aug;30(5-6):625-36
[
9711925.001
]
[Cites]
Dermatology. 1998;197(2):123-6
[
9732159.001
]
[Cites]
Histopathology. 1998 Sep;33(3):240-7
[
9777390.001
]
[Cites]
Blood. 1998 Nov 1;92(9):3376-80
[
9787176.001
]
[Cites]
J Am Acad Dermatol. 1999 Jun;40(6 Pt 1):914-24
[
10365922.001
]
[Cites]
Haematologica. 2005 Feb;90(2):200-6
[
15710572.001
]
[Cites]
J Am Acad Dermatol. 2005 Jul;53(1):158-63
[
15965442.001
]
[Cites]
J Invest Dermatol. 2006 Mar;126(3):575-83
[
16410787.001
]
[Cites]
Am J Clin Pathol. 2006 May;125(5):727-36
[
16707374.001
]
[Cites]
J Am Acad Dermatol. 2006 Aug;55(2):276-84
[
16844512.001
]
[Cites]
J Clin Oncol. 2007 Mar 1;25(7):805-12
[
17327602.001
]
[Cites]
Br J Dermatol. 2007 Aug;157(2):284-9
[
17573879.001
]
[Cites]
Blood. 2007 Sep 15;110(6):1713-22
[
17540844.001
]
[Cites]
Prilozi. 2007 Jul;28(1):39-55
[
17921917.001
]
[Cites]
J Am Acad Dermatol. 2007 Nov;57(5):782-90
[
17646032.001
]
[Cites]
J Dermatol Sci. 2008 Feb;49(2):125-32
[
17826963.001
]
[Cites]
G Ital Dermatol Venereol. 2008 Feb;143(1):15-9
[
18833048.001
]
[Cites]
Br J Dermatol. 2008 Sep;159(4):881-6
[
18644018.001
]
[Cites]
Blood. 2008 Oct 15;112(8):3082-7
[
18647960.001
]
[Cites]
Leuk Lymphoma. 2008 Nov;49(11):2081-90
[
19021050.001
]
[Cites]
J Am Acad Dermatol. 2009 Feb;60(2):231-5
[
19026464.001
]
[Cites]
J Clin Pathol. 2009 Feb;62(2):128-38
[
18794197.001
]
[Cites]
Mod Pathol. 2000 May;13(5):502-10
[
10824921.001
]
[Cites]
Am J Dermatopathol. 2000 Jun;22(3):212-6
[
10871063.001
]
[Cites]
Blood. 2001 Feb 1;97(3):624-30
[
11157477.001
]
[Cites]
J Cutan Pathol. 2001 Aug;28(7):356-62
[
11437941.001
]
[Cites]
Arch Dermatol. 2002 Feb;138(2):199-203
[
11843640.001
]
[Cites]
Eur J Haematol. 2002 Jul;69(1):11-20
[
12270057.001
]
[Cites]
Blood. 2002 Nov 1;100(9):3369-73
[
12384439.001
]
[Cites]
Arch Dermatol. 2003 Jul;139(7):857-66
[
12873880.001
]
[Cites]
Diagn Mol Pathol. 2003 Sep;12(3):142-50
[
12960696.001
]
[Cites]
Cancer Treat Rep. 1979 Apr;63(4):725-8
[
445521.001
]
[Cites]
Am J Pathol. 1988 Aug;132(2):265-77
[
3261136.001
]
[Cites]
Ann Intern Med. 1988 Sep 1;109(5):372-82
[
3408055.001
]
[Cites]
Am J Pathol. 1990 Feb;136(2):261-6
[
1968314.001
]
[Cites]
Hematol Oncol. 1990 Jul-Aug;8(4):215-27
[
2210690.001
]
[Cites]
Am J Pathol. 1990 Dec;137(6):1447-51
[
2260631.001
]
[Cites]
J Dermatol. 1991 Mar;18(3):152-60
[
1885849.001
]
[Cites]
J Cutan Pathol. 1995 Feb;22(1):11-7
[
7751472.001
]
[Cites]
Am J Surg Pathol. 1995 Dec;19(12):1423-30
[
7503364.001
]
[Cites]
Anticancer Res. 1997 Jan-Feb;17(1A):487-91
[
9066700.001
]
[Cites]
J Am Acad Dermatol. 1997 Jul;37(1):58-67
[
9216524.001
]
[Cites]
Haematologica. 1997 May-Jun;82(3):281-5
[
9234572.001
]
[Cites]
Blood. 1997 Sep 15;90(6):2429-36
[
9310494.001
]
[Cites]
Am J Dermatopathol. 1998 Feb;20(1):1-6
[
9504661.001
]
(PMID = 19898220.001).
[ISSN]
1532-0979
[Journal-full-title]
The American journal of surgical pathology
[ISO-abbreviation]
Am. J. Surg. Pathol.
[Language]
ENG
[Grant]
United States / NCRR NIH HHS / RR / M01 RR000056; United States / NCRR NIH HHS / RR / RR000056-440857; United States / NCRR NIH HHS / RR / UL1 RR024153; United States / NCRR NIH HHS / RR / M01 RR000056-440857
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, CD30; 0 / Ki-67 Antigen
[Other-IDs]
NLM/ NIHMS153861; NLM/ PMC3733448
92.
Willis SN, Stadelmann C, Rodig SJ, Caron T, Gattenloehner S, Mallozzi SS, Roughan JE, Almendinger SE, Blewett MM, Brück W, Hafler DA, O'Connor KC:
Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain.
Brain
; 2009 Dec;132(Pt 12):3318-28
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Epstein-Barr
virus
infection is not a characteristic feature of multiple sclerosis brain.
Multiple sclerosis is an inflammatory demyelinating
disease
of the central nervous system (CNS) that is thought to be caused by a combination of genetic and environmental factors.
To date, considerable evidence has
associated
Epstein-Barr
virus
(EBV) infection with
disease
development.
To assess whether EBV infection is a characteristic feature of multiple sclerosis brain, a large cohort of multiple sclerosis specimens containing white matter lesions (nine
adult
and three paediatric cases) with a heterogeneous B
cell
infiltrate and a second cohort of multiple sclerosis specimens (12 cases) that included B
cell
infiltration within the meninges and parenchymal B
cell
aggregates, were examined for EBV infection using multiple methodologies including in situ hybridization, immunohistochemistry and two independent real-time polymerase chain reaction (PCR) methodologies that detect genomic EBV or the abundant EBV encoded RNA (EBER) 1, respectively.
We report that EBV could not be detected in any of the multiple sclerosis specimens containing white matter lesions by any of the methods employed, yet EBV was readily detectable in multiple Epstein-Barr
virus
-
positive
control tissues including several CNS
lymphomas
.
Our
finding
that CNS EBV infection was rare in multiple sclerosis brain indicates that EBV infection is unlikely to contribute directly to multiple sclerosis brain pathology in the vast majority of cases.
Genetic Alliance.
consumer health - Multiple Sclerosis
.
MedlinePlus Health Information.
consumer health - Multiple Sclerosis
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Arch Neurol. 1987 Dec;44(12):1237-41
[
2823754.001
]
[Cites]
J Immunol. 1986 Jul 15;137(2):498-501
[
3013992.001
]
[Cites]
Nature. 1990 Jul 12;346(6280):183-7
[
1694970.001
]
[Cites]
J Gen Virol. 1990 Jul;71 ( Pt 7):1481-95
[
2165133.001
]
[Cites]
J Virol. 1991 Jul;65(7):3958-63
[
1645805.001
]
[Cites]
Neuroepidemiology. 1991;10(2):62-5
[
2062419.001
]
[Cites]
Neurology. 1992 Sep;42(9):1798-804
[
1381067.001
]
[Cites]
J Neurol Neurosurg Psychiatry. 1994 Aug;57(8):975-6
[
7520057.001
]
[Cites]
Cell. 1995 Mar 10;80(5):695-705
[
7534214.001
]
[Cites]
Leuk Lymphoma. 1995 Sep;19(1-2):1-12
[
8574154.001
]
[Cites]
Int Immunol. 1997 May;9(5):739-43
[
9184919.001
]
[Cites]
J Exp Med. 1998 May 4;187(9):1395-402
[
9565632.001
]
[Cites]
Ann Neurol. 1999 Jul;46(1):6-14
[
10401775.001
]
[Cites]
Lancet. 1964 Mar 28;1(7335):702-3
[
14107961.001
]
[Cites]
Eur J Neurol. 2004 Dec;11(12):833-4
[
15667414.001
]
[Cites]
J Clin Invest. 2005 May;115(5):1352-60
[
15841210.001
]
[Cites]
JAMA. 2005 May 25;293(20):2496-500
[
15914750.001
]
[Cites]
Ann Neurol. 2006 Mar;59(3):499-503
[
16502434.001
]
[Cites]
Brain. 2006 Jun;129(Pt 6):1493-506
[
16569670.001
]
[Cites]
Arch Neurol. 2006 Jun;63(6):839-44
[
16606758.001
]
[Cites]
Curr Opin Rheumatol. 2006 Sep;18(5):462-7
[
16896283.001
]
[Cites]
Rev Med Virol. 2006 Sep-Oct;16(5):297-310
[
16927411.001
]
[Cites]
Lancet Neurol. 2006 Oct;5(10):887-94
[
16987736.001
]
[Cites]
Neurology. 2006 Dec 12;67(11):2063-5
[
17159123.001
]
[Cites]
Ann Neurol. 2007 Apr;61(4):288-99
[
17444504.001
]
[Cites]
J Neurol. 2007 Apr;254(4):425-30
[
17385083.001
]
[Cites]
J Virol. 2007 Jul;81(13):6777-84
[
17459939.001
]
[Cites]
J Exp Med. 2007 Nov 26;204(12):2899-912
[
17984305.001
]
[Cites]
Semin Neurol. 2008 Feb;28(1):17-28
[
18256984.001
]
[Cites]
Neurology. 2008 Mar 25;70(13 Pt 2):1113-8
[
18272866.001
]
[Cites]
Autoimmunity. 2008 May;41(4):298-328
[
18432410.001
]
[Cites]
Mult Scler. 2008 Jun;14(5):595-601
[
18566025.001
]
[Cites]
Brain. 2008 Jul;131(Pt 7):1712-21
[
18550621.001
]
[Cites]
J Exp Med. 2008 Aug 4;205(8):1763-73
[
18663124.001
]
[Cites]
Curr Opin Neurol. 2009 Jun;22(3):201-6
[
19359987.001
]
[Cites]
J Neurol Sci. 2009 Nov 15;286(1-2):62-4
[
19361810.001
]
[Cites]
Neurology. 1989 Jun;39(6):825-9
[
2725877.001
]
[Cites]
IARC Sci Publ. 1985;(60):475-6
[
4065951.001
]
[Cites]
Virchows Arch. 1999 Aug;435(2):79-86
[
10599304.001
]
[Cites]
J Neurol Sci. 2000 Feb 1;173(1):32-9
[
10675577.001
]
[Cites]
Neurology. 2000 Jul 25;55(2):178-84
[
10908887.001
]
[Cites]
Hum Pathol. 2001 Dec;32(12):1382-7
[
11774173.001
]
[Cites]
Nat Rev Immunol. 2001 Oct;1(1):75-82
[
11905817.001
]
[Cites]
Clin Exp Immunol. 2003 Apr;132(1):137-43
[
12653848.001
]
[Cites]
Trends Immunol. 2003 Nov;24(11):584-8
[
14596882.001
]
[Cites]
N Engl J Med. 2004 Mar 25;350(13):1328-37
[
15044644.001
]
[Cites]
J Clin Invest. 2004 Mar;113(6):788-94
[
15067307.001
]
[Cites]
JAMA. 2004 Apr 21;291(15):1875-9
[
15100207.001
]
[Cites]
J Virol. 2004 May;78(10):5194-204
[
15113901.001
]
[Cites]
Lancet. 1971 Jan 23;1(7691):167-8
[
4102189.001
]
[Cites]
Acta Neurol Scand. 1971;47(3):315-30
[
5096759.001
]
[Cites]
JAMA. 1972 Apr 17;220(3):393-4
[
5067110.001
]
[Cites]
Arch Neurol. 1983 Jul;40(7):406-8
[
6860175.001
]
[Cites]
Arthritis Rheum. 1983 Jun;26(6):712-20
[
6190485.001
]
[Cites]
Ann Neurol. 1985 Apr;17(4):371-7
[
2988410.001
]
[CommentIn]
Brain. 2010 Dec;133(Pt 12):e157
[
20739348.001
]
[CommentIn]
Brain. 2010 May;133(Pt 5):e137
[
19917644.001
]
(PMID = 19638446.001).
[ISSN]
1460-2156
[Journal-full-title]
Brain : a journal of neurology
[ISO-abbreviation]
Brain
[Language]
ENG
[Grant]
United States / NIAID NIH HHS / AI / P01AI39671; United States / NINDS NIH HHS / NS / P01NS38037; United States / NINDS NIH HHS / NS / R01NS024247; United States / NIDDK NIH HHS / DK / U01DK6192601
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / RNA, Viral
[Other-IDs]
NLM/ PMC2792367
93.
Chaiworapongsa T, Romero R, Tarca AL, Kusanovic JP, Gotsch F, Mittal P, Kim SK, Vaisbuch E, Mazaki-Tovi S, Erez O, Dong Z, Kim CJ, Yeo L, Hassan SS:
A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsia.
Am J Obstet Gynecol
; 2010 Jun;202(6):550.e1-10
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A decrease in maternal plasma concentrations of sVEGFR-2 precedes the
clinical diagnosis
of preeclampsia.
OBJECTIVE: The aim of this study was to examine if maternal plasma concentrations of soluble vascular endothelial growth factor receptor (sVEGFR)-2 change prior to the
diagnosis
of preeclampsia.
Cross-sectional analysis suggested that the median plasma sVEGFR-2 concentration in women destined to develop preeclampsia was significantly lower than that in normal pregnant women from 28-31 weeks of gestation (P = .001) or 6-10 weeks prior to the
diagnosis
(P < .001).
[MeSH-major]
Pre-Eclampsia / blood. Pre-Eclampsia /
diagnosis
. Vascular Endothelial Growth Factor Receptor-2 / blood
[MeSH-minor]
Adolescent.
Adult
. Biomarkers / blood. Cross-Sectional Studies. Enzyme-Linked Immunosorbent Assay. Female. Gestational Age. Humans. Longitudinal Studies. Middle Aged. Patient Selection. Pregnancy. Statistics, Nonparametric
Genetic Alliance.
consumer health - Preeclampsia
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2010 Mosby, Inc. All rights reserved.
[Cites]
Cancer Biol Ther. 2002 Sep-Oct;1(5):548-53
[
12496487.001
]
[Cites]
J Matern Fetal Neonatal Med. 2008 Jan;21(1):41-52
[
18175243.001
]
[Cites]
J Clin Endocrinol Metab. 2003 May;88(5):2348-51
[
12727995.001
]
[Cites]
Nat Med. 2003 Jun;9(6):669-76
[
12778165.001
]
[Cites]
Hypertens Pregnancy. 2003;22(2):143-8
[
12908998.001
]
[Cites]
Am J Obstet Gynecol. 2001 Jan;184(2):146-52
[
11174494.001
]
[Cites]
Invest Ophthalmol Vis Sci. 2002 Feb;43(2):474-82
[
11818393.001
]
[Cites]
Surgery. 2002 Nov;132(5):857-65
[
12464871.001
]
[Cites]
Mediators Inflamm. 2003 Oct;12(5):293-8
[